Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
Search
Advanced Search
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

91
results for

"Non-alcoholic fatty liver"

Article category

More +

Keywords

More +

Publication year

More +

"Non-alcoholic fatty liver"

Research Letter

Burden of cardiovascular complications in steatotic liver disease in the United States
Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed
Clin Mol Hepatol 2026;32(3):e326-e330.
Published online March 25, 2026
DOI: https://doi.org/10.3350/cmh.2026.0249
  • 888 View
  • 62 Download

Letters to the Editor

Navigating discordant non-invasive fibrosis assessments in metabolic dysfunction-associated steatotic liver disease: Implications for generalizability, clinical decision-making, and resource allocation: Letter to the editor on “Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement”
Jiajing Zhao, Liping Liu
Clin Mol Hepatol 2026;32(3):e300-e302.
Published online February 20, 2026
DOI: https://doi.org/10.3350/cmh.2025.0157
  • 977 View
  • 49 Download
Critical considerations on the study of normal-weight metabolic dysfunction-associated steatotic liver disease across diverse populations: Letter to the Editor on “Normal-weight metabolic dysfunction-associated steatotic liver disease: Reclassification, characteristics, and adverse liver outcomes across diverse populations”
Qingshang Li, Xiaona Hu, Yuanwen Chen, Zhijun Bao
Clin Mol Hepatol 2026;32(3):e309-e311.
Published online February 5, 2026
DOI: https://doi.org/10.3350/cmh.2026.0067
  • 997 View
  • 40 Download

Editorial

Rethinking lean metabolic dysfunction-associated steatotic liver disease: Unrecognized risk in lean populations: Editorial on “Normal-weight metabolic dysfunction-associated steatotic liver disease: Reclassification, characteristics, and adverse liver outcomes across diverse populations”
Donghee Kim, Anoushka Shenoy, Aijaz Ahmed
Clin Mol Hepatol 2026;32(3):1441-1443.
Published online January 27, 2026
DOI: https://doi.org/10.3350/cmh.2026.0056
  • 766 View
  • 65 Download

Original Article

DNMT1 facilitates the progression of metabolic dysfunction-associated steatotic liver disease by impeding transcription mediated by HNF4α and PPARα
Hyun Ahm Sohn, Hanyong Go, Tae Hyeon An, Jun Min Lee, Hee-Jin Kim, Keeok Haam, Amal Magdy, Hyo-Jung Jung, Yang-Ji Shin, Hyun Jung Lim, Yujin Jeong, Yejin Bae, Youngae Jung, Seong-Hwan Park, Kyung Chan Park, Myeong Jun Song, Eun-Wie Cho, Eun-Soo Kwon, Jeong Hwan Park, Murim Choi, Geum-Sook Hwang, Dong Hyeon Lee, Kyoung-Jin Oh, Won Kim, Mirang Kim, on behalf of the Innovative Target Exploration of NAFLD (ITEN) Consortium
Clin Mol Hepatol 2026;32(3):1201-1224.
Published online January 27, 2026
DOI: https://doi.org/10.3350/cmh.2025.1099
Background/Aims
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide. Aberrant DNA methylation, which is primarily maintained by DNA methyltransferase 1 (DNMT1), has been linked to metabolic dysregulation; however, its contribution to MASLD pathogenesis remains poorly defined. This study aimed to elucidate the role of DNMT1-mediated methylation in transcriptional regulation during MASLD progression and to determine whether DNMT1 inhibition can reverse disease-associated epigenetic and transcriptional alterations.
Methods
We conducted integrated analyses of the liver transcriptome (n=131) and DNA methylome (n=106) of patients with biopsy-proven MASLD. We evaluated the effect of DNMT1 inhibition with 5-aza-4′-thio-2′-deoxycytidine (Aza-TdC) on a diet-induced MASLD mouse model. Multiomics approaches, including DNA methylome profiling, lipidomics, RNA sequencing, and chromatin immunoprecipitation sequencing, were applied to elucidate the role of DNMT1-mediated DNA methylation in regulating pathogenic gene expression.
Results
DNA methylome profiling revealed increased methylation variability associated with increased DNMT1 expression in MASLD patients. DNMT1 inhibition ameliorated dysregulated lipid metabolism by reducing hepatic triacylglycerol accumulation and inflammation. Aza-TdC treatment partially reversed MASLD-related hypermethylation of hepatocyte nuclear factor 4 alpha (HNF4α)- and peroxisome proliferator-activated receptor alpha (PPARα)-regulated genes, restoring their transcriptional activity. Notably, Aza-TdC reactivated the gluconeogenic enzyme-encoding gene phosphoenolpyruvate carboxykinase 1 (PCK1), which was hypermethylated and transcriptionally repressed in MASLD. Targeted DNA methylation of the PCK1 promoter using CRISPRoff confirmed the direct epigenetic regulation of PCK1 expression.
Conclusions
Targeting DNMT1 may mitigate lipid dysregulation and inflammation by reversing hypermethylation and restoring HNF4α- and PPARα-dependent gene transcription, highlighting DNMT1 as a potential therapeutic target for MASLD.

Citations

Citations to this article as recorded by  Crossref logo
  • Sus scrofa domesticus reveals the genetic evolution of adaptive traits during early divergence
    Bohan Rong, Naiqi Niu, Wencheng Zong, Run Zhang, Xiaomei Ma, Na Zhang, Zhentong Shen, Yu Pang, Xu Lin, Di Liu, Yulong Yin, Longchao Zhang, Xiuqin Yang
    The Innovation Life.2026; : 100222.     CrossRef
  • Metabolic Reprogramming-Driven Cardiovascular Immune Damage: From Glyco-Lipotoxicity and Epigenetic Memory to Multidimensional Cross-Organ Communication Networks
    Zijin Sun, Yongchao Liu, Kai Wang, Haojia Zhang, Rui Zhou, Wei Shao
    International Journal of Molecular Sciences.2026; 27(12): 5526.     CrossRef
  • 2,571 View
  • 378 Download
  • Crossref

Letter to the Editor

Clinical implications of discordant FIB-4 and LSM in MASLD: Integrating evidence and optimizing pathways: Letter to the editor on “Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement”
Deliang Huang, Jun Chen
Clin Mol Hepatol 2026;32(3):e294-e296.
Published online January 20, 2026
DOI: https://doi.org/10.3350/cmh.2026.0027
  • 636 View
  • 10 Download

Original Article

Outcomes of oral antidiabetic drugs in metabolic dysfunction-associated steatotic liver disease: a nationwide target trial emulation study
Heejoon Jang, Yeonjin Kim, Yoo Kyoung Lim, Dong Hyeon Lee, Sae Kyung Joo, Bo Kyung Koo, Gi-Ae Kim, Woojoo Lee, Stefano Romeo, Won Kim, Innovative Target Exploration of NAFLD (ITEN) consortium
Clin Mol Hepatol 2026;32(2):737-750.
Published online January 6, 2026
DOI: https://doi.org/10.3350/cmh.2025.1006
Background/Aims
Patients with concurrent type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) face elevated cardiovascular risks. However, optimal oral antidiabetic drug (OAD) selection for this population remains unclear.
Methods
Using the Korean National Health Information Database, we conducted a target trial emulation comparing cardiovascular outcomes among patients with T2DM and MASLD (defined by fatty liver index ≥30) who initiated sodium-glucose cotransporter 2 (SGLT2) inhibitors, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, or sulfonylureas with metformin. The primary outcome was major adverse cardiovascular events (MACE), including cardiovascular mortality, nonfatal myocardial infarction, and nonfatal stroke.
Results
Among 71,071 patients (331,726 person-years), SGLT2 inhibitor users experienced a significantly lower MACE risk compared to sulfonylurea users (adjusted subdistribution hazard ratio [aSHR], 0.44; 95% confidence interval [CI], 0.31–0.62). SGLT2 inhibitors also demonstrated a lower MACE risk compared to thiazolidinediones (aSHR, 0.61; 95% CI, 0.39–0.96) and DPP-4 inhibitors (aSHR, 0.59; 95% CI, 0.42–0.83). Cardiovascular mortality risk was notably reduced with SGLT2 inhibitors compared to sulfonylureas (aSHR, 0.13; 95% CI, 0.03–0.50), thiazolidinediones (aSHR, 0.19; 95% CI, 0.04–0.86), and DPP-4 inhibitors (aSHR, 0.22; 95% CI, 0.06–0.84). Mediation analysis revealed that MASLD regression accounted for 8.7% of the total cardiovascular benefit when comparing SGLT2 inhibitors to sulfonylureas.
Conclusions
In patients with concurrent T2DM and MASLD, SGLT2 inhibitors demonstrated better cardiovascular outcomes compared to other OADs. These findings suggest that SGLT2 inhibitors may be the preferred OAD choice for cardiovascular risk reduction in this high-risk population.

Citations

Citations to this article as recorded by  Crossref logo
  • Longitudinal changes in fatty liver index, genetic susceptibility, and incident atrial fibrillation
    Siyang Liu, Houde He, Hualan Chen, Hualin Duan, Ying Sun, Dan Deng, Zihao Gui, Lan Liu, Ningjian Wang, Jie Shen, Heng Wan
    Clinica Chimica Acta.2026; 589: 121028.     CrossRef
  • 4,828 View
  • 290 Download
  • 1 Web of Science
  • Crossref

Correspondence

SAFE score in chronic liver diseases: A tool for risk enrichment and personalized surveillance: Correspondence to letter to the editor on “High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated steatotic liver disease”
Tung-Hung Su, Jia-Horng Kao
Clin Mol Hepatol 2026;32(3):e396-e398.
Published online September 1, 2025
DOI: https://doi.org/10.3350/cmh.2025.0940
  • 2,456 View
  • 32 Download

Original Articles

Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study
Xianhua Mao, Xinrong Zhang, Rongtao Lai, Ka-Shing Cheung, Man-Fung Yuen, Ramsey Cheung, Wai-Kay Seto, Mindie H. Nguyen
Clin Mol Hepatol 2025;31(3):1084-1099.
Published online April 23, 2025
DOI: https://doi.org/10.3350/cmh.2024.1096
Background/Aims
Information about the association of glucagon-like peptide-1 receptor (GLP-1RA) with liver and non-liver complications is insufficient in patients with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD). We conducted a target trial emulation study to evaluate whether GLP-1RA decreases the risk of liver and non-liver outcomes.
Methods
Patients with T2D and MASLD initiating GLP-1RA or dipeptidyl peptidase-4 inhibitor (DPP-4i) were included from 2013 to 2022 in Merative™ Marketscan® Research Databases. Primary outcomes included incidences of (1) hepatocellular carcinoma (HCC) and cirrhosis, and (2) cardiovascular disease (CVD), chronic kidney disease (CKD), and non-liver cancer. Inverse probability of treatment weighting was applied to balance baseline characteristics and Cox regression models were conducted to estimate hazard ratio (HR) and 95% confidence interval (CI).
Results
In the intention-to-treat design, GLP-1RA, compared with DPP-4i, had a significantly lower incidence (per 1,000 person-years) of HCC (0.8 vs. 1.7; HR 0.53, 95% CI 0.39–0.71), of cirrhosis (29.3 vs. 32.9; HR 0.91, 95% CI 0.86–0.96), of CVD (57.2 vs. 73.9; HR 0.90, 95% CI 0.86–0.95), of CKD (4.5 vs. 6.8; HR 0.73, 95% CI 0.64–0.84), and of non-liver cancer (16.9 vs. 22.9; HR 0.82, 95% CI 0.77–0.89). In the per-protocol design, significant inverse associations for these study outcomes still were observed, with HR 0.60–0.77.
Conclusions
In this emulated target trial of nationwide patients with T2D and MASLD, GLP-1RA use, when compared with DPP-4i, was associated with a significantly lower risk of liver and non-liver complications.

Citations

Citations to this article as recorded by  Crossref logo
  • Tirzepatide versus SGLT2 inhibitors for MASLD: a multi-institutional propensity score-matched cohort study
    Jheng-Yan Wu, Yu-Min Lin, Wan-Hsuan Hsu, Ting-Hui Liu, Ya-Wen Tsai, Po-Yu Huang, Min-Hsiang Chuang, Tsung Yu, Chih-Cheng Lai
    Hepatology International.2026; 20(2): 292.     CrossRef
  • Impact of newer antihyperglycemic agents on hepatic complications: A systematic review and meta-analysis of data from 5.3 million patients with type 2 diabetes mellitus
    Jiwon Yang, Yeongseok Hwang, Jin-Sung Ju, Seungbong Han, Jihyun An, Ju Hyun Shim
    Hepatology.2026;[Epub]     CrossRef
  • Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population‐Based Cohort Study
    Assaf Issachar, Talish Razi, Ilya Borochov, Hadar Duskin Bitan, Ronen Arbel
    Diabetes, Obesity and Metabolism.2026; 28(7): 5704.     CrossRef
  • Early cancer risk reduction after GLP-1RA use: Signal or bias?: Letter to the editor on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic l
    Shio-Shin Jean, Chih-Cheng Lai
    Clinical and Molecular Hepatology.2026; 32(2): e163.     CrossRef
  • Letter to the editor on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study”
    Chunyan Wang, Xu Han, Yinyan Li
    Clinical and Molecular Hepatology.2026; 32(2): e167.     CrossRef
  • Correspondence to letter to the editor 1 on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study
    Xianhua Mao, Mindie H. Nguyen
    Clinical and Molecular Hepatology.2026; 32(2): e231.     CrossRef
  • Correspondence to letter to the editor 2 on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study
    Xianhua Mao, Mindie H. Nguyen
    Clinical and Molecular Hepatology.2026; 32(2): e249.     CrossRef
  • Letter to the editor on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study”
    Xingyu Yao
    Clinical and Molecular Hepatology.2026; 32(2): e165.     CrossRef
  • Correspondence to editorial on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study”
    Xianhua Mao, Mindie H. Nguyen
    Clinical and Molecular Hepatology.2026; 32(2): e219.     CrossRef
  • Reply to correspondence on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study”
    Xingyu Yao
    Clinical and Molecular Hepatology.2026; 32(2): e267.     CrossRef
  • GLP-1RA may open a new era for MASLD treatment: Editorial on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target tria
    Ye Feng, Chengfu Xu
    Clinical and Molecular Hepatology.2026; 32(2): 924.     CrossRef
  • Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach
    Beom Kyung Kim
    The Kaohsiung Journal of Medical Sciences.2026;[Epub]     CrossRef
  • Secular Trend in Glycaemic Management in Type 2 Diabetes Patients With and Without Cirrhosis Between 2000 and 2023: A Territory‐Wide Cohort Study
    Mary Yue Wang, Sherlot Juan Song, Nana Peng, Grace Lai‐Hung Wong, Vincent Wai‐Sun Wong, Jimmy Che‐To Lai, Terry Cheuk‐Fung Yip
    Alimentary Pharmacology & Therapeutics.2026; 64(3): 356.     CrossRef
  • GLP-1 receptor agonist–SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes
    Xianhua Mao, Hong Fan, Man-Fung Yuen, Ramsey Cheung, Wai-Kay Seto, Mindie H. Nguyen
    Hepatology.2026;[Epub]     CrossRef
  • Tumor microenvironment and metabolic reprogramming in MASLD-related hepatocellular carcinoma
    Vanilla X. Zhang, Tiffany C.-Y. Yu, Yu M. Tsui, Irene O.-L. Ng
    Trends in Molecular Medicine.2026;[Epub]     CrossRef
  • Hepatic Events Prevention by Antihyperglycemic Therapies and Intervention Comparisons in Type 2 Diabetes: The HEPATIC-T2DM Network Meta-analysis
    Pedro Robson Costa Passos, Rodrigo Motta, Valbert Oliveira Costa Filho, Mariana Macambira Noronha, Roberto Cavalcante Venâncio, Guilherme Grossi Lopes Cançado, Amanda Adler, Jeremy F. Cobbold, Jeremy W. Tomlinson
    Diabetes Care.2026; 49(6): 1144.     CrossRef
  • Predictors of Discordance Between Controlled Attenuation Parameter and Magnetic Resonance-Proton Density Fat Fraction in Hepatic Steatosis
    Dong Yun Kim, Hyung-Jin Rhee, Beom Kyung Kim
    Clinical and Translational Gastroenterology.2026;[Epub]     CrossRef
  • Glucagon-Like Peptide-1 Receptor Agonist Use and Liver-Related Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes in the All of Us Research Program
    Erik Almazan, Jonggi Choi, Tushar Kamath, Vy H. Nguyen, Eric Przybyszewski, Jiunn Song, Allison Carroll, Megan Michta, Tracey G. Simon, Raymond T. Chung
    American Journal of Gastroenterology.2026;[Epub]     CrossRef
  • Association between hemoglobin glycation index and new-onset diabetes mellitus in individuals with chronic liver disease: Findings from a prospective cohort study using CHARLS data
    Yanyan Mao, Hui Kong, Li Wang, Fangyan Liao, Xiangwen Li
    Medicine.2026; 105(27): e49567.     CrossRef
  • Glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors after liver resection for hepatocellular carcinoma in patients with type 2 diabetes: a target trial emulation study
    Yan-Jun Xiang, Zong-Han Liu, Jin-Kai Feng, Ying-Yi Qin, Hong-Ming Yu, Yu-Qiang Cheng, Gang Chen, Jia-Yi Wu, Yong-Yi Zeng, Yu-Fu Tang, Jian-Hua Rao, Feng-Min Zhang, Shi-Ye Yang, Gui-Ran Wang, Lin-Sen Ye, Ren Lang, Jian-Hua Lin, Yi-Tao Zheng, Ye-Fan Mao, Ho
    Gut.2026; : gutjnl-2026-338462.     CrossRef
  • How Negative Controls Are Used in Pharmacoepidemiology: A Methodological Scoping Review of Real‐World Observational Studies of Glucagon‐Like Peptide‐1 Receptor Agonists
    Zhengxuan Li, Yinan Huang, Hua Chen, Jieni Li
    Pharmacoepidemiology and Drug Safety.2026;[Epub]     CrossRef
  • Evaluating causal protective effect of dual GLP-1R/GIPR agonists on MASLD: A Mendelian randomization and colocalization study
    Yangke Cai, Siyuan Xie, Liyi Xu, Jiamin Chen, Jianting Cai
    European Journal of Pharmacology.2025; 1005: 178088.     CrossRef
  • Impaired Thyroid Hormone Sensitivity is Associated with Increased Risk of Liver Fibrosis in Euthyroid Population: A Cross-Sectional Analysis of NHANES
    Xingyu Yao, Kaiwen Xiao, Hein Ko Oo
    Hormone and Metabolic Research.2025; 57(09): 511.     CrossRef
  • 15,219 View
  • 332 Download
  • 21 Web of Science
  • Crossref
High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated steatotic liver disease
Tung-Hung Su, Sheng-Shun Yang, Mei-Hsuan Lee, Wei-Yu Kao, Shang-Chin Huang, Fen-Fang Chen, Francis SK Poon, Lung-Wen Tsai, Yi-Ting Chen, Che Lin, Weichung Wang, W Ray Kim, Jia-Horng Kao
Clin Mol Hepatol 2025;31(3):796-809.
Published online January 6, 2025
DOI: https://doi.org/10.3350/cmh.2024.0822
Background/Aims
There are no hepatocellular carcinoma (HCC) surveillance recommendations for non-viral chronic liver diseases (CLD), such as metabolic dysfunction-associated steatotic liver disease (MASLD). We explored the Steatosis-Associated Fibrosis Estimator (SAFE) score to predict HCC in MASLD and other CLD etiologies.
Methods
Patients with various CLDs were included from medical centers in Taiwan. The SAFE score, consisting of age, body mass index, diabetes, and laboratory data, was calculated at baseline, and patients were traced for new development of HCC. The predictability of the SAFE score for HCC was analyzed using the sub-distribution hazard model with adjustments for competing risks.
Results
Among 12,963 CLD patients with a median follow-up of 4 years, 258 developed HCC. The SAFE score classifies 1-, 3-, and 5-year HCC risk regardless of CLD etiologies. High (≥100) and intermediate (0–100) SAFE scores increased 11 and 2 folds HCC risks compared to low (<0) SAFE scores. Combining two lower risk tiers (SAFE<100), a high SAFE score (≥100) was associated with a 7.5-fold risk of HCC (adjusted sub-distributional hazard ratio [aSHR] 7.54; 95% confidence interval (CI) 5.38–10.60). A high SAFE score increased the risks of HCC in subgroups of viral hepatitis, non-viral hepatitis (aSHR 11.10; 95% CI 3.97–31.30) and MASLD (aSHR 4.23; 95% CI 1.43–12.50). A hospital cohort (n=8,103) and a community MASLD cohort (n=120,166) validated the high SAFE score (≥100) for HCC risk prediction.
Conclusions
The SAFE score stratifies high risks for HCC in CLD patients regardless of etiologies and helps to select at-risk candidates for HCC surveillance.

Citations

Citations to this article as recorded by  Crossref logo
  • HCC predictors in routine practice for patients with chronic liver diseases: Correspondence to editorial on “High SAFE scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction associated steatotic liver disease”
    Tung-Hung Su, Jia-Horng Kao
    Clinical and Molecular Hepatology.2026; 32(1): e52.     CrossRef
  • Can SAFE score be utilized as a universal hepatocellular carcinoma prediction score?: Editorial on “High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated
    Michael Kwan-Lung Ko, Loey Lung-Yi Mak
    Clinical and Molecular Hepatology.2026; 32(1): 371.     CrossRef
  • Risk stratification for hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: Editorial on “High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic
    Ho Soo Chun, Minjong Lee
    Clinical and Molecular Hepatology.2026; 32(1): 368.     CrossRef
  • Editorial: Residual HCC Risk After Hepatitis C Cure—Can Polygenic Risk Scores Refine Surveillance?
    Heechul Nam, Sung Won Lee
    Alimentary Pharmacology & Therapeutics.2026; 63(10): 1427.     CrossRef
  • Absence of steatosis combined with cardiometabolic risk factors confers the highest hepatocellular carcinoma risk in treated chronic hepatitis B
    Hung-Wei Wang, Hsueh-Chou Lai, Wei-Fan Hsu, Sheng-Hung Chen, Yi-Chun Kuo, Cheng-Yuan Peng
    Annals of Medicine.2026;[Epub]     CrossRef
  • Predictors of Discordance Between Controlled Attenuation Parameter and Magnetic Resonance-Proton Density Fat Fraction in Hepatic Steatosis
    Dong Yun Kim, Hyung-Jin Rhee, Beom Kyung Kim
    Clinical and Translational Gastroenterology.2026;[Epub]     CrossRef
  • 16,057 View
  • 435 Download
  • 5 Web of Science
  • Crossref

Editorial

Steatotic liver disease

Vibration-controlled transient elastography in shaping the epidemiology and management of steatotic liver disease: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023”
Xiao-Dong Zhou, Terry Cheuk-Fung Yip, Daniel Q Huang, Mark Dhinesh Muthiah, Mazen Noureddin, Ming-Hua Zheng
Clin Mol Hepatol 2025;31(2):620-624.
Published online December 26, 2024
DOI: https://doi.org/10.3350/cmh.2024.1131

Citations

Citations to this article as recorded by  Crossref logo
  • Liver Fibrosis and the Risk of Coronary Artery Disease, Stent Thrombosis, Restenosis and Adverse Clinical Outcomes
    Na Tian, Tie Xiao, Tianyi Xia, Hai‐Yang Yuan, Michael D. Shapiro, Gregory Y. H. Lip, Cheng‐Han Fanren, Li‐You Lian, Chen‐Xiao Huang, Yi‐Xuan Wei, Giovanni Targher, Christopher D. Byrne, Cheng‐Lv Hong, Shenghong Ju, Ming‐Hua Zheng
    Alimentary Pharmacology & Therapeutics.2026; 63(1): 70.     CrossRef
  • Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply
    Xiao‐Dong Zhou, Yusuf Yilmaz, Ming‐Hua Zheng
    Alimentary Pharmacology & Therapeutics.2026; 63(1): 155.     CrossRef
  • Long-Term Glycemic Control and the Risk of Liver Stiffness Progression and Liver-Related Events in MASLD
    Xiao-Dong Zhou, Qin-Fen Chen, Seung Up Kim, Terry Cheuk-Fung Yip, Salvatore Petta, Atsushi Nakajima, Emmanuel Tsochatzis, Jérôme Boursier, Elisabetta Bugianesi, Hannes Hagström, Wah-Kheong Chan, Manuel Romero-Gomez, José Luis Calleja, Victor de Lédinghen,
    Clinical Gastroenterology and Hepatology.2026; 24(5): 1332.     CrossRef
  • Progression of Liver Fibrosis and Liver-related Event Risk in Metabolic Dysfunction-associated Steatotic Liver Disease at High Cardiovascular Risk
    Xiao-Dong Zhou, Qin-Fen Chen, Seung Up Kim, Terry Cheuk-Fung Yip, Salvatore Petta, Atsushi Nakajima, Emmanuel Tsochatzis, Jérôme Boursier, Elisabetta Bugianesi, Hannes Hagström, Wah-Kheong Chan, Manuel Romero-Gomez, José Luis Calleja, Victor de Lédinghen,
    Clinical Gastroenterology and Hepatology.2026;[Epub]     CrossRef
  • MASLD as a systemic metabolic disease: expanding the scope of cardiovascular-kidney-metabolic (CKM) syndrome
    Xiao-Dong Zhou, Qiong-Yue Fan, Giovanni Targher, Christopher D. Byrne, Qin-Fen Chen, Michael D. Shapiro, Yuxing Dong, Ki-Chul Sung, Gregory Y. H. Lip, Jeffrey V. Lazarus, Ming-Hua Zheng
    Science China Life Sciences.2026; 69(6): 1950.     CrossRef
  • Statins in MASLD: Challenges and Future
    Xiao-Dong Zhou, Mark D. Muthiah, Ming-Hua Zheng
    JHEP Reports.2025; : 101372.     CrossRef
  • Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
    Clinical and Molecular Hepatology.2025; 31(2): e180.     CrossRef
  • The association of advanced lung cancer inflammation index with non-alcoholic fatty liver disease in NHANES 2017–2020
    Lin Cheng, Shumeng Li, Hui Li, Jiafeng You, Mingwei Yu, Guowang Yang
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • 8,772 View
  • 77 Download
  • 7 Web of Science
  • Crossref

Reviews

Steatotic liver disease

Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease
Huma Saeed, Luis Antonio Díaz, Antonio Gil-Gómez, Jeremy Burton, Jasmohan S. Bajaj, Manuel Romero-Gomez, Marco Arrese, Juan Pablo Arab, Mohammad Qasim Khan
Clin Mol Hepatol 2025;31(Suppl):S94-S111.
Published online November 28, 2024
DOI: https://doi.org/10.3350/cmh.2024.0811
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a significant global health issue, affecting over 30% of the population worldwide due to the rising prevalence of metabolic risk factors such as obesity and type 2 diabetes mellitus. This spectrum of liver disease ranges from isolated steatosis to more severe forms such as steatohepatitis, fibrosis, and cirrhosis. Recent studies highlight the role of gut microbiota in MASLD pathogenesis, showing that dysbiosis significantly impacts metabolic health and the progression of liver disease. This review critically evaluates current microbiome-centered therapies in MASLD management, including prebiotics, probiotics, synbiotics, fecal microbiota transplantation, and emerging therapies such as engineered bacteria and bacteriophage therapy. We explore the scientific rationale, clinical evidence, and potential mechanisms by which these interventions influence MASLD. The gut-liver axis is crucial in MASLD, with notable changes in microbiome composition linked to disease progression. For instance, specific microbial profiles and reduced alpha diversity are associated with MASLD severity. Therapeutic strategies targeting the microbiome could modulate disease progression by improving gut permeability, reducing endotoxin-producing bacteria, and altering bile acid metabolism. Although promising, these therapies require further research to fully understand their mechanisms and optimize their efficacy. This review integrates findings from clinical trials and experimental studies, providing a comprehensive overview of microbiome-centered therapies’ potential in managing MASLD. Future research should focus on personalized strategies, utilizing microbiome features, blood metabolites, and customized dietary interventions to enhance the effectiveness of these therapies.

Citations

Citations to this article as recorded by  Crossref logo
  • Probiotic-Derived Strain-Specific Metabolites Ameliorate Metabolic Dysfunction–Associated Steatotic Liver Disease through Modulation of the Gut-Liver Axis
    Sang Jun Yoon, Jieun Choi, Sung-Min Won, Jeong Seok Yu, Hee Young Kim, Hyun Chae Joung, In Gyu Park, Jung A Eom, Sang Hak Han, Do Yup Lee, Ki Tae Suk
    Probiotics and Antimicrobial Proteins.2026; 18(3): 4353.     CrossRef
  • Sarcopenia and MASLD: novel insights and the future
    Chang-Hai Liu, Qing-Min Zeng, Won Kim, Seung Up Kim, Zobair M. Younossi, Giovanni Targher, Christopher D. Byrne, Christos S. Mantzoros, Phunchai Charatcharoenwitthaya, Isabelle Anne Leclercq, Manuel Romero-Gómez, Hong Tang, Ming-Hua Zheng
    Nature Reviews Endocrinology.2026; 22(3): 139.     CrossRef
  • Digoxin-induced gut dysbiosis: Mechanistic links to prostaglandin dysregulation and lipid metabolic imbalance
    Nila Ganamurali, Sarvesh Sabarathinam
    Prostaglandins & Other Lipid Mediators.2026; 182: 107055.     CrossRef
  • Guideline comparison for fatty liver disease: European (EASL-EASD-EASO) and Asian (APASL) perspectives
    Ludovico Abenavoli
    Expert Review of Gastroenterology & Hepatology.2026; 20(1): 5.     CrossRef
  • The Metabolic Dysfunction–Associated Steatotic Liver Disease–CKD Axis: Intersecting Pathways and Opportunities for Early Intervention
    Sriram Sriperumbuduri, Prathab Balaji Saravanan, Gaurav Gupta, Arun J. Sanyal
    Kidney International Reports.2026; 11(4): 103757.     CrossRef
  • Exercise-mimicking effects of betaine in chronic disease prevention and management
    Yuhui Xu, Jianhong Gao, Minghui Wang, Hu Zhang
    Frontiers in Nutrition.2026;[Epub]     CrossRef
  • Bacteroides eggerthii ameliorates metabolic dysfunction-associated steatotic liver disease through host–microbe signaling and highlights 2-hydroxyisocaproate as a potential effector
    Jiyi Choi, Moon Gyeong Yoon, Se Ha Jang, Geum Ok Baek, Hyun Sun Jung, Na-Rae Lee, Choong Hwan Lee, Ji Eun Han, Jae Youn Cheong, Jung Woo Eun, Soon Sun Kim
    Clinical and Molecular Hepatology.2026; 32(1): 239.     CrossRef
  • The Gut Commensal Butyricimonas Virosa Modulates Gut Microbiota‐Dependent Thiamine Metabolism and Attenuates Mouse Steatotic Liver Disease
    Ningning He, Haoyu Wang, Zizhen Yang, Hui Li, Bei Liu, Kaiwei Chen, Zhinan Wu, Xinnan Zhao, Hewei Liang, Mengmeng Wang, Xiaofang Li, Yiyi Zhong, Haifeng Zhang, Liang Xiao, Karsten Kristiansen, Jixing Peng, Yuanqiang Zou, Shangyong Li
    Advanced Science.2026;[Epub]     CrossRef
  • The Gut–Liver Axis in MASLD: From Host–Microbiome Crosstalk to Precision Therapeutics
    Ji Zhou, Bowen Zhu, Ziqian Bing, Tingting Wang, Yue Zhao
    Microorganisms.2026; 14(2): 471.     CrossRef
  • Therapeutic modulation of the gut-liver axis with faecalibacterium prausnitzii in metabolic dysfunction-associated steatohepatitis
    Han Chen, Yan Wang, Wei Su, Yicheng Liu, Shuo Li, Yun Liu, Xiaoying Zhou
    BMC Microbiology.2026;[Epub]     CrossRef
  • MetALD at the crossroads of metabolic and alcohol-related liver disease
    Gustavo Ayares, Luis Antonio Díaz, Juan Pablo Arab, Marco Arrese
    Trends in Endocrinology & Metabolism.2026;[Epub]     CrossRef
  • Prebiotic modulation of FMT donor microbiota enhances MASLD-relevant taxa and functions in an in vitro gut model
    Kait F Al, Suyang Jia, Michael Silverman, Gregor Reid, Jeremy P Burton, Seema Nair Parvathy
    Journal of Applied Microbiology.2026;[Epub]     CrossRef
  • Association of gut microbiota dietary index with MAFLD and the risk of liver fibrosis: the mediating effect of vitamins
    Jinlu Han, Teng Zhou, Jiong Chen, Ling Xu, Wen Shan, Qinghui Zhang
    Journal of Nutritional Science.2026;[Epub]     CrossRef
  • The Microbiome‐Gut‐Liver Axis Drives Post‐Kasai Fibrosis in Biliary Atresia: From Mechanism to Precision Intervention
    Jiwen Cheng
    Hepatology Research.2026; 56(5): 648.     CrossRef
  • Effects of Probiotic and Synbiotic Supplementation on Metabolic and Hepatic Outcomes in Children and Adolescents With Obesity, Including Those With Obesity‐Related Metabolic Dysfunction–Associated Steatotic Liver Disease: A Systematic Review and Meta‐Anal
    Pedram Pam, Mohammad Safari, Ali Hojati, Rasoul Zarrin, Amir Hossein Faghfouri
    Journal of Paediatrics and Child Health.2026; 62(5): 678.     CrossRef
  • Correspondence to letter to the editor on “Role of amino acids in the regulation of hepatic gluconeogenesis and lipogenesis in metabolic dysfunctionassociated steatotic liver disease”
    Eiji Kakazu, Masaaki Mino, Tatsuya Kanto
    Clinical and Molecular Hepatology.2026; 32(2): e235.     CrossRef
  • Gut microbiome and metabolic health: mechanisms and precision interventions
    Zhengrui Li, Sudeshna Samui, Ji'an Liu, Yang Yang, Xue Liu, Qingyu Chen, Jing Li, Divya Gopinath, Peng Luo, Dan Shan
    Gut Microbes.2026;[Epub]     CrossRef
  • Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach
    Beom Kyung Kim
    The Kaohsiung Journal of Medical Sciences.2026;[Epub]     CrossRef
  • Microbial dysbiosis in metabolic disorders: linking epigenomic regulation and pathological mechanisms
    Arun K. Sharma, Md Sayeed Akhtar, Khalid Orayj, Sadaf Farooqui, Abida Khan, Gunjan Sharma
    Drug Discovery Today.2026; 31(4): 104698.     CrossRef
  • Impact of probiotics and prebiotics on glucose/lipid metabolism in metabolic dysfunction-associated steatotic liver disease: mechanisms and implications
    Yinan Zhao, Ziyan Li, Guoying Yu
    Frontiers in Nutrition.2026;[Epub]     CrossRef
  • Maternal-Infant Gut Microbiota Transmission and the Early Origins of Metabolic Liver Diseases: Mechanisms and Interventional Opportunities
    Xinrui Meng, Xueping Wu, Huihui Sun, Jing Cong, Yuchao Gu
    Nutrition Reviews.2026;[Epub]     CrossRef
  • The Gut-Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Mechanisms, Microbiome Interactions and Therapeutic Targets
    Poonam Sahu, Trilochan Satapathy
    Probiotics and Antimicrobial Proteins.2026;[Epub]     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease: pathogenesis and novel treatment options
    Ruizhe Ren, Xiao Liang, Xiyang Wei
    Molecular Biomedicine.2026;[Epub]     CrossRef
  • Nutritional Interventions Targeting the Gut Microbiome in MASLD: From Prebiotics and Probiotics to Postbiotics and Fecal Microbiota Transplantation
    Carlo Acierno, Alfredo Caturano, Fannia Barletta, Luca Rinaldi, Ferdinando Carlo Sasso, Luigi Elio Adinolfi, Riccardo Nevola
    Nutrients.2026; 18(11): 1765.     CrossRef
  • Structural characterization of the pectic polysaccharide from corn silk and its protective mechanism against MASLD via regulation of the gut-liver axis
    Haichao Wang, Jiajing Yan, Haolin Jia, Xiaoyan Li, Bingxuan Li, Xuefang Zhang, Shujun Wang, Zheng Li, Yuhong Liu, Yifei Bian
    Carbohydrate Polymers.2026; : 125510.     CrossRef
  • Association between oral microbiome alpha and beta diversity and MASLD risk: a large-scale, population-based retrospective study
    Zeru Liu, Yizhi Mao, Lei Zhang, Beibei Wang, Jiaxuan Tian, Yanjun Li, Shuangshuang Li, Yinglong He, Meiyan Zeng, Pan Meng, Houpan Song
    Frontiers in Cellular and Infection Microbiology.2026;[Epub]     CrossRef
  • Association of prebiotic/probiotic intake with MASLD: evidence from NHANES and randomized controlled trials in the context of prediction, prevention, and a personalized medicine framework
    Senlin Wang, Ruimin Zhang, Peisen Guo, Huawu Yang, Yanjun Liu, Hongmei Zhu
    EPMA Journal.2025; 16(1): 183.     CrossRef
  • Deciphering the role of dietary modifications and gut dysbiosis in Non-Alcoholic Fatty Liver Disease
    Meenakshi Vachher, Kohinoor Kaur, Manisha Marothia, Archana Burman, Deepanjana, Savita Bansal
    Human Nutrition & Metabolism.2025; 40: 200305.     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management
    Luigi Elio Adinolfi, Aldo Marrone, Luca Rinaldi, Riccardo Nevola, Antonio Izzi, Ferdinando Carlo Sasso
    Exploration of Medicine.2025;[Epub]     CrossRef
  • Electroacupuncture Attenuates Intestinal Barrier Disruption via the α7nAChR-Mediated HO-1/p38 MAPK/NF-κB Pathway in a Mouse Model of Metabolic Dysfunction-Associated Fatty Liver Disease: A Randomized, Single-Blind, Controlled Trial
    Xiao Wang, Jiasen Sun, Peng Wang, Yimin Zhang, Jiuyang Chang, Zhijun Duan
    Biomedicines.2025; 13(4): 802.     CrossRef
  • Unraveling MASLD: The Role of Gut Microbiota, Dietary Modulation, and AI-Driven Lifestyle Interventions
    Carolina Jiménez-González, Marta Alonso-Peña, Paula Argos Vélez, Javier Crespo, Paula Iruzubieta
    Nutrients.2025; 17(9): 1580.     CrossRef
  • Harnessing nutrition to combat MASLD: a comprehensive guide to food-based therapeutic strategies
    Claudia Reytor-González, Daniel Simancas-Racines, Martín Campuzano-Donoso, Janeth Castano Jimenez, Náthaly Mercedes Román-Galeano, Gerardo Sarno, Evelyn Frias-Toral
    Food and Agricultural Immunology.2025;[Epub]     CrossRef
  • Gut microbiota modulation by Traditional Chinese Medicine: a translational strategy for metabolic dysfunction-associated steatotic liver disease
    Ting Zhou, Ziwen Jin, Rilei Jiang, Weiwei Li
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Orchestration of Gut–Liver-Associated Transcription Factors in MAFLD: From Cross-Organ Interactions to Therapeutic Innovation
    Ao Liu, Mengting Huang, Yuwen Xi, Xiaoling Deng, Keshu Xu
    Biomedicines.2025; 13(6): 1422.     CrossRef
  • Gut microbiota in liver diseases: initiation, development and therapy
    Jian-Xiu Yu, Jun Wu, Xin Chen, Su-gang Zang, Xue-bin Li, Li-Pei Wu, Shi-hai Xuan
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Medical Implications of Renaming Non-Alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Yu-Jin Choi, Chang-Gue Son
    Journal of Korean Medicine.2025; 46(2): 40.     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease (MASLD): emerging insights into gut microbiota interactions and therapeutic perspectives
    Wenchu Qian, Ling He, Chenxue Fu, Tiantian Zeng, Hanyu Wang, Haifang Li
    Exploration of Digestive Diseases.2025;[Epub]     CrossRef
  • Immune Microenvironment on the Molecular Mechanisms and Therapeutic Targets of MAFLD
    Zhonghao Jiang, Baolin Qian, Tongjie Xu, Junjie Bai, Wenguang Fu
    ImmunoTargets and Therapy.2025; Volume 14: 719.     CrossRef
  • Gut-Liver Axis: The Role of Intestinal Microbiota and Their Metabolites in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Chao Cui, Shuai Gao, Jingfei Shi, Kai Wang
    Gut and Liver.2025; 19(4): 479.     CrossRef
  • Association of the dietary index for gut microbiota and dietary inflammation index with metabolic dysfunction-associated steatotic liver disease and metabolic alcohol-associated liver disease
    Wenhao Wu, Zebin Hou
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Cholesterol and the gut-liver axis: unraveling their role in the onset and progression of metabolic-associated steatotic liver disease
    Luis A. Rodríguez-Rojas, Leticia Bucio-Ortiz, Verónica Souza-Arroyo, María Concepción Gutiérrez-Ruiz, Luis E. Gómez-Quiroz, Roxana U. Miranda-Labra
    Exploration of Digestive Diseases.2025;[Epub]     CrossRef
  • Exploring the interplay between metabolic dysfunction-associated fatty liver disease and gut dysbiosis: Pathophysiology, clinical implications, and emerging therapies
    Said A Al-Busafi, Ahmed Alwassief, Ali Madian, Hassan Atalla, Mohamed Alboraie, Ashraf Elbahrawy, Mohammed Eslam
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Present and Future Perspectives in the Treatment of Liver Fibrosis
    Lucia Cerrito, Linda Galasso, Jacopo Iaccarino, Alessandro Pizzi, Fabrizio Termite, Giorgio Esposto, Raffaele Borriello, Maria Elena Ainora, Antonio Gasbarrini, Maria Assunta Zocco
    Pharmaceuticals.2025; 18(9): 1321.     CrossRef
  • Mechanism of Huanglian Wendan Decoction in ameliorating non-alcoholic fatty liver disease via modulating gut microbiota-mediated metabolic reprogramming and activating the LKB1/AMPK pathway
    Jianping Zhu, Yuzhen Chen, Yidi Han, Ji Li, Fahrul Nurkolis
    PLOS One.2025; 20(9): e0331303.     CrossRef
  • Genome-Based Mexican Diet Bioactives Target Molecular Pathways in HBV, HCV, and MASLD: A Bioinformatic Approach for Liver Disease Prevention
    Leonardo Leal-Mercado, Arturo Panduro, Alexis José-Abrego, Sonia Roman
    International Journal of Molecular Sciences.2025; 26(18): 8977.     CrossRef
  • Impact of non-alcoholic hepatic steatosis on prognosis and clinical outcomes in gastric cancer patients undergoing laparoscopic distal gastrectomy
    Yi-Fan Zou, Yi-Gang Zhang, Zi-Chu Zhao, Zheng Li, Hong-Da Liu, Qing-Ya Li, Ze-Tian Chen, Cheng-Jun Zhu, Hai-Tao Liu, Ji-Wei Wang, Feng-Yuan Li, Lin-Jun Wang, Dian-Cai Zhang, Li Yang, Hao Xu, Ze-Kuan Xu, Sen Wang
    World Journal of Gastrointestinal Surgery.2025;[Epub]     CrossRef
  • Recent research advances in RNA m5C methylation modification in liver diseases
    Wenjuan Chen, Lifan Zhang, Xinyu Gu, Yafeng Liu, Shujun Zhang, Xinjun Hu, Penghui Li
    Frontiers in Molecular Biosciences.2025;[Epub]     CrossRef
  • Integrative gut microbiota and metabolomics reveals the mechanism of chicory extract in improving metabolic dysfunction-associated steatotic liver disease via gut-liver axis
    Haifeng Wang, Songlin Liu, Yonggang Chen, Weiwei Fang, Ying Cheng, Zhigang Zhang, Haiming Hu, Baifei Hu, Hongtao Liu
    Phytomedicine.2025; 148: 157404.     CrossRef
  • Harnessing Gut Microbiome–Brain–Liver Crosstalk: Novel Therapeutic Strategies for Metabolic Dysfunction‐Associated Steatotic Liver Disease
    Xingtao Zhao, Ruolan Li, Jingdong Zhao, Ruiqi Sun, Shuo Zhang, Qiong Pan, Hongyan Lu, Jin Chai
    Medicine Bulletin.2025; 1(2): 136.     CrossRef
  • Honeysuckle-derived exosome-like nanovesicles ameliorate metabolic-associated fatty liver disease by modulating gut microbiota and its metabolites
    Ping Li, Qingyuan Wu, Yuanhao Zhou, Xiaojuan Hu, Yan Tang, Yuanyuan Wang, Weijiao Fan, Yiyi Shan, Kexin Yu, Jie Wang, Shibing Wang, Xiao Ye, Huiyu Liu, Xiaozhou Mou
    Nano Research.2025; 18(12): 94907986.     CrossRef
  • Perturbed microbial ecology in pediatric systemic lupus erythematosus: Evidence from the gut microbiome and serum metabolome
    Bo Li, Tao Ma, Yanjun Jia, Chunfeng Mou, Meng Zeng, Jie Yu, Lin Zou, Xiaoqiang Li, Han Wang
    Genes & Diseases.2025; : 101932.     CrossRef
  • The Gut-Liver Axis: Molecular Mechanisms and Therapeutic Targeting in Liver Disease
    Liang Ma, He Wang, Qiuyu Jin, Zhiwen Sun, Shuang Yu, Yang Zhang
    International Journal of General Medicine.2025; Volume 18: 7531.     CrossRef
  • Interindividual variability in gut microbiome mediates the efficacy of resistant starch on MASLD
    Xiaoxue Long, Hui Wang, Yuwei Lu, Xiaojing Gao, Yuanyuan Xiao, Mingliang Zhang, Jingyi Guo, Jingyi Yang, Ruiqi Zhang, Qian Li, Guiyun Zhou, Ruibao Yang, Feng Chen, Qingqing Wu, Liming Sun, Chengshuang Chu, Xuexue Zhu, Zhengjun Wu, Quanlu Ren, Chunping You
    Cell Metabolism.2025; 37(12): 2342.     CrossRef
  • Gut microbiota in hepatic encephalopathy: a 3PM-guided three-tier health strategy
    Jing Chen, Mingliao Niu, Longjiang Zhang
    EPMA Journal.2025; 17(1): 135.     CrossRef
  • An umbrella meta-analysis of microbial therapy on hepatic steatosis, fibrosis, and liver stiffness in metabolic dysfunction-associated steatotic liver disease
    Gvzalnur Kurban, Xiangjun Chen, Xingyi Jin, Hui Xia, Shaokang Wang, Guiju Sun
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Drug treatment of MASH from none to (too) many options?
    Amedeo Lonardo, Ralf Weiskirchen
    Exploration of Medicine.2025;[Epub]     CrossRef
  • Prebiotic and Probiotic Foods in MASLD: Microbiome-Mediated Therapeutic Strategies
    Cui Beiming, Liu Yujie, Hui-Eun Chang Joyce, Chen Jieying, Xu Jiahang, Teoh Jian-Peng, Loong Ho Chun
    Synthetic Biology and Engineering.2025; 3(4): 10018.     CrossRef
  • 16,739 View
  • 498 Download
  • 54 Web of Science
  • Crossref

Viral hepatitis

Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B
Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto
Clin Mol Hepatol 2025;31(Suppl):S182-S195.
Published online November 21, 2024
DOI: https://doi.org/10.3350/cmh.2024.0837
Chronic hepatitis B (CHB) poses a major global public health challenge and is a leading cause of cirrhosis and liver cancer. Hepatic steatosis is common in individuals with CHB compared to the non-CHB population and is particularly prevalent in hepatitis B virus (HBV)-endemic regions, affecting about one-third of CHB patients. The interaction between hepatic steatosis and CHB-related disease progression is complex and still under debate. Evidence demonstrates that co-existing steatosis may worsen liver fibrosis while paradoxically increasing the likelihood of achieving better HBV control. In particular, despite the association of steatotic liver disease (SLD) with lower HBV viral loads and higher rates of HBsAg seroclearance, the coexistence of CHB and SLD can potentially accelerate liver disease progression. Factors such as fat deposition, lipotoxicity, oxidative stress, and chronic inflammation in SLD may foster a pro-fibrotic and pro-carcinogenic environment, accelerating the disease progression. Additionally, loss of global DNA methylation, changes in the immune microenvironment, and genetic susceptibility further contribute to the development of CHB-related cirrhosis and hepatocellular carcinoma (HCC). This review examines the mechanisms driving liver disease progression and the heightened risk of cirrhosis and HCC in patients with concurrent CHB and steatotic liver disease, underscoring the importance of prioritizing antiviral therapy for CHB in addition to addressing SLD.

Citations

Citations to this article as recorded by  Crossref logo
  • Unraveling the metabolic thread: Type 2 diabetes and fibrosis in chronic hepatitis B with steatosis
    Won-Mook Choi, Wai-Kay Seto
    Hepatology.2026; 83(5): 1046.     CrossRef
  • Letter to the editor on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023”
    Sisi Yang, Zhenxuan Ma
    Clinical and Molecular Hepatology.2026; 32(1): e4.     CrossRef
  • Evaluation of PNPLA3 genetic variants in Egyptian HBV-infected patients concomitant with metabolic-associated steatotic liver disease (MASLD)
    Mai Abd El-Meguid, Ghada M. Salum, Basma E. Fotouh, Naglaa Zayed, Shereen Abdel Alem, Ayman Yosry, Reham M. Dawood
    Diagnostic Microbiology and Infectious Disease.2026; 114(2): 117105.     CrossRef
  • Diagnostic Performance of Ultrasound-Derived Fat Fraction and Automated Point Shear Wave Elastography for Hepatic Steatosis and Fibrosis in Suspected Steatotic Liver Disease: A Prospective Multicenter Study
    Jing Liang, Xueqi Li, Guangwen Cheng, Huixiong Xu, Yuli Zhu, Zhe Ma, Dong Jiang, Hao Han, Lin Chen, Liyun Xue, Xiaohui Qiao, Hong Ding
    Ultrasound in Medicine & Biology.2026; 52(1): 227.     CrossRef
  • The impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of pegylated interferon-based therapy in patients with chronic hepatitis B
    Jiaxin Han, Lianxin Xu, Yuqin Li, Ziling Wang, Minghui Zeng, Jieru Gao, Yuqiang Mi, Wentao Kuai, Huiling Xiang, Liang Xu
    Frontiers in Immunology.2026;[Epub]     CrossRef
  • Type 2 diabetes as a key metabolic risk factor for adverse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)id
    Heejoon Jang, Won Kim
    Clinical and Molecular Hepatology.2026; 32(1): 426.     CrossRef
  • Progress in research on the hepatoprotective effects of C-21 steroidal glycosides from Baishouwu
    Meitong Lu, Yongfang Ding, Yingyu Wang, Jinao Duan, Yunru Peng
    Journal of Ethnopharmacology.2026; 360: 121211.     CrossRef
  • Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: real-world data and 9-year extended follow-up of a randomized controlled trial
    Hyunjae Shin, Youngsu Park, Byeong Geun Song, Won-Mook Choi, Hyung Joon Han, Youngwoo Lee, Tae-Jin Song, Jong-Eun Yeon, Young-Suk Lim, Moon Haeng Hur, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Joon Hyeok Lee, Jung-Hwan Yoon, Jeong-Hoon Lee
    Cancer Immunology, Immunotherapy.2026;[Epub]     CrossRef
  • The nuclear transport machinery in hepatocellular carcinoma: From precancerous lesions to progression and therapeutic targeting
    Hongwei Yang, Haomin Wu, Haonan Zhou, Shiqi Liu, Mohan Xu, Di Wu, Yifan Jin, Ruilin Xing, Huili Zhang, Guang Wang, Gang Wu
    Genes & Diseases.2026; : 102065.     CrossRef
  • The impact of the COVID-19 pandemic on liver health: exploring shifts in social and psychosocial determinants of steatosis and fibrosis
    Yuan Zhao, Xuanhui Li, Jiacheng Cheng, Dongyu Hu, Huili Cao, Xiaojuan Wang, Junhua He, Yikun Zhu, Jin Li
    Frontiers in Medicine.2026;[Epub]     CrossRef
  • Concurrent Steatotic Liver Disease and Prognosis After Curative Resection of Hepatocellular Carcinoma
    Yan-Wen Liu, Chih-Chi Wang, Yueh-Wei Liu, Wei-Feng Li, Yi-Hao Yen, Yuan-Hung Kuo, Hsin-Ming Wang, Ming-Chao Tsai
    Journal of Hepatocellular Carcinoma.2026; Volume 13: 1.     CrossRef
  • HBV reprograms the tumor microenvironment in hepatocellular carcinoma: mechanisms and therapeutic implications
    Xiaodong Shen, Hechen Huang, Jianpeng Sheng, Xiaofeng Tang
    Clinical and Experimental Medicine.2026;[Epub]     CrossRef
  • Regulatory Role of Ribosome Biogenesis-Related Genes in Hepatocellular Carcinoma Prognosis and Construction of a Risk Prediction Model
    Shijing Tang, Hao Chen
    Digestive Diseases and Sciences.2026;[Epub]     CrossRef
  • Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of HCC Development in Patients With CHB
    Seong Hee Kang, Hyung Joon Yim, Seul Ki Han, Sun Young Yim, Tae Hyung Kim, Young‐Sun Lee, Seung Kak Shin, Young Kul Jung, Moon Young Kim, Ji Hoon Kim, Yeon Seok Seo, Oh. Sang Kwon, Jong Eun Yeon, Soon Koo Baik
    Journal of Gastroenterology and Hepatology.2026; 41(5): 1583.     CrossRef
  • The multifaceted roles of interleukin-36 in liver diseases: from pathogenesis to therapeutic potential
    Gui-Rong Rao, Shu-Ming Zhang, Xiao-Fei Yang, Li-Min Luo, Jian-Qi Lian, Ye Zhang
    International Immunopharmacology.2026; 177: 116566.     CrossRef
  • Steatosis paradox: Unraveling pathways of suppressive effect of hepatic steatosis on hepatitis B virus
    Shang-Chin Huang, Jia-Horng Kao
    Biomedical Journal.2026; 49(3): 100969.     CrossRef
  • Mechanisms and Management Strategies of Hepatocarcinogenesis Driven by Chronic Hepatitis B Comorbid with Type 2 Diabetes
    Qin Lou, Jiarong Cai, Jianhua Yin
    Microorganisms.2026; 14(4): 853.     CrossRef
  • Treatment strategies for patients with hepatitis B virus infection coexisting with hepatitis C virus or metabolic dysfunction-associated steatotic liver disease
    Chieh Liu, Yi-Fen Shih, Chun-Jen Liu
    Clinical and Molecular Hepatology.2026; 32(2): 565.     CrossRef
  • Absence of steatosis combined with cardiometabolic risk factors confers the highest hepatocellular carcinoma risk in treated chronic hepatitis B
    Hung-Wei Wang, Hsueh-Chou Lai, Wei-Fan Hsu, Sheng-Hung Chen, Yi-Chun Kuo, Cheng-Yuan Peng
    Annals of Medicine.2026;[Epub]     CrossRef
  • Retrospective analysis of predictors for significant hepatic inflammation in metabolic-associated fatty liver disease with chronic hepatitis B
    Long Hao Xu, Run Yan He, Yan Neng Kang, Heng Hong Lin, Jia En Yang, Hua Xiao Chen, Xue Ting Huang, Xiao Lu Wu, Bao Hui Pei, Chao Zhou, Min Wang
    PeerJ.2026; 14: e21186.     CrossRef
  • Impact of Chronic Hepatitis B and Its Clinical Phases on Liver Fibrosis and Cirrhosis in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Fajuan Rui, Jing Zhang, Hongshan Li, Yixuan Zhu, Yongfeng Yang, Liang Xu, Ming-Hua Zheng, Qi Zheng, Haijun Huang, Youwen Tan, Li Zhu, Wenjing Ni, Yan Wang, Fang Ji, Weimao Ding, Yuanwang Qiu, Zebao He, Qing-Lei Zeng, Chao Wu, Qing Xie, Junping Shi, Yuemin
    Clinical Gastroenterology and Hepatology.2026;[Epub]     CrossRef
  • Diagnostic efficacy and influencing factors of non-invasive liver fibrosis scores in chronic hepatitis B fibrosis: Cross-sectional study
    Chun-Xia Wang, Pan Yan, Li-Juan Lan, Ben-Nan Zhao, Jun Kang, Mao-Quan Li, Da-Feng Liu
    World Journal of Hepatology.2026;[Epub]     CrossRef
  • Aloe emodin isolated from Cassiae semen upregulates IFITM1 to suppress hepatitis B virus replication via the interferon signaling pathway
    Xin Wen, Xincan Yu, Yuxin Hu, Jiamin Chen, Dongwei Zhang, Yalin Hou, Shui Liu, Xuemeng Shi, Jun Xu, Felicia Goodrum
    mSphere.2026;[Epub]     CrossRef
  • Predictors of HBV-associated hepatocarcinoma: a scientific review
    M. A. Lobanova, N. E. Danilova, S. S. Sleptsova, S. S. Sleptsov
    Yakut Medical Journal.2026; (2): 91.     CrossRef
  • Liver-targeted alkaline phosphatase-activatable fluorescent probe for imaging liver fibrosis and screening anti-fibrotic natural products
    Yalin Li, Caijin Tang, Feng Bao, Bill Zhereng Liao, Chuzhen Zhang, Chen Chen, Lingyi Kong, Jianguang Luo
    Biosensors and Bioelectronics.2026; 311: 118958.     CrossRef
  • Pollutants in Microenvironmental Cellular Interactions During Liver Inflammation Cancer Transition and the Application of Multi-Omics Analysis
    Yulun Jian, Yuhan Li, Yanfeng Zhou, Wei Mu
    Toxics.2025; 13(3): 163.     CrossRef
  • Identification and evaluation of biomarkers for diagnosis of chronic hepatitis B using RNA-seq
    Hong Hong, Xintong Han, Qiuxiang Hu, Huafeng Song, Bing Han
    Virus Research.2025; 358: 199589.     CrossRef
  • Exosome in HBV infection: current concepts and future perspectives
    XueLan Yuan, ChunXia Huang, Yan Ran
    Frontiers in Cellular and Infection Microbiology.2025;[Epub]     CrossRef
  • Impact of Concurrent Steatotic Liver Disease and Chronic Hepatitis B on Treatment Response to Nucleos(t)ide Analogs
    Angela Chau, Jie Li, Dae Won Jun, Yao‐Chun Hsu, Hidenori Toyoda, Ming‐Lun Yeh, Tsunamasa Watanabe, Takashi Honda, Huy Trinh, Akito Nozaki, Haruki Uojima, Toru Ishikawa, Daniel Q. Huang, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masanori Atsukawa, Ma
    Journal of Viral Hepatitis.2025;[Epub]     CrossRef
  • Preoperative HBsAg seroclearance affects long-term outcomes for hepatitis B virus-related hepatocellular carcinoma after liver resection: a multicenter analysis
    Si-Yu Liu, Lin Zhu, Wen-Feng Lu, Gui-Lin Xie, Lei Liang, Jun-Wei Liu, Bin Ye, Mu-Gen Dai
    BMC Cancer.2025;[Epub]     CrossRef
  • Efficacy and safety of bifidobacterium triple viable capsules combined with entecavir in the treatment of Hepatitis B cirrhosis
    Rongquan Liu, Yun Ji, Jie Zhang
    Biomedical Papers.2025;[Epub]     CrossRef
  • EMP1 + hepatic stellate cells drive hepatic fibrosis progression to hepatocellular carcinoma and predict prognosis
    Jie You, Yihuan Huang, Chenhao Jiang, Jiaqi Xiao, Jiebin Zhang, Yasong Liu, Xin Sui, Yingcai Zhang, Jia Yao, Tongyu Lu
    Journal of Translational Medicine.2025;[Epub]     CrossRef
  • Prognostic Value of the PET/CT-Derived Maximum Standardized Uptake Value Combined with the Neutrophil–Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Undergoing Hepatectomy
    Tianyi Zhou, Chaoliu Dai
    Current Oncology.2025; 33(1): 13.     CrossRef
  • 12,160 View
  • 310 Download
  • 29 Web of Science
  • Crossref

Correspondence

Liver fibrosis, cirrhosis, and portal hypertension

Correspondence to editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis”
Young Eun Chon, Jung Hwan Yu, Seung Up Kim
Clin Mol Hepatol 2025;31(1):e61-e63.
Published online October 15, 2024
DOI: https://doi.org/10.3350/cmh.2024.0878

Citations

Citations to this article as recorded by  Crossref logo
  • Advances in Diagnostic and Therapeutic Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease
    Ryan Njeim, Omar Abureesh, Ali Sohail, Ryan Tam, Liliane Deeb
    Livers.2026; 6(3): 35.     CrossRef
  • 6,581 View
  • 45 Download
  • Crossref

Letter to the Editor

Steatotic liver disease

Letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”
Xiao-Song Li, Xi-Ping Shen, Hang Li
Clin Mol Hepatol 2025;31(1):e15-e16.
Published online September 12, 2024
DOI: https://doi.org/10.3350/cmh.2024.0784

Citations

Citations to this article as recorded by  Crossref logo
  • Correspondence to letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”
    Yuri Cho, Dae Won Jun
    Clinical and Molecular Hepatology.2025; 31(1): e103.     CrossRef
  • 6,102 View
  • 53 Download
  • 1 Web of Science
  • Crossref

Original Article

Steatotic liver disease

Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis
Young Eun Chon, Young-Joo Jin, Jihyun An, Hee Yeon Kim, Miyoung Choi, Dae Won Jun, Mi Na Kim, Ji Won Han, Han Ah Lee, Jung Hwan Yu, Seung Up Kim
Clin Mol Hepatol 2024;30(Suppl):S117-S133.
Published online August 21, 2024
DOI: https://doi.org/10.3350/cmh.2024.0392
Background/aims
Opinions differ regarding vibration-controlled transient elastography and magnetic resonance elastography (VCTE/MRE) cut-offs for diagnosing advanced fibrosis (AF) in patients with non-alcoholic fatty liver disease (NAFLD). We investigated the diagnostic performance and optimal cut-off values of VCTE and MRE for diagnosing AF.
Methods
Literature databases, including Medline, EMBASE, Cochrane Library, and KoreaMed, were used to identify relevant studies published up to June 13, 2023. We selected studies evaluating VCTE and MRE regarding the degree of liver fibrosis using liver biopsy as the reference. The sensitivity, specificity, and area under receiver operating characteristics curves (AUCs) of the pooled data for VCTE and MRE for each fibrosis stage and optimal cut-offs for AF were investigated.
Results
A total of 19,199 patients from 63 studies using VCTE showed diagnostic AUC of 0.83 (95% confidence interval: 0.80–0.86), 0.83 (0.80–0.86), 0.87 (0.84–0.90), and 0.94 (0.91–0.96) for ≥F1, ≥F2, ≥F3, and F4 stages, respectively. Similarly, 1,484 patients from 14 studies using MRE showed diagnostic AUC of 0.89 (0.86–0.92), 0.92 (0.89–0.94), 0.89 (0.86–0.92), and 0.94 (0.91–0.96) for ≥F1, ≥F2, ≥F3, and F4 stages, respectively. The diagnostic AUC for AF using VCTE was highest at 0.90 with a cut-off of 7.1–7.9 kPa, and that of MRE was highest at 0.94 with a cut-off of 3.62–3.8 kPa.
Conclusions
VCTE (7.1–7.9 kPa) and MRE (3.62–3.8 kPa) with the suggested cut-offs showed favorable accuracy for diagnosing AF in patients with NAFLD. This result will serve as a basis for clinical guidelines for non-invasive tests and differential diagnosis of AF.

Citations

Citations to this article as recorded by  Crossref logo
  • Even Lower Alcohol Intake Might Be Harmful for East Asian Males With MASLD Spectrum
    Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon
    Clinical Gastroenterology and Hepatology.2026; 24(6): 1644.     CrossRef
  • Non-invasive Risk-based Surveillance Strategy for Hepatocellular Carcinoma in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease
    Ji Won Han
    The Korean Journal of Gastroenterology.2026; 86(1): 62.     CrossRef
  • Liver fibrosis biomarkers as a prognostic tool beyond the defining components in cardiovascular-kidney-metabolic syndrome
    Zhenyang Cao, Binyan Chen, Jinghao Zhou, Jijie Jin, Dmitry Abramov, Shengzhang Chen, Pan Huang, Jianghua Zhou
    American Journal of Preventive Cardiology.2026; 26: 101438.     CrossRef
  • Diagnostic Value of MR Elastography and MRI‐Proton Density Fat Fraction in Cirrhosis Based on Explant Liver Histology
    Eun‐Ki Min, Seung‐seob Kim, Byungsoo Ahn, Deok‐Gie Kim, Dong Jin Joo, Sang Hoon Ahn, Seung Up Kim, Jae Geun Lee
    Journal of Gastroenterology and Hepatology.2026; 41(4): 1323.     CrossRef
  • Risk Stratification of Chronic Kidney Disease in Adults Using Noninvasive Fibrosis Tests Based on the American Diabetes Association Algorithm
    Chan‐Young Jung, Hye Won Lee, Jung Il Lee, Han Ah Lee, Seung Up Kim
    Diabetes, Obesity and Metabolism.2026; 28(6): 5240.     CrossRef
  • Metabolic dysfunction associated steatotic liver disease: mechanisms, diagnosis, and management in adults
    Tina Reinson, Josh Bilson, Caroline Childs, Ryan M Buchanan, Giovanni Targher, Christopher D Byrne
    BMJ Medicine.2026; 5(1): e002038.     CrossRef
  • Electroacupuncture in the treatment of non-alcoholic fatty liver disease: mechanistic insights and therapeutic potential
    Yi Wang, Lai Zhang
    Frontiers in Medicine.2026;[Epub]     CrossRef
  • Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach
    Beom Kyung Kim
    The Kaohsiung Journal of Medical Sciences.2026;[Epub]     CrossRef
  • Liver Fibrosis: Molecular Pathogenesis and Therapeutic Interventions
    Jiaorong Qu, Wenqing Qin, Minghang Dong, Zhi Ma, Si Li, Runping Liu, Ranyun Chen, Changmeng Li, Xiaojiaoyang Li
    MedComm.2026;[Epub]     CrossRef
  • Evolving B-mode ultrasound-based techniques for assessing metabolic dysfunction-associated steatotic liver disease: Now and beyond
    Walaa Abdelhamed, Mohamed Elbadry, Mohamed El-Kassas
    Liver Research.2026; 10(2): 109.     CrossRef
  • Gravitational 3D Magnetic Resonance Elastography for Differentiating Focal Nodular Hyperplasia and Hepatic Adenoma
    Leon David Gruenewald, Shayan Mansouri, Christian Booz, Jennifer Gotta, Philipp Reschke, Tommaso D’Angelo, Mohamed Alrahmoun, Scherwin Mahmoudi, Simon S. Martin, Katrin Eichler, Tatjana Gruber-Rouh, Stefan Zeuzem, Esra Görgülü, Melis Onay, Eva Herrmann, M
    Diagnostics.2026; 16(10): 1569.     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Clinical Profile, Phenotypes, and Risk Stratification. A Narrative Review
    Zalina Yuryevna Sozaeva, Marina Vsevolodovna Atayeva, Elizaveta Olegovna Salatova, Irina Kazbekovna Alikova, Alexandra Evgenievna Dolgaya, Amin Gasaevich Magomedov, Kamilla Ramisovna Hafsi, Nur-Mukhamed Aslanovich Shomakhov, Elena Mukhadinovna Pshukova, Y
    Journal of Biochemical Technology.2026; 17(2): 30.     CrossRef
  • Integrative and interpretable machine learning framework for early non-invasive detection of clinically significant liver fibrosis
    Dong Cao, Junjie Wang, Chenxi Hou, Jingyu Zeng, Baiyue Tian, Yuan Liu, Xing Luo, Jiaxin Tian, Mingbo Zhou, Pan Li, Huilong Fang, Ze Liu, Zheng Gong
    Frontiers in Medicine.2026;[Epub]     CrossRef
  • Rule-Out Cutoff of Two-Dimensional Shear Wave Elastography for Significant Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease: Systematic Review, Meta-Analysis, and External Validation
    Joo Hyun Oh, Jonghyun Lee, Miyoung Choi, Kento Imajo, Masato Yoneda, Hideki Fujii, Hyo Young Lee, Eileen L. Yoon, Mimi Kim, Dae Won Jun
    Clinical Gastroenterology and Hepatology.2026;[Epub]     CrossRef
  • Correspondence to editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analy
    Young Eun Chon, Jung Hwan Yu, Seung Up Kim
    Clinical and Molecular Hepatology.2025; 31(1): e61.     CrossRef
  • Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fib
    Won Sohn
    Clinical and Molecular Hepatology.2025; 31(1): 277.     CrossRef
  • Correspondence to editorial on “Optimal cutoffs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analys
    Jung Hwan Yu, Seung Up Kim
    Clinical and Molecular Hepatology.2025; 31(1): e52.     CrossRef
  • Towards unification of liver stiffness measurement cutoffs: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver d
    Yangyue Zhang, Vincent Wai-Sun Wong
    Clinical and Molecular Hepatology.2025; 31(1): 264.     CrossRef
  • Sustainability of General Population Screening for Steatotic Liver Disease: A Proof-of-Concept Study
    Laura De Rosa, Gabriele Ricco, Maurizia Rossana Brunetto, Ferruccio Bonino, Francesco Faita
    Healthcare.2025; 13(7): 759.     CrossRef
  • Therapeutic Efficacy of Silymarin, Vitamin E, and Essential Phospholipid Combination Therapy on Hepatic Steatosis, Fibrosis, and Metabolic Parameters in MASLD Patients: A Prospective Clinical Study
    Dan-Ionuț Gheonea, Cristina Tocia, Victor-Mihai Sacerdoțianu, Alexandra-Georgiana Bocioagă, Irina-Paula Doica, Nicolae Cătălin Manea, Adina Turcu-Știolică, Carmen-Nicoleta Oancea, Eugen Dumitru
    International Journal of Molecular Sciences.2025; 26(12): 5427.     CrossRef
  • Deep learning radiomics of elastography for diagnosing compensated advanced chronic liver disease: an international multicenter study
    Xue Lu, Haoyan Zhang, Hidekatsu Kuroda, Matteo Garcovich, Victor de Ledinghen, Ivica Grgurević, Runze Linghu, Hong Ding, Jiandong Chang, Min Wu, Cheng Feng, Xinping Ren, Changzhu Liu, Tao Song, Fankun Meng, Yao Zhang, Ye Fang, Sumei Ma, Jinfen Wang, Xiaol
    Visual Computing for Industry, Biomedicine, and Art.2025;[Epub]     CrossRef
  • Liver disease in people with latent autoimmune diabetes in adults (LADA): A cross-sectional study using magnetic resonance elastography
    Ernesto Maddaloni, Marta Zerunian, Vincenzo Cardinale, Annalisa Zurru, Rocco Amendolara, Daniela Luverà, Renata Risi, Luca D’Onofrio, Benedetta Masci, Francesco Covotta, Damiano Caruso, Domenico Alvaro, Andrea Laghi, Raffaella Buzzetti
    Diabetes Research and Clinical Practice.2025; 229: 112465.     CrossRef
  • Paired snRNA-seq and scRNA-seq analysis of MASLD patients to identify early-stage markers for disease progression
    Suebin Park, Su-Hyeon Lee, Se-eun Han, Beom Kyung Kim, Byungjin Hwang
    Hepatology Communications.2025;[Epub]     CrossRef
  • Lean Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Wolf in Sheep's Clothing
    Xixi Fang, Chenhao Xu, Jun Lu, Runzhou Zhuang, Xiao Xu, Xuyong Wei
    Cell Biochemistry and Function.2025;[Epub]     CrossRef
  • Mistakes in the utilization of vibration-controlled transient elastography in the evaluation of liver fibrosis: a narrative review
    Madunil Anuk Niriella, Uditha Bandara Dassanayake, Charith Priyanga Madurapperuma, Indeewari Prathibha Wijesingha, Arjuna Priyadarshin De Silva, Hithnadura Janaka de Silva
    Expert Review of Gastroenterology & Hepatology.2025; 19(12): 1299.     CrossRef
  • Transient Elastography and Fibroscan: Stethoscope of a Hepatologist in Today’s World
    Sajid Jalil, Mangesh Pagadala, Nicholas Dunn, Hanna Blaney, Mohamed Elfeki, Nimish Thakral, Ashwani K. Singal
    Current Hepatology Reports.2025;[Epub]     CrossRef
  • Comparative analysis of non-invasive fibrosis markers: Insights from chronic HBV, HBV+HDV, and HCV infections
    Aziza Saydullaevna Khikmatullaeva, Krestina Stepanovna Brigida, Nargiza Mirzakhidovna Мirrakhimova, Muazzam Alievna Аbdukadirova, Nargiz Sapievna Ibadullaeva, Allabergan Kadirovich Bayjanov, Nataliya Georgiyevna Kan, Malika Erkinovna Khodjaeva, Nargiza An
    Infectious Medicine.2025; 4(4): 100220.     CrossRef
  • 12,624 View
  • 260 Download
  • 26 Web of Science
  • Crossref

Reply to Correspondence

Steatotic liver disease

Reply to correspondence on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”
Jae Hyun Bae
Clin Mol Hepatol 2024;30(4):1047-1049.
Published online August 19, 2024
DOI: https://doi.org/10.3350/cmh.2024.0666
  • 5,166 View
  • 59 Download

Editorial

Steatotic liver disease

Racial and ethnic disparities in metabolic dysfunction-associated steatotic liver disease outcomes: A call for culturally sensitive interventions: Editorial on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”
Jae Hyun Bae
Clin Mol Hepatol 2024;30(4):665-668.
Published online July 29, 2024
DOI: https://doi.org/10.3350/cmh.2024.0562

Citations

Citations to this article as recorded by  Crossref logo
  • Prevalence and risk factors for metabolic dysfunction–associated steatotic liver disease in Sweden: Insights from the SCAPIS cohort
    Oumarou Nabi, Jonas Spaak, Göran Bergström, Gunnar Engström, Carl Johan Östgren, Andrei Malinovschi, Joel Kullberg, Anders Blomberg, Tomas Jernberg, Daniel P. Andersson, Hannes Hagström
    Journal of Internal Medicine.2026; 299(4): 481.     CrossRef
  • Resveratrol dual efficacy in high-altitude hypoxia and NAFLD: inhibits ferroptosis by modulating key proteins, including HIF-1α, ACSL4, and TfR1
    Minghui Zhao, Hongfang Mu, Qian Ji, Jiale Song, Fuyixuan Zheng, Tianlong Liu, Wenbin Li, Rong Wang
    Phytomedicine.2026; 153: 157992.     CrossRef
  • Association of serum uric acid and serum uric acid/creatinine ratio with metabolic dysfunction-associated fatty liver disease in young adults: a retrospective study
    Yue Li, Zixian Li, Siyu Wu, Ling Cao, Beibei Qian, Junxian Tao, Zhimin Qian, Li Xie, Xiaoli Cai, Xiaofang Sun, Ying Li, Zhenwen Zhang, Caifeng Yan, Dunmin She
    BMC Endocrine Disorders.2026;[Epub]     CrossRef
  • MASLD In Children - A Distinct Phenotype?
    Pervej Alom Barbhuiya, Manash Pratim Pathak
    Current Obesity Reports.2026;[Epub]     CrossRef
  • Hepatic Outcomes in Lean Versus Nonlean Metabolic Dysfunction–Associated Steatotic Liver Disease: Propensity‐Matched Cohort Study
    Rishi Chowdhary, Manjeet Kumar Goyal, Ashita Rukmini Vuthaluru, Megh Patel, Tanisha Sehgal, Kirti Arora, Rahul Chowdhary, Varun Mehta, Akash Batta, Omesh Goyal
    Hepatology Research.2026; 56(6): 1026.     CrossRef
  • Use of Hepatoscope 2DTE for non-invasive assessment of liver stiffness among Mexican immigrant adults in a community-based setting
    Edgar A. Villavicencio, Cindy Serdjebi, Adriana Maldonado, Estefania Ochoa Mora, Adrien Besson, Naim Alkhouri, David O. Garcia
    Clinics and Research in Hepatology and Gastroenterology.2025; 49(5): 102581.     CrossRef
  • Frailty and MASLD in the Arab region: An urgent call for regional clinical and public health strategies
    Mohamed El-Kassas, Khalid Alswat, Asma Labidi, Maen Almattooq, Doaa Zakaria, Nabil Debzi, Faisal M Sanai, Mohamed Elbadry, Ali Tumi, Imam Waked, Abdel-Naser Elzouki, Khalid M. AlNaamani
    Arab Journal of Gastroenterology.2025; 26(4): 315.     CrossRef
  • Dietary Interventions in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review of Evidence, Mechanisms, and Translational Challenges
    Alejandra Paredes-Marin, Yulu He, Xiaotao Zhang
    Nutrients.2025; 17(21): 3491.     CrossRef
  • Research and clinical trial design in patients with metabolic dysfunction and alcohol-associated steatotic liver disease (MetALD): a narrative review
    Pedro Acuña, Omar Albhaisi, Francisco Idalsoaga, Naim Alkhouri, Mazen Noureddin, Luis Antonio Díaz, Juan Pablo Arab
    Metabolism and Target Organ Damage.2025;[Epub]     CrossRef
  • Correspondence to editorial on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”
    Vy H. Nguyen, Mindie H. Nguyen
    Clinical and Molecular Hepatology.2024; 30(4): 1000.     CrossRef
  • Reply to correspondence on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”
    Jae Hyun Bae
    Clinical and Molecular Hepatology.2024; 30(4): 1047.     CrossRef
  • 6,904 View
  • 106 Download
  • 13 Web of Science
  • Crossref

Correspondence

Steatotic liver disease

The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease”
Yiyuan Zheng, Zhekun Xiong, Lina Zhao, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Fengbin Liu, Yong Li
Clin Mol Hepatol 2024;30(4):1019-1022.
Published online July 8, 2024
DOI: https://doi.org/10.3350/cmh.2024.0471

Citations

Citations to this article as recorded by  Crossref logo
  • Integrative Bioinformatics Analysis of Liver Transcriptomics and Serum Fibroblast Growth Factor 21 Protein Levels in Monitoring Progressive Fibrotic Liver Disease
    Hawraa M. Alaa Alden, Haneen Rafea Ali, Afrah Jabbar Lazim, Ahmed AbdulJabbar Suleiman
    Mathematical Biology and Bioinformatics.2026; 21(1): 175.     CrossRef
  • Selenoprotein P deficiency in MASLD: association with insulin resistance and liver fibrosis: a prospective case-control study
    Mona A Hegazy, Samar Saad Mohamed, Eman H Saad, Ahmed Abdelghani, Dalia Abd el Fattah, Mohamed Ahmed Elsayed Mekki, Mona Fathy, Nora Hassan, Omar Ashoush
    BMC Gastroenterology.2026;[Epub]     CrossRef
  • Single‑cell RNA sequencing analysis of intrahepatic cholangiocarcinoma reveals SPP1 facilitates disease progression via interaction with CD4+ T cells
    Xian Lin, Huanyan Peng, Ke Liu, Wenqi Chen, Ximing Shao, Chun Ning, Hongchang Li, Dongye Yang
    Oncology Letters.2025; 30(2): 1.     CrossRef
  • 6,583 View
  • 81 Download
  • 1 Web of Science
  • Crossref

Editorial

Steatotic liver disease

Macrophage ATG16L1: Potential candidate for metabolic dysfunction-associated steatohepatitis treatment: Editorial on “Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy”
Junjie Yu
Clin Mol Hepatol 2024;30(4):721-723.
Published online June 18, 2024
DOI: https://doi.org/10.3350/cmh.2024.0443
  • 5,214 View
  • 83 Download
  • 1 Web of Science

Letters to the Editor

Steatotic liver disease

Changing from NAFLD to MASLD: Cumulative incidence of gallstones between patients with NAFLD and those with MASLD in Asia
Shuhei Fukunaga, Tomoyuki Nakane, Michita Mukasa, Hidetoshi Takedatsu, Takumi Kawaguchi
Clin Mol Hepatol 2024;30(4):959-961.
Published online May 10, 2024
DOI: https://doi.org/10.3350/cmh.2024.0233

Citations

Citations to this article as recorded by  Crossref logo
  • Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases
    Yiyuan Xiao, Sihua Xu, Wenyan Hu, Jiapeng Huang, Deke Jiang, Rong Na, Zhaoqing Yin, Jingjing Zhang, Haitao Chen
    Annals of Hepatology.2025; 30(1): 101750.     CrossRef
  • Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma
    Toru Nakamura, Atsutaka Masuda, Dan Nakano, Keisuke Amano, Tomoya Sano, Masahito Nakano, Takumi Kawaguchi
    Cells.2025; 14(6): 428.     CrossRef
  • Association between fibrosis-4 index (FIB-4) and gallstones: an analysis of the NHANES 2017–2020 cross-sectional study
    Huqiang Dong, Zufa Zhang, Chang Fu, Mixue Guo, Haifeng Zhang, Xintian Cai, Hongping Cheng
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • The effects of next generation probiotics on metabolic dysfunction-associated steatotic liver disease: a parallel, double-blind, randomized, placebo-controlled trial
    Sung-Min Won, Hyunchae Joung, In Gyu Park, Sang Hak Han, Young Lim Ham, Ji Sook Han, Yoojin Kwon, Dong Joon Kim, Ki Tae Suk
    Journal of Translational Medicine.2025;[Epub]     CrossRef
  • Association between nonalcholic fatty liver disease and pancreatic cancer: Epidemiology, mechanisms, and antidiabetic medication
    Takahiko Sakaue, Hiroya Terabe, Hidetoshi Takedatsu, Takumi Kawaguchi
    Hepatology Research.2024; 54(8): 729.     CrossRef
  • The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic
    Yiyuan Zheng, Zhekun Xiong, Lina Zhao, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Fengbin Liu, Yong Li
    Clinical and Molecular Hepatology.2024; 30(4): 1019.     CrossRef
  • 5,494 View
  • 80 Download
  • 6 Web of Science
  • Crossref

Steatotic liver disease

Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia
Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi
Clin Mol Hepatol 2024;30(3):577-579.
Published online March 6, 2024
DOI: https://doi.org/10.3350/cmh.2024.0157

Citations

Citations to this article as recorded by  Crossref logo
  • Serum Desmosterol Level Reflects Hepatic Inflammation Grade in Patients with Biopsy-Confirmed Metabolic Dysfunction-Associated Steatotic Liver Disease
    Takashi Omatsu, Masahiro Koseki, Kaori Ito, Ayami Saga, Hiroshi Sawabe, Katsunao Tanaka, Hiroyasu Inui, Takeshi Okada, Makoto Nishida, Hirokazu Takahashi, Shinichi Aishima, Yoshihiro Kamada, Hiroshi Yoshida, Yasushi Sakata
    Journal of Atherosclerosis and Thrombosis.2026; 33(1): 29.     CrossRef
  • Assessing Nutritional Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease via Diverse Statistical Tools
    Yea-Chan Lee, Hye Sun Lee, Soyoung Jeon, Yae-Ji Lee, Yu-Jin Kwon, Ji-Won Lee
    Diabetes & Metabolism Journal.2026; 50(1): 178.     CrossRef
  • Reduced skeletal muscle mass and elevated phase angle are linked to metabolic dysfunction-associated steatotic liver disease in Japanese males
    Satoko Tajirika, Takao Miwa, Masahito Shimizu, Mayumi Yamamoto
    Nutrition.2026; 146: 113118.     CrossRef
  • Burden and Health System Challenges in MASLD Across East and Southeast Asia: A Narrative Review
    Jonathan Jaime G. Guerrero, Paolo C. Encarnacion, Wan‐Yu Wang, Shu‐Fen Liao, Ching‐Wen Chang
    Health Science Reports.2026;[Epub]     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases
    Yiyuan Xiao, Sihua Xu, Wenyan Hu, Jiapeng Huang, Deke Jiang, Rong Na, Zhaoqing Yin, Jingjing Zhang, Haitao Chen
    Annals of Hepatology.2025; 30(1): 101750.     CrossRef
  • Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease
    Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip
    Clinical and Molecular Hepatology.2025; 31(Suppl): S51.     CrossRef
  • Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma
    Toru Nakamura, Atsutaka Masuda, Dan Nakano, Keisuke Amano, Tomoya Sano, Masahito Nakano, Takumi Kawaguchi
    Cells.2025; 14(6): 428.     CrossRef
  • C-C motif chemokines ligand 7 contributes to metabolic dysfunction-associated steatotic liver disease by enabling redox-sensitive induction of hypermethylated in cancer 1
    Xinyue Sun, Jinge Wu, Huiqian Lv, Ben Wang, Xuelian Chen, Wenjing Ren, Xiulian Miao, Yan Guo, Xiaocen Kong, Huihui Xu, Zeqing Bao, Yong Xu, Zilong Li
    Metabolism.2025; 168: 156242.     CrossRef
  • Pemafibrate Reduced Liver Stiffness in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease Complicated with Hyperlipidemia and Liver Fibrosis with a Fibrosis-4 Index Above 1.3
    Tatsuki Ichikawa, Mio Yamashima, Shinobu Yamamichi, Makiko Koike, Yusuke Nakano, Hiroyuki Yajima, Osamu Miyazaki, Tomonari Ikeda, Takuma Okamura, Naohiro Komatsu, Sayuri Sugio, Miruki Yoshino, Hisamitsu Miyaaki
    Internal Medicine.2025; 64(9): 1296.     CrossRef
  • All-cause and disease-specific mortality in young adults with MASLD: A nationwide cohort study
    Jeayeon Park, Goh Eun Chung, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Eun Ju Cho
    JHEP Reports.2025; 7(9): 101477.     CrossRef
  • Evolving Public Attention to Steatotic Liver Disease: A 20‐Year Analysis (2004–2024)
    Pojsakorn Danpanichkul, Charat Thongprayoon, Kanokphong Suparan, Donghee Kim, Ornpailin Wanichthanaolan, Phuuwadith Wattanachayakul, Yanfang Pang, Mark D. Muthiah, Anand V. Kulkarni, Ju Dong Yang, Apichat Kaewdech, Wisit Cheungpasitporn, Karn Wijarnpreech
    Journal of Gastroenterology and Hepatology.2025; 40(8): 2053.     CrossRef
  • Impact of Continuous Nutritional Counseling on Liver Function and Body Composition in Patients with MASLD/MASH
    Shiho Asai, Naoto Kawabe, Akemi Ito, Teiji Kuzuya, Eizaburo Ohno, Takuji Nakano, Kazunori Nakaoka, Hiroyuki Tanaka, Yuka Ochi, Sayuri Miyaji, Sayaka Morisaki, Yoshiki Hirooka
    Kanzo.2025; 66(6): 222.     CrossRef
  • Temporal Trends in Cardiovascular Mortality in Underlying Viral Hepatitis: A Retrospective Analysis of Gender, Racial/Ethnic, and Regional Disparities
    Wania Sultan, Haider Ashfaq, Hamza Ashraf, Ahmad Khan, Ayman Omair Hashmi, Muhammad Omar Larik, Maheen Zahid, Yasir Majeed, Pratik Bhattarai, Ashujot K. Dang, Ahmed Ali Aziz, Hafiz Muhammad Sharjeel Arshad
    JGH Open.2025;[Epub]     CrossRef
  • Phocaeicola dorei ameliorates progression of steatotic liver disease by regulating bile acid, lipid, inflammation and proliferation
    Jieun Choi, Ye Rin Choi, Min Kyo Jeong, Hyun Ho Song, Jeong Seok Yu, Seol Hui Song, Jeong Ha Park, Min Ju Kim, Hyunjoon Park, Young Lim Ham, Sang Hak Han, Dong Joon Kim, Do Yup Lee, Ki Tae Suk
    Gut Microbes.2025;[Epub]     CrossRef
  • Usefulness of health checkup‐based indices in identifying metabolic dysfunction‐associated steatotic liver disease
    Takao Miwa, Satoko Tajirika, Nanako Imamura, Miho Adachi, Ryo Horita, Tatsunori Hanai, Cheng Han Ng, Mohammad Shadab Siddiqui, Taku Fukao, Masahito Shimizu, Mayumi Yamamoto
    JGH Open.2024;[Epub]     CrossRef
  • Association between nonalcholic fatty liver disease and pancreatic cancer: Epidemiology, mechanisms, and antidiabetic medication
    Takahiko Sakaue, Hiroya Terabe, Hidetoshi Takedatsu, Takumi Kawaguchi
    Hepatology Research.2024; 54(8): 729.     CrossRef
  • Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
    Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi
    Clinical and Molecular Hepatology.2024; 30(4): 962.     CrossRef
  • 7,319 View
  • 187 Download
  • 20 Web of Science
  • Crossref

Steatotic liver disease

Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Tsubasa Tsutsumi, Dan Nakano, Machiko Kawaguchi, Hirokazu Takahashi, Takumi Kawaguchi
Clin Mol Hepatol 2024;30(2):266-268.
Published online January 30, 2024
DOI: https://doi.org/10.3350/cmh.2024.0028

Citations

Citations to this article as recorded by  Crossref logo
  • Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease
    Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip
    Clinical and Molecular Hepatology.2025; 31(Suppl): S51.     CrossRef
  • Is type 2 diabetes a link between lung function and metabolic dysfunction–associated steatotic liver disease? Insights from population studies and Mendelian randomization
    Runmin Cao, Yurun Zhang, Ling Cao, Honghe Jiang
    European Journal of Gastroenterology & Hepatology.2025; 37(5): 652.     CrossRef
  • In-silico identification and experimental validation of shared genes and pathways to decipher the molecular links between COPD and MASLD
    Anupama Dubey, Praveen Kumar, Tahseen Khan, Suneel Kateriya, Dinesh Mani Tripathi, Umesh C.S. Yadav
    Computers in Biology and Medicine.2025; 194: 110532.     CrossRef
  • Increased risk of acute exacerbation in obstructive airway disease: the impact of metabolic dysfunction-associated steatotic liver disease and small airway dysfunction
    Che-Hao Tseng, Bor-Yang Jou, Hsiao-Chin Shen, Hsiao-Yun Yeh, Shiao-Ya Hong, Yi-Hsuan Lin, Hung-Cheng Tsai, Tzu-Hao Li, Chien-Wei Su, Kun-Ta Chou, Diahn Warng Perng, Ying-Ying Yang, Ming-Chih Hou
    BMJ Open Respiratory Research.2025; 12(1): e003352.     CrossRef
  • Association of hepatic steatosis and liver fibrosis with chronic obstructive pulmonary disease among adults
    Dayang Zheng, Xiang Liu, Wei Zeng, Wangyan Zhou, Chunxiang Zhou
    Scientific Reports.2024;[Epub]     CrossRef
  • 6,786 View
  • 80 Download
  • Crossref

Correspondence

Artificial intelligence, epidemiology, methodology, or others

Correspondence on Letter regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”
Yee Hui Yeo, Ju Dong Yang
Clin Mol Hepatol 2024;30(1):124-125.
Published online November 14, 2023
DOI: https://doi.org/10.3350/cmh.2023.0470

Citations

Citations to this article as recorded by  Crossref logo
  • Assessing ChatGPT for Clinical Decision-Making in Radiation Oncology, With Open-Ended Questions and Images
    Wei-Kai Chuang, Yung-Shuo Kao, Yen-Ting Liu, Cho-Yin Lee
    Practical Radiation Oncology.2025; 15(5): e412.     CrossRef
  • ChatGPT-4o, Gemini Advanced and DeepSeek R1 in preoperative decision-making for thyroid surgery: a comparative assessment with human surgeons
    Long Zou, Peng Zhang, Yu-qi Jiang, Xiao-wen Wang, Xi-jing Yan, Jie-zhong Wu, Jia Qi, Wen-chao Li, Qing-qing Cai, Zhi-rong Xuan, Kun-peng Hu
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Response to “ChatGPT’s ability to comprehend and answer cirrhosis related questions: Comment”
    Jamil S. Samaan, Yee Hui Yeo, Walid S. Ayoub
    Arab Journal of Gastroenterology.2024; 25(2): 237.     CrossRef
  • Research Progress in Predicting Hepatocellular Carcinoma with Portal Vein Tumour Thrombus in the Era of Artificial Intelligence
    Yaduo Li, Ningning Fan, Xu He, Jianjun Zhu, Jie Zhang, Ligong Lu
    Journal of Hepatocellular Carcinoma.2024; Volume 11: 1429.     CrossRef
  • 7,805 View
  • 61 Download
  • 2 Web of Science
  • Crossref

Letter to the Editor

Artificial intelligence, epidemiology, methodology, or others

Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”
Yiwen Zhang, Liwei Wu, Zepeng Mu, Linlin Ren, Ying Chen, Hanyun Liu, Lili Xu, Yangang Wang, Yaxing Wang, Susan Cheng, Yih Chung Tham, Bin Sheng, Tien Yin Wong, Hongwei Ji
Clin Mol Hepatol 2024;30(1):113-117.
Published online November 10, 2023
DOI: https://doi.org/10.3350/cmh.2023.0440

Citations

Citations to this article as recorded by  Crossref logo
  • Accuracy and readability of LLM-generated responses for gout management: a benchmark study based on ACR guidelines
    Zhuhai Shao, Yiwen Zhang, Bingfei Cheng, Fang Zhang, Xuhua Zhu, Zhongchao Wang, Yangang Wang, Lili Xu, Zepeng Mu
    Clinical Rheumatology.2026; 45(6): 3685.     CrossRef
  • Revolutionizing MASLD: How Artificial Intelligence Is Shaping the Future of Liver Care
    Nicola Pugliese, Arianna Bertazzoni, Cesare Hassan, Jörn M. Schattenberg, Alessio Aghemo
    Cancers.2025; 17(5): 722.     CrossRef
  • Large language models in thyroid diseases: Opportunities and challenges
    Yiwen Zhang, Pengfei Li, Lili Xu, Xuejuan Zhang, Hongwei Ji, Yangang Wang
    EngMedicine.2025; 2(2): 100076.     CrossRef
  • Preliminary fatty liver disease grading using general-purpose online large language models: ChatGPT-4 or Bard?
    Yiwen Zhang, Hanyun Liu, Bin Sheng, Yih Chung Tham, Hongwei Ji
    Journal of Hepatology.2024; 80(6): e279.     CrossRef
  • The performance of large language model-powered chatbots compared to oncology physicians on colorectal cancer queries
    Shan Zhou, Xiao Luo, Chan Chen, Hong Jiang, Chun Yang, Guanghui Ran, Juan Yu, Chengliang Yin
    International Journal of Surgery.2024; 110(10): 6509.     CrossRef
  • 8,779 View
  • 97 Download
  • 6 Web of Science
  • Crossref

Snapshot

Steatotic liver disease

Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease
Young Chang, Soung Won Jeong, Jae Young Jang
Clin Mol Hepatol 2024;30(1):129-133.
Published online October 13, 2023
DOI: https://doi.org/10.3350/cmh.2023.0356

Citations

Citations to this article as recorded by  Crossref logo
  • Efruxifermin in patients with metabolic dysfunction-associated steatohepatitis: A GRADE-assessed systematic review and meta-analysis
    Umama Alam, Shree Rath, Muhammad Ansab, Aamna Kashif, Furqan Ahmad Sethi, Hafiza Tooba Siddiqui, Zarar Ahmad Khan Afridi, Muhammad Burhan, Muhammad Abdullah Ali, Abdul Moiz, Zaryab Bacha, Ahmad Khan, Raheel Ahmed, Monsurah Bisola Alatise, Kamil Ahmad Kami
    World Journal of Hepatology.2026;[Epub]     CrossRef
  • Engineering Murine Cross‐Reactivity Into an Affibody to Human Death Receptor 5
    Tse‐Han Kuo, Nagamani Vunnam, Jonathan N. Sachs, Benjamin J. Hackel
    Biotechnology and Bioengineering.2026; 123(7): 1783.     CrossRef
  • Therapeutic Strategies for MASH: An Update on Drug Candidates Under Investigation in Late-Phase Clinical Trials
    Samuel Dinerman, Yan Shu
    International Journal of Translational Medicine.2025; 5(1): 7.     CrossRef
  • Identification of Novel Therapeutic Targets for MAFLD Based on Bioinformatics Analysis Combined with Mendelian Randomization
    Jialin Ren, Min Wu
    International Journal of Molecular Sciences.2025; 26(7): 3166.     CrossRef
  • Inflammation in MASLD progression and cancer
    Yeonsoo Kim, Yunseo Park, Hyunsoo Rho, Tiantian Yao, Bin Gao, Seonghwan Hwang
    JHEP Reports.2025; 7(8): 101414.     CrossRef
  • Chronic Inflammation and Immune Dysregulation in Metabolic-Dysfunction-Associated Steatotic Liver Disease Progression: From Steatosis to Hepatocellular Carcinoma
    Young-Min Jee, Jeong-Yoon Lee, Tom Ryu
    Biomedicines.2025; 13(5): 1260.     CrossRef
  • Isolation and Characterization of Secondary Metabolites from Hydractinia-Associated Fungus, Penicillium brevicompactum MSW10-1, and Their Inhibitory Effects on Hepatic Lipogenesis
    Hyeon-Jeong Hwang, Hyeokjin Lim, Jae Sik Yu, Eun Seo Jang, Youngsang Nam, Yeo Jin Lee, Eun La Kim, Seonghwan Hwang, Seoung Rak Lee
    Marine Drugs.2025; 23(7): 275.     CrossRef
  • Nanomedicines in the Treatment of Liver Fibrosis: A Review
    Xiao Du, Runyan Niu, Xuexue Liu, Fang Wu, Xian Yang, Xiaolong Ma, Jinping Zhang, Haihui Zhou, Lihua Shao, Siliang Wang
    International Journal of Nanomedicine.2025; Volume 20: 9641.     CrossRef
  • Neuro-endocrine-immune regulation of metabolic homeostasis
    Cong Xie, Yuhan Lin, Cong Qi, Wei Wang, Yulian Yuan, Dechao Song, Zheng Wang, Hanjie Liu, Xingzhong Feng, Huijuan Gao
    Cytokine & Growth Factor Reviews.2025; 85: 165.     CrossRef
  • Targeting Stearoyl-CoA Desaturase-1 (SCD1) by the Drug–Nutraceutical Combination of Montelukast and Bixin in Ameliorating Steatotic NAFLD
    Sonakshi Puri, Shivani Kirad, Shubhashree Dash, Pankaj Kumar Sharma, Murugesan Sankaranarayanan, Perinkulam Ravi Deepa
    ACS Omega.2025; 10(40): 47022.     CrossRef
  • Physicochemical characterization, lipid-modulating effects, and proteomic insights of Malaysian Sacha Inchi (Plukenetia volubilis L.) seed oil in HepG2 cells
    Mariam Fardush, Norsyahida Mohd Fauzi, Ho Wen Yan, Armania Nurdin, Ibrahim Jantan, Nor Azlan bin Nor Muhammad, Siti Nurlisa Hazim, Sarmila Hanim binti Mustafa, Kimberlyn Feguro
    Food Bioscience.2025; 74: 107891.     CrossRef
  • Redox Modulation in Hepatic Fibrosis: Translating NOX1/4 Inhibition to Therapy
    Ghaith K. Mansour, Ahmad W. Hajjar, Irene Marafini, Giovanni Monteleone
    International Journal of Molecular Sciences.2025; 27(1): 158.     CrossRef
  • Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: a Mendelian randomization and population-based cohort study
    Sung Won Chung, Hye-Sung Moon, Hyunjae Shin, Hyein Han, Sehoon Park, Heejin Cho, Jeayeon Park, Moon Haeng Hur, Min Kyung Park, Sung-Ho Won, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Dong Ki Kim, Jung-Hwan Yoon, Jeong-Hoon Lee, Yoon Jun Kim
    Hepatology.2024; 80(3): 633.     CrossRef
  • Effectiveness of the ALT/AST ratio for predicting insulin resistance in a Korean population: A large-scale, cross-sectional cohort study
    Seul Ki Han, Myung Jae Seo, Taesic Lee, Moon Young Kim, Anna Di Sessa
    PLOS ONE.2024; 19(5): e0303333.     CrossRef
  • Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis
    Renuka Suvarna, Sahana Shetty, Joseph M. Pappachan
    Scientific Reports.2024;[Epub]     CrossRef
  • Exploring the Role of Peroxisome Proliferator-Activated Receptors and Endothelial Dysfunction in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Ana Paula Madariaga Traconis, Misael Uribe-Esquivel, Varenka Julieta Barbero Becerra
    Cells.2024; 13(24): 2055.     CrossRef
  • 15,689 View
  • 209 Download
  • Crossref

Correspondence

Steatotic liver disease

Correspondence on Letter regarding “Risk factors in nonalcoholic fatty liver disease”
Eileen L. Yoon, Dae Won Jun
Clin Mol Hepatol 2023;29(4):1050-1051.
Published online August 29, 2023
DOI: https://doi.org/10.3350/cmh.2023.0310

Citations

Citations to this article as recorded by  Crossref logo
  • Reply to correspondence on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study”
    Eileen Laurel Yoon, Dae Won Jun
    Clinical and Molecular Hepatology.2024; 30(4): 1033.     CrossRef
  • 7,904 View
  • 52 Download
  • Crossref

Special Review

Steatotic liver disease

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
Gi-Ae Kim, Joon Ho Moon, Won Kim
Clin Mol Hepatol 2023;29(4):831-843.
Published online August 25, 2023
DOI: https://doi.org/10.3350/cmh.2023.0277
The existing term non-alcoholic fatty liver disease (NAFLD) has raised substantial concerns due to its inherent disadvantages of using exclusionary diagnostic criteria and the stigmatizing word ‘fatty.’ Three pan-national liver associations set out to explore a new nomenclature to replace both NAFLD and its suggested alternative, metabolic (dysfunction)-associated fatty liver disease (MAFLD). They surveyed if a change in nomenclature and/or definition is favored and which nomenclature best communicates disease characteristics and increases awareness. In lieu of NAFLD/MAFLD, metabolic dysfunction-associated steatotic liver disease (MASLD) has been chosen, and an umbrella term, steatotic liver disease (SLD), encompassing the whole spectrum of liver disease, has been proposed. It has been suggested that cardiometabolic risk factors should be considered when categorizing SLD patients. Furthermore, a new subcategory, MASLD with increased alcohol intake (MetALD), casts light on a neglected group of patients with moderate or more alcohol consumption. The importance of metabolic dysfunction was acknowledged in this new nomenclature, but the precise contribution of metabolic dysfunction and alcohol consumption to the development and progression of SLD remains unclear. Herein, we review hepatologists’ and endocrinologists’ perspectives on the new nomenclature, along with its possible impact on clinical practice. Although it is premature to predict the settlement of the new nomenclature, this review may help build more evidence for a soft landing of it in the future.

Citations

Citations to this article as recorded by  Crossref logo
  • Association between dietary amino acid intake and the risk of metabolic dysfunction-associated steatotic liver disease
    Ruoqi Zhou, Xinrong Zhang, Xinxin Liu, Rui Huang, Yuwei Wang, Dajing Xia, Xue Li, Yihua Wu, Yu Shi
    Journal of Advanced Research.2026; 80: 893.     CrossRef
  • Prevalence and Associated Factors of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease: An Updated Global Systematic Review and Meta-Analysis of over 1.5 Million Individuals
    Narsimha Keetha Rao, Shahriar Ghodous, Anoop Gurram, Mehrdad Khorasani, Madhusudhan Ponnala, Arman Habibi, Kwame Agyeman, Parsa Saberian, Pubali Biswas, Negin Letafatkar, Simran Joshi, Yasmin Sahli, Reza Amani-Beni, Bahar Darouei, Yussif Issaka, Kiran San
    Inflammatory Bowel Diseases.2026; 32(2): 350.     CrossRef
  • Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed
    Alimentary Pharmacology & Therapeutics.2026; 63(5): 662.     CrossRef
  • Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD—Insights From a National Analysis. Authors' Reply
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed
    Alimentary Pharmacology & Therapeutics.2026; 63(5): 752.     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease and adverse pregnancy outcomes: a nationwide cohort study
    Young Mi Jung, Taesu Kim, Min-Jeong Oh, Dong Hyeon Lee, Geum Joon Cho, Won Kim
    Hepatology International.2026; 20(1): 69.     CrossRef
  • Similar hepatic outcome by SGLT2i vs. DPP4i for at-risk cohort with CHB & T2DM: A nationwide target trial emulation study
    Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon
    Annals of Hepatology.2026; 31(1): 102175.     CrossRef
  • Revisiting MASLD-based pregnancy risk stratification: a critical appraisal of Jung et al.’s nationwide cohort study
    Jianfeng Luo
    Hepatology International.2026;[Epub]     CrossRef
  • Mortality and Cardiovascular Outcomes in Patients with MAFLD Compared with Patients with MASLD: A Systematic Review and Meta-Analysis
    Jiwon Yang, Ye Rim Kim, Seong Kyun Na, Seonok Kim, Jihyun An, Ju Hyun Shim
    Gut and Liver.2026; 20(1): 137.     CrossRef
  • RAB25/GCN1 signaling promotes endoplasmic reticulum stress to mediate alcohol-associated liver disease progression
    Xue-Wen Liu, Zi-Bin Zhan, Ze-Hua Li, Yue Zhang, Xue-Yan Qiao, Xin-Ming Li, Xiang-Jing Liang, Kun-Hao Bai, Xian-Feng Xia, Fan-Hon Zeng, Yi Gao, Jun Weng
    Clinical and Molecular Hepatology.2026; 32(1): 200.     CrossRef
  • Multicenter Prospective Cohort Study on Clinical Outcomes and Fibrosis Patterns in Biopsy-Proven Steatotic Liver Disease Subtypes
    Gi-Ae Kim, Heejoon Jang, Moon Young Kim, Jeong Hwan Park, Jung Gil Park, Eun-Young Cho, Jae Yoon Jeong, Seogsong Jeong, Seul Ki Han, Heesu Kwon, Youngae Jung, Geum-Sook Hwang, Yu Rim Lee, Soo Young Park, Sang Gyune Kim, Won Kim
    Gastroenterology.2026; 170(7): 1571.     CrossRef
  • Liver Stiffness Directs Intrahepatic Cholesterol Accumulation Through YAP/TAZ in Metabolic Dysfunction‐Associated Steatotic Liver Disease
    Na Young Lee, Myeung Gi Choi, Ho Jae Ryu, Young Jin Min, Seon Min Kim, Yeonseok Chung, Bo Kyung Koo, Yun Pyo Kang, Won Kim, Ja Hyun Koo
    Advanced Science.2026;[Epub]     CrossRef
  • Risk stratification for patients with MASLD based on cardiometabolic risk factors
    Yiheng Zhang, Yan Wang, Yaping Xu, Xu Liu, Yundong Qu, Tao Li
    BMC Public Health.2026;[Epub]     CrossRef
  • Metabolically associated fatty liver disease: What hepatologists need to know about this systemic disease
    Alexander Plakida, Olga Iushkovska, Lidia Elżbieta Sierpińska
    World Journal of Hepatology.2026;[Epub]     CrossRef
  • Fucoxanthin Ameliorates MASLD by Directly Targeting GRP78 to Restore ER Homeostasis and Activate AMPK Signaling
    Lin Zhang, Ruifen Zhang, Yu Wu, Binbin Chen, Chao Wang, Cheng Wang, Zhengshun Wen, Jingui Zhang, Haibin Tong, Liang Hong
    Food Science & Nutrition.2026;[Epub]     CrossRef
  • Pilot Study on the Use of Rheology and Low Field Nmr to Characterize the Liver of Obese Patients Undergoing Metabolic and Bariatric Surgery
    Alice Biasin, Silvia Palmisano, Michela Abrami, Deborah Bonazza, Fabrizio Zanconati, Domenico Tierno, Federica Tonon, Nhung Hai Truong, Thanh Dang Minh, Ralf Weiskirchen, Fulvia Felluga, Bruna Scaggiante, Mario Grassi, Gabriele Grassi
    International Journal of Molecular Sciences.2026; 27(9): 4040.     CrossRef
  • Association of alcohol intake with pre-sarcopenia risk in steatotic liver disease: a dose-dependent relationship
    Qiyang Chen, Ruifang Xu, Linxue Qian, Yujiang Liu, Xiangdong Hu
    European Journal of Gastroenterology & Hepatology.2026;[Epub]     CrossRef
  • Nutraceutical Synergy: Unraveling the Protective Effects of Methyl Gallate and Chia Seed Oil in Doxorubicin-induced Hepatic Injury and Bax/Bcl2 Imbalance
    Shakta Mani Satyam, Mohamed El-Tanani, Akheruz Zaman Ahmed, Manfredi Rizzo, Dimitrios Patoulias, Prakashchandra Shetty Kanyana, Kalyan Chakravarthi Kosuri, Rashmi Kumari, Sainath Prabhakar
    Current Pharmaceutical Design.2026; 32(20): 1592.     CrossRef
  • Comparison of NAFLD, MAFLD, and MASLD Prevalence and Clinical Characteristics in Asia Adults
    Xinjuan Huang, Ruoling Yu, Xinyun Tan, Manjie Guo, Yuanqin Xia, Huihui Zou, Xuelian Liu, Chunxiang Qin
    Journal of Clinical and Experimental Hepatology.2025; 15(1): 102420.     CrossRef
  • Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply
    Yewan Park, Jooyi Jung, Gi‐Ae Kim
    Alimentary Pharmacology & Therapeutics.2025; 61(2): 400.     CrossRef
  • Statin use and liver-related prognosis among patients with MASLD
    Byungyoon Yun, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon
    JHEP Reports.2025; 7(4): 101313.     CrossRef
  • Diet quality and physical activity affect metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction and etiology-associated steatohepatitis, and compensated advanced chronic liver disease among United States adults: NHANES 2017–2020
    Peng Wang, Bingxin Xia, Shuang Wang
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Optimal BMI cutoff for lean MASLD/MetALD and adverse hepatic outcomes in East-Asian populations
    Byungyoon Yun, Juyeon Oh, Heejoo Park, Beom Kyung Kim, Jin-Ha Yoon
    European Journal of Internal Medicine.2025; 133: 141.     CrossRef
  • Cardiovascular Risk From Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factor Count, and Their Longitudinal Changes: A Nationwide Cohort Study
    Hyeok-Hee Lee, Han Ah Lee, Eun-Jin Kim, Hwi Young Kim, Hyeon Chang Kim, Sang Hoon Ahn, Hokyou Lee, Seung Up Kim
    American Journal of Gastroenterology.2025; 120(10): 2321.     CrossRef
  • Correspondence to editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analy
    Young Eun Chon, Jung Hwan Yu, Seung Up Kim
    Clinical and Molecular Hepatology.2025; 31(1): e61.     CrossRef
  • Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes
    Meng-Yuan Miao, Jie-Qiong Lyu, Wei Jiang, Zhong-Yue Liu, Guo-Chong Chen
    Clinical and Molecular Hepatology.2025; 31(1): e35.     CrossRef
  • Cigarette Smoke Contributes to the Progression of MASLD: From the Molecular Mechanisms to Therapy
    Jiatong Xu, Yifan Li, Zixuan Feng, Hongping Chen
    Cells.2025; 14(3): 221.     CrossRef
  • Prognostic and predictive effects of new steatotic liver disease nomenclatures: a large population‐based study
    Huixian Zeng, Letian Fang, Zhiyu Yang, Xinyu Zhao, Hongsen Chen, Puyi Xing, Zheyun Niu, Zheng Li, Zishuai Li, Jiayi Zhao, Wenbin Liu, Chunxia Jing, Hong You, Guangwen Cao
    MedComm.2025;[Epub]     CrossRef
  • Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease
    Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip
    Clinical and Molecular Hepatology.2025; 31(Suppl): S51.     CrossRef
  • Dapansutrile Regulates Mitochondrial Oxidative Stress and Reduces Hepatic Lipid Accumulation in Diabetic Mice
    Ying Wu, Jiaqiang Zhou
    Current Issues in Molecular Biology.2025; 47(3): 148.     CrossRef
  • Dietary Patterns Rich in Soybean Products, Vegetables, Fish, Fruits, and Miso Soup Were Inversely Associated with Fatty Liver Index: The Nagahama Study
    Yoko UEBA, Kaori IKEDA, Yasuharu TABARA, Takeo NAKAYAMA, Daisuke TANAKA, Yoshimitsu TAKAHASHI, Shinji KOSUGI, Kazuya SETOH, Takahisa KAWAGUCHI, Fumihiko MATSUDA, Nobuya INAGAKI
    Journal of Nutritional Science and Vitaminology.2025; 71(1): 25.     CrossRef
  • Is type 2 diabetes a link between lung function and metabolic dysfunction–associated steatotic liver disease? Insights from population studies and Mendelian randomization
    Runmin Cao, Yurun Zhang, Ling Cao, Honghe Jiang
    European Journal of Gastroenterology & Hepatology.2025; 37(5): 652.     CrossRef
  • Impact of binge drinking on alcoholic liver disease
    Jisoo Kang, Seol Hee Park, Mushira Khanam, Seo Bhin Park, Sumin Shin, Wonhyo Seo
    Archives of Pharmacal Research.2025;[Epub]     CrossRef
  • Synbiotic combination of fructooligosaccharides and probiotics ameliorates the metabolic dysfunction-associated steatotic liver disease
    Sang Yoon Lee, Su-Been Lee, Goo-Hyun Kwon, Seol Hee Song, Jeong Ha Park, Min Ju Kim, Jung A Eom, Kyeong Jin Lee, Sang Jun Yoon, Hyunjoon Park, Sung-Min Won, Jin-Ju Jeong, Ki-Kwang Oh, Young Lim Ham, Gwang Ho Baik, Dong Joon Kim, Satya Priya Sharma, Ki Tae
    Journal of Microbiology.2025; 63(2): e2411002.     CrossRef
  • Impact of healthy lifestyles on the risk of metabolic dysfunction‐associated steatotic liver disease among adults with comorbid hypertension and diabetes: Novel insight from a largely middle‐aged and elderly cohort in South China
    Jun‐Yan Xi, Yi‐Jing Wang, Xiao‐Heng Li, Nuo‐Min Sun, Rui‐Qi Ming, Hua‐Ling Yan, Huan‐Le Cai, Jian‐Jun Bai, Yi‐Ning Xiang, Jing Gu, Xiao Lin, Gang Liu, Yuan‐Tao Hao
    Diabetes, Obesity and Metabolism.2025; 27(5): 2800.     CrossRef
  • Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank
    Tae Seop Lim, Sujin Kwon, Sung A. Bae, Hye Yeon Chon, Seol A. Jang, Ja Kyung Kim, Chul Sik Kim, Seok Won Park, Kyoung Min Kim
    Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub]     CrossRef
  • Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
    Alimentary Pharmacology & Therapeutics.2025; 61(11): 1785.     CrossRef
  • Identification of Novel Therapeutic Targets for MAFLD Based on Bioinformatics Analysis Combined with Mendelian Randomization
    Jialin Ren, Min Wu
    International Journal of Molecular Sciences.2025; 26(7): 3166.     CrossRef
  • Linghe granules reduces hepatic lipid accumulation in Non-alcoholic fatty liver disease through regulating lipid metabolism and redox balance
    Yuting Hu, Ni'ao Li, Rumian Zhang, Jia Wang, Dongdong Fang, Qianmei Zhou, Hua Zhang, Hong Cai, Yiyu Lu
    Phytomedicine.2025; 141: 156654.     CrossRef
  • Sex‐Specific Impact of Metabolic Dysfunction‐Associated Fatty Liver Disease on Incident Cardiovascular Diseases and Mortality
    Mahsa Abbaszadeh, Farhad Hosseinpanah, Maryam Tohidi, Sahar Karimpour Reyhan, Maryam Mahdavi, Majid Valizadeh
    Endocrinology, Diabetes & Metabolism.2025;[Epub]     CrossRef
  • The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
    Clinical and Molecular Hepatology.2025; 31(2): e183.     CrossRef
  • Reply to correspondence 1 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
    Yoon-su Ha, Won Kim, Seung-Jin Kim
    Clinical and Molecular Hepatology.2025; 31(2): e226.     CrossRef
  • A comprehensive analysis of the impact of smoking on adverse clinical outcomes of steatotic liver diseases
    Keungmo Yang, Jaejun Lee, Ji Won Han, Hyun Yang, Seung Yun Chae, Beom Sun Chung, Tom Ryu
    Therapeutic Advances in Gastroenterology.2025;[Epub]     CrossRef
  • Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
    Clinical and Molecular Hepatology.2025; 31(2): 382.     CrossRef
  • Comparative Hepatic Outcomes of SGLT2i or DPP4i Compared to GLP‐1RA in CHB and T2DM Patients
    Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin‐Ha Yoon
    Liver International.2025;[Epub]     CrossRef
  • Unraveling the role of GOLM1-OPN-ABCG5 axis in MASH: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
    Yoon-su Ha, Won Kim, Seung-Jin Kim
    Clinical and Molecular Hepatology.2025; 31(2): 628.     CrossRef
  • Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
    Clinical and Molecular Hepatology.2025; 31(2): e180.     CrossRef
  • Fatty liver disease in the pediatric population: history, definitions, and challenges in nomenclature (NAFLD/MAFLD/MASLD)
    Raúl Gómez-Mendoza, Fabiola Sánchez-Hernández, Francisco Javier Valentin-Cortez, Norberto Chávez-Tapia
    Metabolism and Target Organ Damage.2025;[Epub]     CrossRef
  • Cu(OH)2 nanopesticide induced liver dysfunction in mice by targeting lipoylated tricarboxylic acid cycle proteins via ferredoxin 1
    Zhihua Ren, Mengyao Ren, Weibo Ling, Danqin Ren, Jiefeng Liang, Yixue Cai, Xiao Wang, Shuo Wang, Yonghui Duan, Tingting Ku, Xia Ning, Nan Sang
    Journal of Hazardous Materials.2025; 494: 138403.     CrossRef
  • Risks of liver cirrhosis, hepatocellular carcinoma, hepatic-related complications, and mortality in patients with type 2 diabetes in Taiwan
    Hua-Fen Chen, Yung-Yueh Chang, Peter Chen, Xiao-Han Shen, Chin-Huan Chang, Wan-Lun Hsu
    World Journal of Diabetes.2025;[Epub]     CrossRef
  • Serum polychlorinated biphenyls as a risk factor for MASLD: Exploring the association and underlying mechanisms
    Ruichen Yang, Qingqing Jiang, Wentao Liu, Furong Wang, Shiyi Cao
    Science of The Total Environment.2025; 981: 179617.     CrossRef
  • Nanoplastics disrupt hepatic lipid metabolism via the inhibition of PPARγ: a study based on digestive system exposure
    Shenya Xu, Mei Li, Yudan Zheng, Menghuan Xu, Jieyu Zhou, Shizhi Wang, Shuwei Li, Meilin Wang
    Toxicology.2025; 516: 154194.     CrossRef
  • New steatotic liver disease criteria diagnostic performance in an agricultural population in Chile
    Maria Spencer-Sandino, Franco Godoy, Laura Huidobro, Danilo Alvares, Francisco Cruz, Claudia Marco, Macarena Garrido, Daniel Cabrera, Juan Pablo Arab, Marco Arrese, Francisco Barrera, Catterina Ferreccio
    Annals of Hepatology.2025; 30(2): 101919.     CrossRef
  • Chronic Kidney Disease Risk Associated With Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Nationwide Cohort Study in Korea
    Dong Wook Kim, Minkook Son, Hye Jung Lee, Chi Hyeon Choi, Yeo Wool Kang, Sang Yi Moon, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek, Won Suk An
    Hepatology Research.2025; 55(9): 1239.     CrossRef
  • Case Report: Amelioration of severe metabolic dysfunction-associated steatohepatitis after switching from conventional GLP-1RAs to tirzepatide
    Yuki Oe, Takashi Omori, Eriko Aimono, Shin Furukawa, Hirohiko Kitakawa, Masatoshi Tateno, Kiyoshi Sakai, Kyu Yong Cho
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • The Role of Global Physical Capacity Score in Key Parameters of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Nicola Verrelli, Caterina Bonfiglio, Isabella Franco, Claudia Beatrice Bagnato, Dolores Stabile, Endrit Shahini, Antonella Bianco
    Journal of Clinical Medicine.2025; 14(11): 3821.     CrossRef
  • Association Between Meat Intake and Metabolic Dysfunction‐Associated Steatotic Liver Disease Incidence in a Korean Population From the Health Examinees Study
    Uyangamaa Nyamsuren, Yuan Peng, Sangah Shin
    Molecular Nutrition & Food Research.2025;[Epub]     CrossRef
  • Advances in identifying risk factors of metabolic dysfunction-associated alcohol-related liver disease
    Rui-Qi Ye, Yi-Fan Chen, Chang Ma, Xi Cheng, Wei Guo, Sha Li
    Biomedicine & Pharmacotherapy.2025; 188: 118191.     CrossRef
  • Young Adults With Metabolic Dysfunction–Associated Steatotic Liver Disease Have an Increased Risk of Early-Onset Cancer: A Nationwide Cohort Study Differentiating the Risk of 23 Site-Specific Cancers
    Joon Ho Moon, Seogsong Jeong, Heejoon Jang, Dong Hyeon Lee, Sae Kyung Joo, Bo Kyung Koo, Qiang Xia, Meng Sha, Yoosoo Chang, Won Kim
    Clinical Gastroenterology and Hepatology.2025; 23(13): 2540.     CrossRef
  • Chronic Inflammation and Immune Dysregulation in Metabolic-Dysfunction-Associated Steatotic Liver Disease Progression: From Steatosis to Hepatocellular Carcinoma
    Young-Min Jee, Jeong-Yoon Lee, Tom Ryu
    Biomedicines.2025; 13(5): 1260.     CrossRef
  • Early portal hypertension in metabolic dysfunction-associated steatotic liver disease: a concise review
    Iván López-Méndez, Eva Juárez-Hernández, Juan Pablo Soriano-Márquez, Misael Uribe, Graciela Castro-Narro
    Expert Review of Gastroenterology & Hepatology.2025; 19(7): 755.     CrossRef
  • Future Perspectives of Liver Research in the Asia‐Pacific Region: Focus on Hepatitis B and C
    Beom Kyung Kim
    Journal of Gastroenterology and Hepatology.2025; 40(8): 1855.     CrossRef
  • Targeting the gut microbiota and lipid metabolism: potential mechanisms of natural products for the treatment of non-alcoholic fatty liver disease
    Yutian Zhang, Tianlin Wang, Junquan Han, Jielin Song, Chaoshuai Yang, Lei Liang, Huizhen Li, Hong Wang
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Laminin γ2 accelerates non-alcoholic fatty liver disease progression by enhancing lipid accumulation and fibrogenesis in hepatocytes
    Hui Chen, Guanggang Meng, Aiting Yang
    Biochemical and Biophysical Research Communications.2025; 777: 152266.     CrossRef
  • Dietary ω-3 polyunsaturated fatty acid intake improves skeletal muscle mass in patients with metabolic dysfunction-associated fatty liver disease: A nationwide cross-sectional study
    Li-Zhan Bie, Chao Wu, Jia-Lu Wang
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017–2023
    Donghee Kim, Rohit Loomba, Aijaz Ahmed
    Clinical and Molecular Hepatology.2025; 31(3): e235.     CrossRef
  • Gut-Liver Axis: The Role of Intestinal Microbiota and Their Metabolites in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Chao Cui, Shuai Gao, Jingfei Shi, Kai Wang
    Gut and Liver.2025; 19(4): 479.     CrossRef
  • The role of Bergamot Polyphenolic Fraction (BPF) in MASLD-Induced HFpEF: Mitigate diastolic dysfunction by targeting chronic low-grade inflammation
    Cristina Carresi, Antonio Cardamone, Vincenzo Musolino, Rocco Mollace, Annamaria Tavernese, Anna Rita Coppoletta, Micaela Gliozzi, Vincenzo Mollace
    Biomedicine & Pharmacotherapy.2025; 190: 118375.     CrossRef
  • Refining the Classification of Steatotic Liver Disease: Beyond Self-Reported Alcohol Intake
    Won-Mook Choi
    Gut and Liver.2025; 19(5): 639.     CrossRef
  • Understanding MASLD — from molecular pathogenesis to cardiovascular risk: A concise review for the clinical cardiologist
    Carlo Ratti, Mattia Malaguti, D'Aniello Emanuele, Antonio Bellasi, Gianluca Sanna
    Atherosclerosis.2025; 409: 120495.     CrossRef
  • Integrative gut microbiota and metabolomics reveals the mechanism of chicory extract in improving metabolic dysfunction-associated steatotic liver disease via gut-liver axis
    Haifeng Wang, Songlin Liu, Yonggang Chen, Weiwei Fang, Ying Cheng, Zhigang Zhang, Haiming Hu, Baifei Hu, Hongtao Liu
    Phytomedicine.2025; 148: 157404.     CrossRef
  • Paired snRNA-seq and scRNA-seq analysis of MASLD patients to identify early-stage markers for disease progression
    Suebin Park, Su-Hyeon Lee, Se-eun Han, Beom Kyung Kim, Byungjin Hwang
    Hepatology Communications.2025;[Epub]     CrossRef
  • Alcohol-Induced Oxidative Stress and Gut–Liver–Brain Crosstalk: Expanding the Paradigm from ALD to MetALD
    Jeong-Yoon Lee, Young-Min Jee, Keungmo Yang, Tom Ryu
    Antioxidants.2025; 14(10): 1196.     CrossRef
  • Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease
    Anoushka Shenoy, Aijaz Ahmed, Donghee Kim
    Metabolism and Target Organ Damage.2025;[Epub]     CrossRef
  • Association between Relative Skeletal Muscle Mass and Metabolic Dysfunction-Associated Steatotic Liver Disease Development in a Community-Based Population
    Yiting Xu, Tingting Hu, Xiaoya Li, Yun Shen, Yunfeng Xiao, Yufei Wang, Yuqian Bao, Xiaojing Ma
    Journal of Obesity & Metabolic Syndrome.2025; 34(4): 456.     CrossRef
  • Steatotic Liver Disease Subtypes and Their Association with Colorectal Cancer Risk in Korea: A Nationwide Population-Based Study
    Sang Yi Moon, Minkook Son, Jong Yoon Lee, Yeo Wool Kang, Myeongseok Koh
    Digestion.2025; 106(6): 560.     CrossRef
  • Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up
    Hun Jee Choe, Joon Ho Moon, Won Kim, Bo Kyung Koo, Nam H. Cho
    Metabolism.2024; 153: 155800.     CrossRef
  • Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease
    Zobair M. Younossi, James M. Paik, Maria Stepanova, Janus Ong, Saleh Alqahtani, Linda Henry
    Journal of Hepatology.2024; 80(5): 694.     CrossRef
  • From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease: Out with the Old, in with the New
    Iyiad Alabdul Razzak, Mazen Noureddin, Hirsh Trivedi
    Journal of Clinical Medicine.2024; 13(3): 880.     CrossRef
  • Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation
    Byeong Hyun Min, Shivani Devi, Goo Hyun Kwon, Haripriya Gupta, Jin-Ju Jeong, Satya Priya Sharma, Sung-Min Won, Ki-Kwang Oh, Sang Jun Yoon, Hee Jin Park, Jung A Eom, Min Kyo Jeong, Ji Ye Hyun, Nattan Stalin, Tae-Sik Park, Jieun Choi, Do Yup Lee, Sang Hak H
    Gut Microbes.2024;[Epub]     CrossRef
  • Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
    Yewan Park, Jooyi Jung, Seungbong Han, Gi‐Ae Kim
    Alimentary Pharmacology & Therapeutics.2024; 60(11-12): 1599.     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease: An opportunity for collaboration between cardiology and hepatology
    Paolo Raggi, Jovana Milic, Marcella Manicardi, Felice Cinque, Mark G. Swain, Giada Sebastiani, Giovanni Guaraldi
    Atherosclerosis.2024; 392: 117523.     CrossRef
  • Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression
    Sumin Oh, Yang-Hyun Baek, Sungju Jung, Sumin Yoon, Byeonggeun Kang, Su-hyang Han, Gaeul Park, Je Yeong Ko, Sang-Young Han, Jin-Sook Jeong, Jin-Han Cho, Young-Hoon Roh, Sung-Wook Lee, Gi-Bok Choi, Yong Sun Lee, Won Kim, Rho Hyun Seong, Jong Hoon Park, Yeon
    Clinical and Molecular Hepatology.2024; 30(2): 247.     CrossRef
  • Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study
    Michihiro Iwaki, Hideki Fujii, Hideki Hayashi, Hidenori Toyoda, Satoshi Oeda, Hideyuki Hyogo, Miwa Kawanaka, Asahiro Morishita, Kensuke Munekage, Kazuhito Kawata, Tsubasa Tsutsumi, Koji Sawada, Tatsuji Maeshiro, Hiroshi Tobita, Yuichi Yoshida, Masafumi Na
    Clinical and Molecular Hepatology.2024; 30(2): 225.     CrossRef
  • Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
    Tsubasa Tsutsumi, Dan Nakano, Machiko Kawaguchi, Hirokazu Takahashi, Takumi Kawaguchi
    Clinical and Molecular Hepatology.2024; 30(2): 266.     CrossRef
  • Immunopathogenesis of liver fibrosis in steatotic liver disease
    Chaerin Woo, Won-Il Jeong
    Clinical and Molecular Hepatology.2024; 30(2): 299.     CrossRef
  • Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD
    Hiroyuki Suzuki, Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Takumi Kawaguchi
    Clinical and Molecular Hepatology.2024; 30(2): 263.     CrossRef
  • Nonalcoholic fatty liver disease associated with obesity and type 2 diabetes and gut dysbiosis
    T.M. Bentsa
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2024; 20(2): 120.     CrossRef
  • The clinician's view on the advantages and contradictions of the new nomenclature of steatotic liver disease: A review
    Chavdar S. Pavlov, Daria A. Teplyuk, Leonid B. Lazebnik, Aleksandr S. Ametov, Evgeniia Yu. Pashkova, Sergey M. Sorokoletov, Yury P. Uspenskiy, Svetlana V. Turkina, Elizaveta V. Ponomarenko, Aleksandr S. Maslakov
    Terapevticheskii arkhiv.2024; 96(4): 429.     CrossRef
  • Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
    Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, Marlene Chakhtoura, Michael A. Hill, Dimitri P. Mikhailidis, Christos S. Mantzoros
    Pharmacological Reviews.2024; 76(3): 454.     CrossRef
  • Prognostic Impact of Metabolic Syndrome and Steatotic Liver Disease in Hepatocellular Carcinoma Using Machine Learning Techniques
    Sergio Gil-Rojas, Miguel Suárez, Pablo Martínez-Blanco, Ana M. Torres, Natalia Martínez-García, Pilar Blasco, Miguel Torralba, Jorge Mateo
    Metabolites.2024; 14(6): 305.     CrossRef
  • Are transmembrane 6 superfamily member 2 gene polymorphisms associated with steatohepatitis after pancreaticoduodenectomy?
    Tomotaka Mori, Eisuke Ozawa, Ryu Sasaki, Akane Shimakura, Kosuke Takahashi, Yoko Kido, Yasuko Kanda, Satoshi Matsuo, Kazuaki Tajima, Asami Beppu, Yasuhiko Nakao, Masanori Fukushima, Masafumi Haraguchi, Satoshi Miuma, Hisamitsu Miyaaki, Tomohiko Adachi, Su
    JGH Open.2024;[Epub]     CrossRef
  • Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia
    Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi
    Clinical and Molecular Hepatology.2024; 30(3): 577.     CrossRef
  • Impacts of cardiometabolic risk factors and alcohol consumption on all-cause mortality among MASLD and its subgroups
    Mengqi Li, Wenya Chen, You Deng, Wen Xie
    Nutrition, Metabolism and Cardiovascular Diseases.2024; 34(9): 2085.     CrossRef
  • Interleukin-mediated therapies in liver diseases and comorbidity effects
    Nouhoum Bouare, Jean Delwaide
    World Journal of Hepatology.2024; 16(7): 980.     CrossRef
  • A New Korean Nomenclature for Steatotic Liver Disease

    The Korean Journal of Gastroenterology.2024; 84(1): 1.     CrossRef
  • Impact of Physical Activity on Overall Survival and Liver Cirrhosis Incidence in Steatotic Liver Disease: Insights from a Large Cohort Study Using Inverse Probability of Treatment Weighting
    Keungmo Yang, Beom Sun Chung, Tom Ryu
    Nutrients.2024; 16(15): 2532.     CrossRef
  • Machine learning model reveals roles of interferon‑stimulated genes in sorafenib‑resistant liver cancer
    Deok Seo, Ji Park, Hee Jung, Min Kang, Byung Kang, Dong Lee, Jae Lee, Seung Yoon, Jeong Jang, Jae Ahn, Pil Sung
    Oncology Letters.2024;[Epub]     CrossRef
  • Role of Neutrophils in the Development of Steatotic Liver Disease
    You-Jin Choi, Yeonsoo Kim, Seonghwan Hwang
    Seminars in Liver Disease.2024; 44(03): 300.     CrossRef
  • A New Korean Nomenclature for Steatotic Liver Disease

    The Korean Journal of Medicine.2024; 99(4): 189.     CrossRef
  • Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies
    Hao CHEN, Yang ZHOU, Haiping HAO, Jing XIONG
    Chinese Journal of Natural Medicines.2024; 22(8): 724.     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study
    Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon, Hyung Ho Lee, Heejoo Park, Jian Lee, Youngsun Park, Byungyoon Yun, Jinsoo Chung
    Cancers.2024; 16(18): 3161.     CrossRef
  • A New Korean Nomenclature for Steatotic Liver Disease

    Gut and Liver.2024; 18(5): 924.     CrossRef
  • Serum isthmin-1 is a potential biomarker for metabolic dysfunction associated fatty liver disease in patients with metabolic syndrome and type 2 diabetes mellitus
    Xiaohui Lei, HaiYan Chen, YuXin Xu, Zhuoran Yang, Lili Zhang, Cong Wang, Hu Du
    BMJ Open Diabetes Research & Care.2024; 12(5): e004514.     CrossRef
  • A new Korean nomenclature for steatotic liver disease

    Clinical and Molecular Hepatology.2024; 30(Suppl): S214.     CrossRef
  • Association of niacin intake and metabolic dysfunction-associated steatotic liver disease: findings from National Health and Nutrition Examination Survey
    Jing Zhou, Jun Han
    BMC Public Health.2024;[Epub]     CrossRef
  • Diagnostic accuracy of the Fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: A systematic review and meta-analysis
    Ji Won Han, Hee Yeon Kim, Jung Hwan Yu, Mi Na Kim, Young Eun Chon, Ji Hyun An, Young-Joo Jin, Miyoung Choi, Seung Up Kim, Han Ah Lee, Dae Won Jun
    Clinical and Molecular Hepatology.2024; 30(Suppl): S147.     CrossRef
  • Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
    Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi
    Clinical and Molecular Hepatology.2024; 30(4): 962.     CrossRef
  • Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
    Clinical and Molecular Hepatology.2024; 30(4): 982.     CrossRef
  • A Review on the Protecting Effects and Molecular Mechanisms of Berries Against a Silent Public Health Concern: Non-Alcoholic Fatty Liver Disease
    Anshul Sharma, Hae-Jeung Lee
    Antioxidants.2024; 13(11): 1389.     CrossRef
  • Combi-Elastography versus Transient Elastography for Assessing the Histological Severity of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Yun Kyu Lee, Dong Hyeon Lee, Sae Kyung Joo, Heejoon Jang, Young Ho So, Siwon Jang, Dong Ho Lee, Jeong Hwan Park, Mee Soo Chang, Won Kim
    Gut and Liver.2024; 18(6): 1048.     CrossRef
  • Pathogenesis and management of metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma: a narrative review
    Han Ah Lee
    The Ewha Medical Journal.2024;[Epub]     CrossRef
  • Understanding the epidemiology of metabolic dysfunction-associated steatotic liver disease is essential for its management: need for attention to accurate diagnostic coding and classification
    Han Ah Lee
    The Korean Journal of Internal Medicine.2024; 39(6): 869.     CrossRef
  • Association between the Fatty Liver Index (FLI) and incident coronary heart disease: insights from a cohort study on the Chinese population
    Ying Miao, Yu Wang, Pijun Yan, Yi Li, Zhuang Chen, Nanwei Tong, Qin Wan
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Adding to the confusion in more than just the name
    Jacob George
    Clinical and Molecular Hepatology.2023; 29(4): 973.     CrossRef
  • From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials
    Ming-Lun Yeh, Ming-Lung Yu
    Clinical and Molecular Hepatology.2023; 29(4): 969.     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study
    Joon Ho Moon, Seogsong Jeong, Heejoon Jang, Bo Kyung Koo, Won Kim
    eClinicalMedicine.2023; 65: 102292.     CrossRef
  • Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD
    Shuhei Fukunaga, Michita Mukasa, Dan Nakano, Tsubasa Tsutsumi, Takumi Kawaguchi
    Clinical and Molecular Hepatology.2023; 30(1): 121.     CrossRef
  • 14,763 View
  • 437 Download
  • 111 Web of Science
  • Crossref

Original Article

Steatotic liver disease

Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity
Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe
Clin Mol Hepatol 2023;29(4):987-1001.
Published online July 5, 2023
DOI: https://doi.org/10.3350/cmh.2023.0035
Background/Aims
To investigate whether non-alcoholic fatty liver disease (NAFLD) in individuals without generalized obesity is associated with visceral fat obesity (VFO), sarcopenia, and/or myosteatosis.
Methods
This cross-sectional analysis included 14,400 individuals (7,470 men) who underwent abdominal computed tomography scans during routine health examinations. The total abdominal muscle area (TAMA) and skeletal muscle area (SMA) at the 3rd lumbar vertebral level were measured. The SMA was divided into the normal attenuation muscle area (NAMA) and low attenuation muscle area, and the NAMA/TAMA index was calculated. VFO was defined by visceral to subcutaneous fat ratio, sarcopenia by body mass index-adjusted SMA, and myosteatosis by the NAMA/TAMA index. NAFLD was diagnosed with ultrasonography.
Results
Of the 14,400 individuals, 4,748 (33.0%) had NAFLD, and the prevalence of NAFLD among non-obese individuals was 21.4%. In regression analysis, both sarcopenia (men: odds ratio [OR] 1.41, 95% confidence interval [CI] 1.19–1.67, P<0.001; women: OR=1.59, 95% CI 1.40–1.90, P<0.001) and myosteatosis (men: OR=1.24, 95% CI 1.02–1.50, P=0,028; women: OR=1.23, 95% CI 1.04–1.46, P=0.017) were significantly associated with non-obese NAFLD after considering for VFO and other various risk factors, whereas VFO (men: OR=3.97, 95% CI 3.43–4.59 [adjusted for sarcopenia], OR 3.98, 95% CI 3.44–4.60 [adjusted for myosteatosis]; women: OR=5.42, 95% CI 4.53–6.42 [adjusted for sarcopenia], OR=5.33, 95% CI 4.51–6.31 [adjusted for myosteatosis]; all P<0.001) was strongly associated with non-obese NAFLD after adjustment with various known risk factors.
Conclusions
In addition to VFO, sarcopenia and/or myosteatosis were significantly associated with non-obese NAFLD.

Citations

Citations to this article as recorded by  Crossref logo
  • Sarcopenia and MASLD: novel insights and the future
    Chang-Hai Liu, Qing-Min Zeng, Won Kim, Seung Up Kim, Zobair M. Younossi, Giovanni Targher, Christopher D. Byrne, Christos S. Mantzoros, Phunchai Charatcharoenwitthaya, Isabelle Anne Leclercq, Manuel Romero-Gómez, Hong Tang, Ming-Hua Zheng
    Nature Reviews Endocrinology.2026; 22(3): 139.     CrossRef
  • Intrinsic capacity, genetic susceptibility, and the risks of metabolic dysfunction–associated steatotic liver disease and cirrhosis
    Zhuoshuai Liang, Hongrui Zhang, Huizhen Jin, Wenhui Gao, Ruofei Li, Xinmeng Hu, Yi Cheng, Lingfei Guo, Yawen Liu
    International Journal of Surgery.2026; 112(1): 780.     CrossRef
  • Sarcopenia as a risk factor for nonalcoholic fatty liver disease and liver fibrosis: an updated systematic review and meta-analysis
    Xinrong Zuo, Doudou Chen, Yi Kang, Xinyi Hu, Yarong Zhang, Kuo Tang, Junhua Shi, Tao Li, Wangning Shangguan
    Frontiers in Nutrition.2026;[Epub]     CrossRef
  • Type 2 diabetes mellitus
    Melanie J. Davies, Soo Lim, Tommy Slater, Jonathan Goldney, Athena Philis-Tsimikas, Denise R. Franco, Roberta Lamptey, Thomas Yates, Tsvetalina Tankova, Ildiko Lingvay
    Nature Reviews Disease Primers.2026;[Epub]     CrossRef
  • Refining intergenerational MASLD risk: are measurement and mediation shaping the signal?
    Tien Manh Huynh, Thinh Ong, Naveen Gautam, Hung Song Nguyen
    Gut.2026; : gutjnl-2026-338664.     CrossRef
  • CT-assessed abdominal visceral adiposity and MASLD: a sex-stratified cross-sectional analysis
    Linying Xu, Ting Chen, Yitian Xie, Xueyu Xiang, Yupeng Liu, Chongyong Xu, Shuran Wang
    Frontiers in Nutrition.2026;[Epub]     CrossRef
  • Sarcopenia in patients with non-alcoholic fatty liver disease: pathogenesis, diagnosis and treatment (expert opinion)
    L. Yu. Ilchenko, V. A. Akhmedov, E. V. Vinnitskaya, E. I. Dedov, R. G. Myazin, I. G. Nikitin, A. S. Tikhomirova, I. E. Khoroshilov, G. V. Shavkuta, O. A. Ettinger, I. G. Adamova, L. B. Lazebnik
    Experimental and Clinical Gastroenterology.2026; (4): 3.     CrossRef
  • Effects of GLP‐1 Receptor Agonists on Muscle Mass, Strength, and Quality in MASLD: A Systematic Review
    Fernando Iorra, Tanya Jayakar, Michael Yee, Mark R. Thursz, Beatriz D. Schaan, Pinelopi Manousou
    Liver International.2026;[Epub]     CrossRef
  • Association of Abdominal Myosteatosis and Visceral Fat Obesity with Arterial Stiffness
    Min Jung Lee, Hong-Kyu Kim, Eun Hee Kim, Sung Jin Bae, Hyo-Jung Nam, Sang Hoon Lee, Chang Hee Jung, Woo Je Lee
    Endocrinology and Metabolism.2026;[Epub]     CrossRef
  • Beyond BMI: Reassessing the Prevalence of Obesity in Patients With MASLD Under the Lancet Commission Diagnostic Criteria
    Ru‐Tao Lin, Ren‐Qiang Zeng, Xu‐Ting Shen, Qin‐Mei Sun, Xin Xin, Jia‐Mei Chen, Yi‐Yang Hu, Qin Feng
    Diabetes, Obesity and Metabolism.2026;[Epub]     CrossRef
  • From body composition to reflux esophagitis: an interpretable machine learning model based on CT-derived features
    Tianyi Wang, Lu Chen, Yajie Li, Qi Zhang, Xilong Ou, Qin Lu
    Frontiers in Physiology.2026;[Epub]     CrossRef
  • Visceral obesity exacerbates perioperative muscle loss and impairs survival in colorectal cancer
    Yun Wang, Jun Bu, Chen-Yang Zhan, Da-Lin Xu, Jia-Qi Hu, Ming-Hao Zhang, Ke-Jin Zhu, Yang Qi
    World Journal of Gastrointestinal Surgery.2026;[Epub]     CrossRef
  • Emerging insights into PPARα’s role in lean metabolic dysfunction-associated steatotic liver disease: Implications for targeted therapies
    Yafei Yang, Furong Zhang, Zhuang Peng, Yafei Wu, Ling Li, Zixia Shen, Qifa Ye, Jiang Yue, Shufang Na
    Acta Pharmaceutica Sinica B.2026;[Epub]     CrossRef
  • The Relationship Between Remnant Cholesterol and Visceral Adipose Tissue: A National Cross-Sectional Study
    Zhaoxiang Wang, Shao Zhong, Menghuan Wu, Xuejing Shao, Tian Gu, Mengjiao Xu, Qichao Yang
    Hormone and Metabolic Research.2025; 57(01): 47.     CrossRef
  • Frailty and risk of metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases
    Qi Zhong, Rui Zhou, Yi-Ning Huang, Rui-Dian Huang, Fu-Rong Li, Hao-Wen Chen, Yan-Fei Wei, Kuan Liu, Bi-Fei Cao, Kai-Yue Liao, Zheng-Yun Xu, Shi-Ao Wang, Xian-Bo Wu
    Journal of Hepatology.2025; 82(3): 427.     CrossRef
  • Statin use and liver-related prognosis among patients with MASLD
    Byungyoon Yun, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon
    JHEP Reports.2025; 7(4): 101313.     CrossRef
  • AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B
    Hyunjae Shin, Moon Haeng Hur, Byeong Geun Song, Soo Young Park, Gi-Ae Kim, Gwanghyeon Choi, Joon Yeul Nam, Minseok Albert Kim, Youngsu Park, Yunmi Ko, Jeayeon Park, Han Ah Lee, Sung Won Chung, Na Ryung Choi, Min Kyung Park, Yun Bin Lee, Dong Hyun Sinn, Se
    Journal of Hepatology.2025; 82(6): 1080.     CrossRef
  • Lymph Node Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Jessica M. Rubino, Natalie Yanzi Ring, Krishna Patel, Xiaoqing Xia, Todd A. MacKenzie, Roberta M. diFlorio-Alexander
    Biomedicines.2025; 13(1): 80.     CrossRef
  • Is type 2 diabetes a link between lung function and metabolic dysfunction–associated steatotic liver disease? Insights from population studies and Mendelian randomization
    Runmin Cao, Yurun Zhang, Ling Cao, Honghe Jiang
    European Journal of Gastroenterology & Hepatology.2025; 37(5): 652.     CrossRef
  • A cross-sectional study of risk factors associated with sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease
    Johnny Amer, Qusay Abdoh, Zaina Salous, Eithar Abu Alsoud, Sama AbuBaker, Ahmad Salhab, Manal Badrasawi
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
    Mohammed Eslam, Jian-Gao Fan, Ming-Lung Yu, Vincent Wai-Sun Wong, Ian Homer Cua, Chun-Jen Liu, Tawesak Tanwandee, Rino Gani, Wai-Kay Seto, Shahinul Alam, Dan Yock Young, Saeed Hamid, Ming-Hua Zheng, Takumi Kawaguchi, Wah-Kheong Chan, Diana Payawal, Soek-S
    Hepatology International.2025; 19(2): 261.     CrossRef
  • Sarcopenia and non-alcoholic fatty liver disease - complex pathogenetic relationships
    V. A. Akhmedov, V. S. Marinenko
    Experimental and Clinical Gastroenterology.2025; (9): 110.     CrossRef
  • Effects of Pemafibrate on Serum Carnitine and Plasma Myostatin in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease
    Ryohei Tanigawa, Atsushi Nakajima, Yuichiro Eguchi, Hirokazu Takahashi, Rohit Loomba, Hideki Suganami, Masaya Tanahashi, Hidenori Arai
    JCSM Communications.2025;[Epub]     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease (MASLD): Exploring systemic impacts and innovative therapies
    Parag Jain, Akanksha Jain, Rohitas Deshmukh, Pradeep Samal, Trilochan Satapathy, Ajazuddin
    Clinics and Research in Hepatology and Gastroenterology.2025; 49(6): 102584.     CrossRef
  • Comparative Hepatic Outcomes of SGLT2i or DPP4i Compared to GLP‐1RA in CHB and T2DM Patients
    Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin‐Ha Yoon
    Liver International.2025;[Epub]     CrossRef
  • Skeletal muscle and MASLD: Mechanistic and clinical insights
    Thomas Marjot, Matthew J. Armstrong, Jonathan G. Stine
    Hepatology Communications.2025;[Epub]     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease: A story of muscle and mass
    Vasily Isakov
    World Journal of Gastroenterology.2025;[Epub]     CrossRef
  • Association of lean metabolic dysfunction‐associated steatotic liver disease with carotid plaque progression in patients with type 2 diabetes mellitus
    Youngjoon Kim, Yongin Cho, Yong‐ho Lee, Da Hea Seo, Seong Hee Ahn, Seongbin Hong, So Hun Kim
    Journal of Diabetes Investigation.2025; 16(9): 1713.     CrossRef
  • Role of estimated glucose disposal rate in predicting myosteatosis: Insights from abdominal CT analysis
    Myung Jin Kim, Yun Kyung Cho, Eun Hee Kim, Min Jung Lee, Woo Je Lee, Hong-Kyu Kim, Chang Hee Jung
    Nutrition, Metabolism and Cardiovascular Diseases.2025; 35(12): 104225.     CrossRef
  • Non-alcoholic fatty liver disease, metabolic dysfunction and sarcopenia
    G.V. Shavkuta, V.A. Gavrilyukov, V.N. Kovalenko, A.S. Zubkova, Z.M. Nalgieva
    Terapevt (General Physician).2025; (6): 60.     CrossRef
  • Thigh Muscles and Metabolic Dysfunction‐Associated Steatotic Liver Disease: Findings From the SCAPIS/IGT‐Microbiota Study
    Amar Osmancevic, Anders Gummesson, Matthew Allison, Joel Kullberg, Ying Li, Göran Bergström, Bledar Daka
    Liver International.2025;[Epub]     CrossRef
  • Influence of Matcha and Tea Catechins on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)—A Review of Patient Trials and Animal Studies
    Danuta I. Kosik-Bogacka, Katarzyna Piotrowska
    Nutrients.2025; 17(15): 2532.     CrossRef
  • Associations of child-to-adult body size change with risk of hypertension and metabolic dysfunction-associated steatotic liver disease: a population-based cohort study of 226,420 individuals
    Fengyuan Tang, Wenqianzi Yang, Weijia Wu, Shengxuan Jin, Xuemei Zhen, Hengjin Dong
    BMC Public Health.2025;[Epub]     CrossRef
  • The non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio is associated with early onset type 2 diabetes with NAFLD: a cross-sectional study in China
    Nini Wu, Yingqun Ni, Rilong Huang, Junhua Wang, Meimei Li, Haiying Hu, Yuanyuan Zhang, Juyi Li, Jinjun Zhang
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • The Basics of Metabolic Dysfunction–Associated Steatotic Liver Disease for Cardiologists
    Muhammad Shahzeb Khan, Syed Sarmad Javaid, Amreen Dinani, Kara Wegermann, Ambarish Pandey, Ankeet S. Bhatt, Mark Muthiah, Harriette G.C. Van Spall, Faiez Zannad, Javed Butler, Michael L. Volk, Marat Fudim
    JACC.2025; 86(20): 1861.     CrossRef
  • Prevalence and impact on the outcome of myosteatosis in patients with cirrhosis: a systematic review and meta-analysis
    Aikaterini Kamiliou, Vasileios Lekakis, Lampros Chrysavgis, Evangelos Cholongitas
    Hepatology International.2024; 18(2): 688.     CrossRef
  • Prevalence of and Impact on the Outcome of Myosteatosis in Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
    Aikaterini Kamiliou, Vasileios Lekakis, George Xynos, Evangelos Cholongitas
    Cancers.2024; 16(5): 952.     CrossRef
  • Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting
    Alina M. Allen, Michael Charlton, Kenneth Cusi, Stephen A. Harrison, Kris V. Kowdley, Mazen Noureddin, Jay H. Shubrook
    Postgraduate Medicine.2024; 136(3): 229.     CrossRef
  • Metabolic Dysfunction–Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options
    Piero Portincasa, Mohamad Khalil, Laura Mahdi, Valeria Perniola, Valeria Idone, Annarita Graziani, Gyorgy Baffy, Agostino Di Ciaula
    International Journal of Molecular Sciences.2024; 25(11): 5640.     CrossRef
  • Association between metabolic dysfunction‐associated steatotic liver disease and myosteatosis measured by computed tomography
    Myung Jin Kim, Yun Kyung Cho, Eun Hee Kim, Min Jung Lee, Woo Je Lee, Hong‐Kyu Kim, Chang Hee Jung
    Journal of Cachexia, Sarcopenia and Muscle.2024; 15(5): 1942.     CrossRef
  • The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis
    Xiaoyan Li, Jie He, Qiuhua Sun
    Clinical Nutrition.2024; 43(9): 2005.     CrossRef
  • Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular c
    Toru Nakamura, Masahito Nakano, Tsubasa Tsutsumi, Keisuke Amano, Takumi Kawaguchi
    Clinical and Molecular Hepatology.2024; 30(4): 705.     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study
    Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon, Hyung Ho Lee, Heejoo Park, Jian Lee, Youngsun Park, Byungyoon Yun, Jinsoo Chung
    Cancers.2024; 16(18): 3161.     CrossRef
  • Diagnosis and management of metabolic dysfunction- associated steatotic liver disease in South Asians- A clinical review
    Prajith Raj Ramesh, Priya Krishnan, Samyuktha Prabu, Varshini Srinivasan, Varalakshmi Niranjan
    Obesity Pillars.2024; 12: 100142.     CrossRef
  • Diagnosis and Management of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review
    Basile Njei, Prince Ameyaw, Yazan Al-Ajlouni, Lea-Pearl Njei, Sarpong Boateng
    Cureus.2024;[Epub]     CrossRef
  • Reply to correspondence on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”
    Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan
    Clinical and Molecular Hepatology.2024; 30(4): 1039.     CrossRef
  • Correspondence to editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”
    Hayeon Kim, Min Jeong Park, Myeong Gyu Kim, Kyungim Kim
    Clinical and Molecular Hepatology.2024; 30(4): 989.     CrossRef
  • Correlation and predictive value of novel anthropometric indicators with adult sarcopenia and sarcopenia obesity
    Xue Wu, Ziang Chen, Yuanhui Zhao, Hong Ren
    Scientific Reports.2024;[Epub]     CrossRef
  • Sarcopenia as a Risk Factor for Mortality in NAFLD: How Should We Diagnose It?
    Catherine Stankevicius, Rachel H. Davis, Dep Huynh, Martine Hatzi, Stephanie Morgillo, Alice S. Day
    Journal of Digestive Diseases.2024; 25(11-12): 645.     CrossRef
  • Non-alcoholic fatty liver disease in people with normal body weight
    S. V. Turkina, I. A. Tyshchenko, M. N. Titarenko
    Experimental and Clinical Gastroenterology.2024; (10): 36.     CrossRef
  • Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean?
    Eugene Han, Yong-ho Lee
    Clinical and Molecular Hepatology.2023; 29(4): 980.     CrossRef
  • Sodium-glucose co-transporter 2 inhibitors and Sarcopenia: A controversy that must be solved
    Baris Afsar, Rengin Elsurer Afsar
    Clinical Nutrition.2023; 42(12): 2338.     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
    Wah-Kheong Chan, Kee-Huat Chuah, Ruveena Bhavani Rajaram, Lee-Ling Lim, Jeyakantha Ratnasingam, Shireene Ratna Vethakkan
    Journal of Obesity & Metabolic Syndrome.2023; 32(3): 197.     CrossRef
  • The newly proposed Metabolic Score for Visceral Fat is a reliable tool for identifying non-alcoholic fatty liver disease, requiring attention to age-specific effects in both sexes
    Maobin Kuang, Jiajun Qiu, Dongdong Li, Chong Hu, Shuhua Zhang, Guotai Sheng, Yang Zou
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • 13,850 View
  • 414 Download
  • 49 Web of Science
  • Crossref

Correspondence

Steatotic liver disease

Correspondence on Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”
Seul Ki Han, Soon Koo Baik, Moon Young Kim
Clin Mol Hepatol 2023;29(3):817-819.
Published online May 17, 2023
DOI: https://doi.org/10.3350/cmh.2023.0155

Citations

Citations to this article as recorded by  Crossref logo
  • Nanoplastics disrupt hepatic lipid metabolism via the inhibition of PPARγ: a study based on digestive system exposure
    Shenya Xu, Mei Li, Yudan Zheng, Menghuan Xu, Jieyu Zhou, Shizhi Wang, Shuwei Li, Meilin Wang
    Toxicology.2025; 516: 154194.     CrossRef
  • Gut microbiota heterogeneity in non-alcoholic fatty liver disease: a narrative review of drivers, mechanisms, and clinical relevance
    Ying Guo, Naisi Zhang, Dongmei Pei
    Frontiers in Microbiology.2025;[Epub]     CrossRef
  • 7,587 View
  • 55 Download
  • Crossref

Letter to the Editor

Steatotic liver disease

Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”
Seogsong Jeong, Yohwan Lim, Su Kyoung Lee, Hyun Wook Han
Clin Mol Hepatol 2023;29(3):810-811.
Published online May 8, 2023
DOI: https://doi.org/10.3350/cmh.2023.0129

Citations

Citations to this article as recorded by  Crossref logo
  • Association of metabolic dysfunction-associated steatotic liver disease trajectories with incident liver cancer: a UK Biobank cohort study
    Ryuk Jun Kwon, Yohwan Lim
    Frontiers in Endocrinology.2026;[Epub]     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study
    Woo-Young Shin, Eun Seok Kang, Yun Hwan Oh, Meng Sha, Qiang Xia, Seogsong Jeong, Yoosun Cho
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Identification of potentially effective drugs for metabolic dysfunction-associated steatotic liver disease against liver cirrhosis: In-silico drug repositioning-based retrospective cohort study
    Chae Won Lee, Eun Seok Kang, Seogsong Jeong, Hyun Wook Han, Samuel O. Antwi
    PLOS One.2025; 20(6): e0323880.     CrossRef
  • 7,777 View
  • 80 Download
  • 4 Web of Science
  • Crossref

Original Article

Viral hepatitis

Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis
Yu Jun Wong, Vy H. Nguyen, Hwai-I Yang, Jie Li, Michael Huan Le, Wan-Jung Wu, Nicole Xinrong Han, Khi Yung Fong, Elizebeth Chen, Connie Wong, Fajuan Rui, Xiaoming Xu, Qi Xue, Xin Yu Hu, Wei Qiang Leow, George Boon-Bee Goh, Ramsey Cheung, Grace Wong, Vincent Wai-Sun Wong, Ming-Whei Yu, Mindie H. Nguyen
Clin Mol Hepatol 2023;29(3):705-720.
Published online May 8, 2023
DOI: https://doi.org/10.3350/cmh.2023.0004
Background/Aims
Chronic hepatitis B (CHB) and fatty liver (FL) often co-exist, but natural history data of this dual condition (CHB-FL) are sparse. Via a systematic review, conventional meta-analysis (MA) and individual patient-level data MA (IPDMA), we compared liver-related outcomes and mortality between CHB-FL and CHB-no FL patients.
Methods
We searched 4 databases from inception to December 2021 and pooled study-level estimates using a random- effects model for conventional MA. For IPDMA, we evaluated outcomes after balancing the two study groups with inverse probability treatment weighting (IPTW) on age, sex, cirrhosis, diabetes, ALT, HBeAg, HBV DNA, and antiviral treatment.
Results
We screened 2,157 articles and included 19 eligible studies (17,955 patients: 11,908 CHB-no FL; 6,047 CHB-FL) in conventional MA, which found severe heterogeneity (I2=88–95%) and no significant differences in HCC, cirrhosis, mortality, or HBsAg seroclearance incidence (P=0.27–0.93). IPDMA included 13,262 patients: 8,625 CHB-no FL and 4,637 CHB-FL patients who differed in several characteristics. The IPTW cohort included 6,955 CHB-no FL and 3,346 CHB-FL well-matched patients. CHB-FL patients (vs. CHB-no FL) had significantly lower HCC, cirrhosis, mortality and higher HBsAg seroclearance incidence (all p≤0.002), with consistent results in subgroups. CHB-FL diagnosed by liver biopsy had a higher 10-year cumulative HCC incidence than CHB-FL diagnosed with non-invasive methods (63.6% vs. 4.3%, p<0.0001).
Conclusions
IPDMA data with well-matched CHB patient groups showed that FL (vs. no FL) was associated with significantly lower HCC, cirrhosis, and mortality risk and higher HBsAg seroclearance probability.

Citations

Citations to this article as recorded by  Crossref logo
  • Type 2 diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosis
    Jie Li, Liang Xu, Fajuan Rui, Sally Tran, Pei-Chien Tsai, Youwen Tan, Hidenori Toyoda, Qing-Lei Zeng, Huy Trinh, Yao-Chun Hsu, Tsunamasa Watanabe, Hiroshi Abe, Hiroyuki Motoyama, Yoko Yoshimaru, Takanori Suzuki, Taeang Arai, Masanori Atsukawa, Phillip Vut
    Hepatology.2026; 83(5): 1273.     CrossRef
  • Prediction of Hepatocellular Carcinoma and Other Liver‐Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction‐Associated Steatotic Liver Disease
    Lesley A. Patmore, Ivana Carey, Jordan J. Feld, Willem P. Brouwer, Keyur Patel, Maria Buti, Pieter Honkoop, Douwe F. Postma, Hans Blokzijl, Özgur. M. Koc, Eva van Oorschot, Kosh Agarwal, Marc van der Valk, Faydra I. Lieveld, Mai Kilany, Matthijs Kramer, J
    Alimentary Pharmacology & Therapeutics.2026; 63(3): 374.     CrossRef
  • Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy
    Yu Jun Wong
    Alimentary Pharmacology & Therapeutics.2026; 63(4): 574.     CrossRef
  • Impact of Non‐Alcoholic Fatty Liver Disease on the HBsAg Loss of Patients With Chronic Hepatitis B Treated in Pegylated Interferon Alpha
    Chujing Li, Lihua Lin, Pei Zhou, Haiyi Cai, Songlian Liu, Xiaoyuan Chen, Aiqi Lu, Bo Li, Yaping Wang, Chuanghua Luo, Jianping Li, Yujuan Guan, Zhiwei Xie
    Journal of Viral Hepatitis.2026;[Epub]     CrossRef
  • Association between deletions in the preS1/2 region of the hepatitis B virus genome and persistently abnormal ALT levels in patients with chronic hepatitis B treated with nucleos(t)ide analogs
    Yurina Sato, Kotaro Doi, Jun Inoue, Masashi Ninomiya, Mio Tsuruoka, Kosuke Sato, Masazumi Onuki, Satoko Sawahashi, Keishi Ouchi, Kengo Watanabe, Hirofumi Niitsuma, Atsushi Masamune
    Archives of Virology.2026;[Epub]     CrossRef
  • Risk stratification of metabolic dysfunction-associated steatotic liver disease: The KASL pathway: Editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease”
    May Xuan Goh, Xin En Goh, Jarell Jie-Rae Tan, Vincent L Chen, Yu Jun Wong
    Clinical and Molecular Hepatology.2026; 32(1): 429.     CrossRef
  • Metabolic health in antiviral era of chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”
    Shang-Chin Huang, Jia-Horng Kao
    Clinical and Molecular Hepatology.2026; 32(1): 423.     CrossRef
  • Diagnostic value of transient elastography in assessing the degree of liver fibrosis in chronic hepatitis B patients with low alanine aminotransferase levels and concomitant hepatic steatosis
    Aili Wang, Qingqing Wang, Huaie Liu
    Saudi Journal of Gastroenterology.2026; 32(3): 214.     CrossRef
  • Type 2 diabetes as a key metabolic risk factor for adverse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)id
    Heejoon Jang, Won Kim
    Clinical and Molecular Hepatology.2026; 32(1): 426.     CrossRef
  • Correspondence to editorial 2 on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”
    Rui Huang, Mindie H. Nguyen
    Clinical and Molecular Hepatology.2026; 32(1): e85.     CrossRef
  • Association between fatty liver and risk of liver failure in patients with acute hepatitis B: a retrospective cohort study
    Xiao-hao Wang, Yu-nan Chang, Lu Zhang, Yan-li Yang, Lu-wen Liang, Yi Zeng, Zhi Zhou, Shan Zhong, Hu Li
    Frontiers in Cellular and Infection Microbiology.2026;[Epub]     CrossRef
  • Association between diabetes and in‐hospital outcomes in patients with metabolic dysfunction‐associated steatotic liver disease hospitalized for cardiovascular disease: A nationwide database study
    Soichi Komaki, Michikazu Nakai, Yunosuke Matsuura, Kinuko Yamamoto, Hiroki Tanaka, Yuri Komaki, Masashi Yamaguchi, Kohei Moribayashi, Takeshi Ideguchi, Hiroshi Kawakami, Toshihiro Tsuruda, Koichi Kaikita
    Diabetic Medicine.2026;[Epub]     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease and Viral Hepatitis
    George Papatheodoridis, Vasileios Lekakis, Rafael Esteban, Maria Buti
    Clinics in Liver Disease.2026; 30(2): 557.     CrossRef
  • Steatosis paradox: Unraveling pathways of suppressive effect of hepatic steatosis on hepatitis B virus
    Shang-Chin Huang, Jia-Horng Kao
    Biomedical Journal.2026; 49(3): 100969.     CrossRef
  • Correlation analysis of Th1/Th2 cytokines and liver fibrosis indicators in chronic hepatitis B patients
    Chun Yu, Meiling Chen, Xiaonan Han, Yuhang Feng, Hongwei Sun, Hong Yang
    Journal of Medical Biochemistry.2026; 45(4): 749.     CrossRef
  • Multimorbidity patterns and their associations with healthcare services utilisation in inpatients with chronic hepatitis B infection from 2011 to 2023: a retrospective observational study
    Xu Wang, Jinzhao Xie, Yuankai Wu, Guanzi Chen, Huiyu Ao, Zifeng Liu, YuSheng Jie, Jing Gu
    BMJ Open.2026; 16(4): e106218.     CrossRef
  • Absence of steatosis combined with cardiometabolic risk factors confers the highest hepatocellular carcinoma risk in treated chronic hepatitis B
    Hung-Wei Wang, Hsueh-Chou Lai, Wei-Fan Hsu, Sheng-Hung Chen, Yi-Chun Kuo, Cheng-Yuan Peng
    Annals of Medicine.2026;[Epub]     CrossRef
  • Treatment strategies for patients with hepatitis B virus infection coexisting with hepatitis C virus or metabolic dysfunction-associated steatotic liver disease
    Chieh Liu, Yi-Fen Shih, Chun-Jen Liu
    Clinical and Molecular Hepatology.2026; 32(2): 565.     CrossRef
  • Prevalence and clinical impact of hepatic steatosis on autoimmune liver disease: A systematic review and meta-analysis
    Jarell Jie-Rae Tan, Ellina Lytvyak, Joo Wei Ethan Quek, Corrine Lee Singh, Yuan Jie Aidan Low, Shi Jie Ong, Mark Muthiah, Yu Jun Wong, Aldo J. Montano-Loza
    Hepatology Communications.2026;[Epub]     CrossRef
  • What is the impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on outcomes in people living with chronic hepatitis B (CHB)? An umbrella review protocol
    Emily Martyn, Jessica Carter, Maeve Barlow, Flora Olcott, Indrajit Ghosh, Elizabeth Waddilove, Alejandro Arenas-Pinto, Richard Gilson, Stuart Flanagan, WD Francois Venter, Jennifer Manne-Goehler, Sally Hargreaves, Emmanouil Tsochatizis, Douglas MacDonald,
    Wellcome Open Research.2026; 11: 285.     CrossRef
  • Diagnosing and defining MASLD in people living with chronic hepatitis B
    Emily Martyn, Alejandro Arenas-Pinto, Richard Gilson, Nomathemba Chandiwana, Stuart Flanagan, Douglas MacDonald, Emmanuel A. Tsochatzis, W. D. Francois Venter, Jennifer Manne-Goehler, Philippa C. Matthews
    Communications Medicine.2026;[Epub]     CrossRef
  • The Chronic Hepatitis B and Metabolic Dysfunction-Associated Steatotic Liver Disease Paradox: Friend or Foe?
    Shang-Chin Huang, Tai-Chung Tseng
    Gut and Liver.2026; 20(3): 350.     CrossRef
  • Concomitant Liver Steatosis in Chronic Hepatitis B Virus Infection Is Linked to a Distinct Cytokine Profile and Reduced Viral Load
    Katharina John, Marie-Louise Voss, Sherin Al Aoua, Martin Franck, Christine S Falk, Heiner Wedemeyer, Klaus Schulze-Osthoff, Heike Bantel
    The Journal of Infectious Diseases.2026;[Epub]     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease in chronic hepatitis B patients: risks of severe liver disease and cardiovascular disease
    Ningxin Zhang, Zhongwei Xu, Fei Lin, Haozhi Fan, Dehong Zhou, Shiqiu Zheng, Peng Jin, Huiquan Gu, Chengxiao Yu, Longfeng Jiang
    Frontiers in Cellular and Infection Microbiology.2026;[Epub]     CrossRef
  • Steatotic liver disease in autoimmune liver disease: Prevalence and clinical impact in a Southeast Asian cohort
    Jarell Jie-Rae Tan, Shwetha Thiyagarajan, Jessica Tan, Jeannie Ong, Kenneth Lin, Chin-Hock Nicholas Tee, Chin Kimg Tan, Andrew Tan, Daphne Ang, Tiing Leong Ang, Andrew Kwek, Yu Jun Wong
    Canadian Liver Journal.2026;[Epub]     CrossRef
  • Obesity management for the hepatologist—What to do, how to do it and why?
    Kymberly D. Watt, Sonali Paul, Mohammad Qasim Khan, Mohammad Siddiqui, Jenny Lam, Tayyab S. Diwan, Michael Camilleri
    Hepatology.2025; 81(5): 1607.     CrossRef
  • Pre-Existing and New-Onset Metabolic Dysfunctions Increase Cirrhosis and Its Complication Risks in Chronic Hepatitis B
    Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Sih-Han Liao, Shih-Jer Hsu, Chun-Ming Hong, Ting-Yuan Lan, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Jia-Horng Kao
    American Journal of Gastroenterology.2025; 120(2): 401.     CrossRef
  • Outcomes of radiofrequency ablation for hepatocellular carcinoma with concurrent steatotic liver disease
    Feng‐Pai Tsai, Tung‐Hung Su, Shang‐Chin Huang, Tai‐Chung Tseng, Shih‐Jer Hsu, Sih‐Han Liao, Chun‐Ming Hong, Chen‐Hua Liu, Hung‐Chih Yang, Chun‐Jen Liu, Pei‐Jer Chen, Jia‐Horng Kao
    Cancer.2025;[Epub]     CrossRef
  • Impact of age at HBsAg seroclearance on hepatic outcomes and life expectancy in men with chronic HBV infection based on multi-state modeling of the natural history
    Wen-Jie Liu, Wan-Jung Wu, Chih-Lin Lin, Chun-Jen Liu, Yi-Wen Huang, Jui-Ting Hu, Ming-Whei Yu
    Journal of Gastroenterology.2025; 60(1): 107.     CrossRef
  • All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease
    Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Shih-Jer Hsu, Chun-Ming Hong, Ting-Yuan Lan, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Jia-Horng Kao
    Journal of Hepatology.2025; 83(1): 43.     CrossRef
  • The 2024 updated WHO guidelines for the prevention and management of chronic hepatitis B: Main changes and potential implications for the next major liver society clinical practice guidelines
    Grace Lai-Hung Wong, Maud Lemoine
    Journal of Hepatology.2025; 82(5): 918.     CrossRef
  • The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
    Mohammed Eslam, Jian-Gao Fan, Ming-Lung Yu, Vincent Wai-Sun Wong, Ian Homer Cua, Chun-Jen Liu, Tawesak Tanwandee, Rino Gani, Wai-Kay Seto, Shahinul Alam, Dan Yock Young, Saeed Hamid, Ming-Hua Zheng, Takumi Kawaguchi, Wah-Kheong Chan, Diana Payawal, Soek-S
    Hepatology International.2025; 19(2): 261.     CrossRef
  • SLC22A1 Resists Hepatitis B Virus by Activating the JAK/STAT Pathway and Predicts the Effect of Pegylated Interferon α–Based Therapy on Chronic Hepatitis B
    Huiying Yu, Bin Li, Huili Guo, Lin Li, Xiaoquan Liu, Lili Wu, Na Gao, Qiyi Zhao, Xiuqing Pang, Zhiliang Gao
    The Journal of Infectious Diseases.2025; 232(2): 474.     CrossRef
  • Impact of hepatic steatosis on mortality, hepatocellular carcinoma, end-stage liver disease and HBsAg seroclearance in chronic hepatitis B: a United States cohort study
    George A. Yendewa, Abbinaya Elangovan, Temitope Olasehinde, Frank Mulindwa, Mackenzie G. Cater, Robert A. Salata, Jeffrey M. Jacobson
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Cohort Profile: Taizhou Study of Liver Diseases (T-SOLID)
    Zhenqiu Liu, Yanfeng Jiang, Chen Suo, Huangbo Yuan, Ziyu Yuan, Tiejun Zhang, Li Jin, Xingdong Chen
    International Journal of Epidemiology.2025;[Epub]     CrossRef
  • Unraveling Demographic Patterns in Hepatitis B Clinical and Laboratory Profiles: Insights From a Ghanaian Cohort: A Retrospective Study
    Napoleon Bellua Sam, Saeed Folorunsho Majeed, Adams Dramani
    Health Science Reports.2025;[Epub]     CrossRef
  • EASL Clinical Practice Guidelines on the management of hepatitis B virus infection
    Markus Cornberg, Lisa Sandmann, Jerzy Jaroszewicz, Patrick Kennedy, Pietro Lampertico, Maud Lemoine, Sabela Lens, Barbara Testoni, Grace Lai-Hung Wong, Francesco Paolo Russo
    Journal of Hepatology.2025; 83(2): 502.     CrossRef
  • Increasing Treatment Uptake for Chronic Hepatitis B in South America: A Comparative Analysis of Country‐Specific and WHO 2024 Guidelines
    Manuel Mendizabal, Constanza D. Sabate, Esteban González Ballerga, Fernando Gruz, Ezequiel Ridruejo, Alejandro Soza, Jaime Poniachik, Grace Vergara, Victoria Mainardi, Gabriel Mezzano, Fernando Bessone, Margarita Anders, Mario G. Pessoa, Fernando Cairo, D
    Journal of Viral Hepatitis.2025;[Epub]     CrossRef
  • Differential HCC risk among HBV indeterminate types at baseline and by phase transition
    Rui Huang, Huy N Trinh, Satoshi Yasuda, Angela Chau, Mayumi Maeda, Ai-Thien Do, Daniel Q Huang, Takanori Ito, Takashi Honda, Masatoshi Ishigami, Ritsuzo Kozuka, Carmen Monica Preda, Cheng-Hao Tseng, Sebastián Marciano, Pei-Chien Tsai, Dong Hyun Lee, Chris
    Gut.2025; 74(11): 1873.     CrossRef
  • Impact of Metabolic Dysfunction-Associated Fatty Liver Disease of Varying Severity on Antiviral Treatment Outcomes and Clinical Prognosis in Patients with Chronic Hepatitis B: A Systematic Review and Meta-analysis
    Qianqian Zhu, Chengde Su, Mingdan Li, Yali Xu, Qian Liu, Ying Zhang, Xinyi Zhang, Qiuxiang Li, Huajun Wang, Yawen Luo, Ping Yang
    Infectious Diseases and Therapy.2025; 14(8): 1599.     CrossRef
  • Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues
    Rui Huang, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Huy Trinh, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Haruki Uojima, Daniel Q. Huang, Takashi Honda, Yasuhito Tanaka, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masaru Enomoto, Masanori Ats
    Clinical and Molecular Hepatology.2025; 31(3): 1003.     CrossRef
  • Steatotic Liver Disease‐Related Polygenetic Risk Score Prediction of Hepatocellular Carcinoma in Nucleotide/Nucleoside Analog‐Treated Chronic Hepatitis B
    Tyng‐Yuan Jang, Chih‐Wen Wang, Po‐Cheng Liang, Yu‐Ju Wei, Ming‐Lun Yeh, Yi‐Hung Lin, Chao‐Kuan Huang, Pei‐Chien Tsai, Yu‐Min Ko, Yi‐Shan Tsai, Kuan‐Yu Chen, Ching‐Chih Lin, Zu‐Yau Lin, Jee‐Fu Huang, Chia‐Yen Dai, Chung‐Feng Huang, Wan‐Long Chuang, Ming‐Lu
    Journal of Gastroenterology and Hepatology.2025; 40(9): 2290.     CrossRef
  • Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort study
    Rui Huang, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Huy Trinh, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Haruki Uojima, Daniel Q. Huang, Takashi Honda, Yasuhito Tanaka, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masaru Enomoto, Masanori Ats
    eClinicalMedicine.2025; 87: 103407.     CrossRef
  • Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis
    Frances Sze Kei Sun, Jeffrey Sum Lung Wong, Lung-Yi Mak, Carmen Chak-Lui Wong, Valerie Chew, Bryan Cho Wing Li, Roland Leung, Tan To Cheung, Thomas Yau
    Liver Cancer.2025; 15(3): 480.     CrossRef
  • Impact of fatty liver disease on hepatic function and fibrosis progression in chronic hepatitis B patients: a narrative review
    Rushi V. Mukkawar, Nishant Rathod, Rajvardhan Patil, Sunil Kumar, Sourya Acharya
    International Journal of Nutrition, Pharmacology, Neurological Diseases.2025; 15(4): 368.     CrossRef
  • Association Between SGLT2 Inhibitor Use and Reduced Risk of Liver-Related Events, Including Hepatocellular Carcinoma, in Diabetic Patients with Viral Hepatitis: A Nationwide Cohort Study
    Seong Hee Kang, Jimi Choi, Hyung Joon Yim, Young Kul Jung, Sun Young Yim, Young-Sun Lee, Yeon Seok Seo, Ji Hoon Kim, Jong Eun Yeon, Kwan Soo Byun
    Cancers.2025; 18(1): 120.     CrossRef
  • Chronic Hepatitis B and Steatotic Liver Disease: A Blessing in Disguise?
    Xiaoming Xu, Mindie H. Nguyen, Jie Li
    Clinical Gastroenterology and Hepatology.2024; 22(9): 1956.     CrossRef
  • Liver function indicators and risk of hepatocellular carcinoma: a bidirectional mendelian randomization study
    Shanshan Qin, Jing Wang, Haiqing Yuan, Jingzhen He, Shoujing Luan, Yan Deng
    Frontiers in Genetics.2024;[Epub]     CrossRef
  • The co-existence of NAFLD and CHB is associated with suboptimal viral and biochemical response to CHB antiviral therapy: a systematic review and meta-analysis
    Georgia Zeng, Benjamin R. Holmes, Saleh A. Alqahtani, Upkar S. Gill, Patrick T. F. Kennedy
    Frontiers in Gastroenterology.2024;[Epub]     CrossRef
  • Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond
    Allison Soto, Colby Spongberg, Alessandro Martinino, Francesco Giovinazzo
    Biomedicines.2024; 12(2): 397.     CrossRef
  • Impact of chronic hepatitis B and concurrent steatosis on the risk of hepatocellular carcinoma
    Ibrahim Ayada, Jiajing Li, Willem Pieter Brouwer, Robert J. de Knegt, Qiuwei Pan
    Hepatology International.2024; 18(3): 1053.     CrossRef
  • Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study
    Tyng‐Yuan Jang, Po‐Cheng Liang, Dae Won Jun, Jang Han Jung, Hidenori Toyoda, Chih‐Wen Wang, Man‐Fung Yuen, Ka Shing Cheung, Satoshi Yasuda, Sung Eun Kim, Eileen L Yoon, Jihyun An, Masaru Enomoto, Ritsuzo Kozuka, Makoto Chuma, Akito Nozaki, Toru Ishikawa,
    Journal of Gastroenterology and Hepatology.2024; 39(6): 1190.     CrossRef
  • Impact of metabolic disorders on chronic hepatitis B
    Shang-Chin Huang, Chun-Jen Liu, Jia-Horng Kao
    Clinical Liver Disease.2024;[Epub]     CrossRef
  • Antiviral therapy response in patients with chronic hepatitis B and fatty liver: A systematic review and meta‐analysis
    Fajuan Rui, Elizabeth Garcia, Xinyu Hu, Wenjing Ni, Qi Xue, Yayun Xu, Xiaoming Xu, Junping Shi, Mindie H. Nguyen, Ramsey C. Cheung, Jie Li
    Journal of Viral Hepatitis.2024; 31(7): 372.     CrossRef
  • Inpatient Cost Burdens of Treating Chronic Hepatitis B in US Hospitals: A Weighted Analysis of a National Database
    David Uihwan Lee, Kuntal Bhowmick, Sindhura Kolachana, Kimberly Schuster, Aneesh Bahadur, Ashton Harmacinski, Sophie Schellhammer, Gregory Hongyuan Fan, Ki Jung Lee, Catherine Sun, Hannah Chou, Zurabi Lominadze
    Digestive Diseases and Sciences.2024; 69(7): 2401.     CrossRef
  • Hepatocellular carcinoma surveillance after HBsAg seroclearance
    Jimmy Che-To Lai, Vicki Wing-Ki Hui, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip
    Exploration of Digestive Diseases.2024; : 175.     CrossRef
  • Liver health in hemophilia in the era of gene therapy
    Yesim Dargaud, Massimo Levrero, François Bailly, Anne Lienhart, Fabien Zoulim
    Thrombosis Research.2024; 240: 109064.     CrossRef
  • Global epidemiology, natural history, maternal-to-child transmission, and treatment with DAA of pregnant women with HCV: a systematic review and meta-analysis
    Joo Wei Ethan Quek, Jing Hong Loo, En Qi Lim, Ambrose Hon-Lam Chung, Abu Bakar Bin Othman, Jarell Jie-Rae Tan, Scott Barnett, Mindie H. Nguyen, Yu Jun Wong
    eClinicalMedicine.2024; 74: 102727.     CrossRef
  • Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD
    Chun-Jen Liu, Wai Kay Seto, Ming-Lung Yu
    Hepatology International.2024; 18(S2): 897.     CrossRef
  • Canadian Association for the Study of the Liver Single Topic Conference on Hepatitis B Virus: ‘Progress toward hepatitis B elimination in Canada’
    Julian Hercun, Golasa Samadi Kochaksaraei, Simmone D'souza, Rachel Talavlikar, Jennifer Van Gennip, Carla Osiowy, Carla S Coffin, Harley Crowshoe
    Canadian Liver Journal.2024; 7(3): 385.     CrossRef
  • Chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease: Metabolic risk factors are key drivers of hepatocellular carcinoma
    Gupse Adali, Huseyin Aykut, Nermin Mutlu Bilgic, Yusuf Yilmaz
    Heliyon.2024; 10(18): e37990.     CrossRef
  • Influence of nonalcoholic fatty liver disease on the therapeutic effect of nucleoside (acid) analogs for hepatitis B virus
    Hua-Dong Li, Ya-Nan Liu, Shuang Wu, Xu-Feng Quan, Xiao-Yan Wang, Tian-Dan Xiang, Shu-Meng Li, Ling Xu, Tong Wang, Hua Wang, Xin Zheng
    World Journal of Hepatology.2024; 16(12): 1395.     CrossRef
  • Revolutionizing the understanding of liver disease: Metabolism, function and future
    Arnulfo E Morales-Galicia, Mariana M Ramírez-Mejía, Guadalupe Ponciano-Rodriguez, Nahum Méndez-Sánchez
    World Journal of Hepatology.2024; 16(12): 1365.     CrossRef
  • The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B
    Xianhua Mao, Lung Yi Mak, Wai-Kay Seto
    Clinical and Molecular Hepatology.2023; 29(3): 690.     CrossRef
  • Survival of Patients with Hepatitis B-Related Hepatocellular Carcinoma with Concomitant Metabolic Associated Fatty Liver Disease
    Yajing You, Tao Yang, Shuhang Wei, Zongxin Liu, Chenxi Liu, Zijian Shen, Yinuo Yang, Yuemin Feng, Ping Yao, Qiang Zhu
    Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 2283.     CrossRef
  • From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials
    Ming-Lun Yeh, Ming-Lung Yu
    Clinical and Molecular Hepatology.2023; 29(4): 969.     CrossRef
  • Persistent steatosis correlates with decreased fibrosis regression during anti‐HBV treatment in patients with chronic HBV infection
    Mengyang Zhang, Shuyan Chen, Xiaoning Wu, Jialing Zhou, Tailing Wang, Hui Liu, Xinyan Zhao, Bingqiong Wang, Xinyu Zhao, Yuanyuan Kong, Gwyneth Shook Ting Soon, Xiaojuan Ou, Jidong Jia, Wei Chen, Yameng Sun, Hong You
    Journal of Medical Virology.2023;[Epub]     CrossRef
  • Waiting for the changes after the adoption of steatotic liver disease
    Eileen L. Yoon, Dae Won Jun
    Clinical and Molecular Hepatology.2023; 29(4): 844.     CrossRef
  • 15,458 View
  • 422 Download
  • 67 Web of Science
  • Crossref

Editorials

Steatotic liver disease

Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology
Eileen Laurel Yoon, Dae Won Jun
Clin Mol Hepatol 2023;29(2):371-373.
Published online March 14, 2023
DOI: https://doi.org/10.3350/cmh.2023.0086

Citations

Citations to this article as recorded by  Crossref logo
  • Identification of EGR1 as a Key Diagnostic Biomarker in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Through Machine Learning and Immune Analysis
    Xuanlin Wu, Tao Pan, Zhihao Fang, Titi Hui, Xiaoxiao Yu, Changxu Liu, Zihao Guo, Chang Liu
    Journal of Inflammation Research.2025; Volume 18: 1639.     CrossRef
  • Molecular Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Transcriptome Analysis
    Gina Ryu, Eileen Laurel Yoon, Wankyu Kim, Dae Won Jun
    Diagnostics.2025; 15(3): 342.     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease, Recent Revision of Terminology and Its Implications
    Hyo Young Lee, Eileen L. Yoon
    The Korean Journal of Gastroenterology.2025; 85(2): 126.     CrossRef
  • Association of elevated Alpha-1-Acid glycoprotein with MAFLD prevalence in young and middle-aged women: a cross-sectional study based on NHANES 2017–2020
    Yi Xiao, Xian Luo, Yinghao Fu, Haijuan Huang, Qiaoping Gao, Jiansong Liu, Daxin Pang, Xiaolu Liang, Huadi Chen, Hao Xu
    Diabetology & Metabolic Syndrome.2025;[Epub]     CrossRef
  • The emerging phenotype of nonalcoholic fatty liver disease in lean individuals: what’s different?
    Priyankar Dey
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Laboratory monitoring in patients with moderate to severe plaque psoriasis
    Jonathan M. Fenkel, John A. Osborne, April W. Armstrong, Bruce Strober, Linda Stein Gold, Michael Cameron, Mark Lebwohl
    Journal of Dermatological Treatment.2025;[Epub]     CrossRef
  • Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences
    Joo Hyun Oh, Dae Won Jun
    Clinical and Molecular Hepatology.2024; 30(2): 168.     CrossRef
  • Glucose‐lowering drugs and liver‐related outcomes among individuals with type 2 diabetes: A systematic review of longitudinal population‐based studies
    Shaghayegh Khanmohammadi, Amirhossein Habibzadeh, A. B. M. Kamrul‐Hasan, Art Schuermans, Mohammad Shafi Kuchay
    Diabetic Medicine.2024;[Epub]     CrossRef
  • Exploring the relationship between air pollution, non-alcoholic fatty liver disease, and liver function indicators: a two-sample Mendelian randomization analysis study
    Qingliang Song, Jinyue Pan, Maoxing Pan, Chuiyang Zheng, Wen Fan, Jianwei Zhen, Dajin Pi, Zheng Liang, Haiyan Shen, Yuanyou Li, Qinhe Yang, Yupei Zhang
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Waiting for the changes after the adoption of steatotic liver disease
    Eileen L. Yoon, Dae Won Jun
    Clinical and Molecular Hepatology.2023; 29(4): 844.     CrossRef
  • Correspondence on Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”
    Eileen L. Yoon, Dae Won Jun
    Clinical and Molecular Hepatology.2023; 30(1): 126.     CrossRef
  • 8,752 View
  • 150 Download
  • 12 Web of Science
  • Crossref

Steatotic liver disease

Implications of comorbidities in nonalcoholic fatty liver disease
Sherlot Juan Song, Vincent Wai-Sun Wong
Clin Mol Hepatol 2023;29(2):384-389.
Published online March 14, 2023
DOI: https://doi.org/10.3350/cmh.2023.0066

Citations

Citations to this article as recorded by  Crossref logo
  • Meta‐analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non‐alcoholic steatohepatitis and non‐alcoholic steatohepatitis‐related fibrosis
    Rutao Lin, Jianghua Zhou, Qinmei Sun, Xin Xin, Yiyang Hu, Minghua Zheng, Qin Feng
    Alimentary Pharmacology & Therapeutics.2024; 59(7): 802.     CrossRef
  • Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis
    Juchul Hwang, Hyeyoung Hwang, Hyunjae Shin, Bo Hyun Kim, Seong Hee Kang, Jeong-Ju Yoo, Mi Young Choi, Dong eun Lee, Dae Won Jun, Yuri Cho
    Clinical and Molecular Hepatology.2024; 30(3): 561.     CrossRef
  • 10,605 View
  • 102 Download
  • 3 Web of Science
  • Crossref

Steatotic liver disease

Non-obese or lean nonalcoholic fatty liver disease matters, but is it preventable or inevitable in light of its risk factors?
Heejoon Jang, Won Kim
Clin Mol Hepatol 2023;29(2):381-383.
Published online March 9, 2023
DOI: https://doi.org/10.3350/cmh.2023.0088

Citations

Citations to this article as recorded by  Crossref logo
  • Serum vitamin D and lean non-alcoholic fatty liver disease: a nonlinear ‘L-shaped’ association in a national cross-sectional study
    Gang Ma, Chongxiao Li, Erzhuo Xia, Jingbo Wang, Ying Han
    Annals of Medicine.2026;[Epub]     CrossRef
  • Ceramide‐mediated mitochondrial dysfunction in nonobese nonalcoholic fatty liver disease: A regulatory role for serine palmitoyltransferase subunit 2
    Li‐Jun Xue, Guang‐Yan Yao, Fei‐Fei Fan, Kai‐Min Li, Wen‐Ming Wu
    Journal of Cell Communication and Signaling.2026;[Epub]     CrossRef
  • Genetic and Metabolic Characteristics of Lean Nonalcoholic Fatty Liver Disease in a Korean Health Examinee Cohort
    Huiyul Park, Eileen L. Yoon, Goh Eun Chung, Eun Kyung Choe, Jung Ho Bae, Seung Ho Choi, Mimi Kim, Woochang Hwang, Hye-Lin Kim, Sun Young Yang, Dae Won Jun
    Gut and Liver.2024; 18(2): 316.     CrossRef
  • Dietary inflammatory impact on NAFLD development in obese vs. lean individuals: an analysis based on NHANES 2003–2018
    Lurao Li, Xiawen Shu, Yun Yi, Chun Wang, Jianghui Li, Yang Ding, Jin Li, Ying Chang
    Lipids in Health and Disease.2024;[Epub]     CrossRef
  • Obesity and risk for liver disease: a two-sample Mendelian randomisation study
    Wen An, Jing Luo, Zhe Yu, Mengqi Li, Herui Wei, Aqian Song, Yuanpeng Mao, Hao Bian, Lingling He, Fan Xiao, Hongshan Wei
    British Journal of Nutrition.2024; 132(10): 1403.     CrossRef
  • Epigenetic Regulation in Lean Nonalcoholic Fatty Liver Disease
    Ioanna Aggeletopoulou, Maria Kalafateli, Efthymios P. Tsounis, Christos Triantos
    International Journal of Molecular Sciences.2023; 24(16): 12864.     CrossRef
  • 9,195 View
  • 116 Download
  • 6 Web of Science
  • Crossref

Steatotic liver disease

How to optimize the outcome of liver transplantation for non-alcoholic fatty liver disease
Byeong Geun Song, Dong Hyun Sinn
Clin Mol Hepatol 2023;29(2):411-413.
Published online March 6, 2023
DOI: https://doi.org/10.3350/cmh.2023.0058

Citations

Citations to this article as recorded by  Crossref logo
  • Microemulsion co-delivering curcumin and DHA-rich algal oil alleviates nonalcoholic fatty liver disease
    Jianlin He, Weizhu Chen, Sisi Chen, Menglei Shi, Ling Lin, Yiping Zhang, Bihong Hong
    Journal of Functional Foods.2024; 112: 105998.     CrossRef
  • Liver transplantation for alcohol-related liver disease in Korea: The need for patient management guidelines
    Soon Kyu Lee
    Annals of Liver Transplantation.2024; 4(2): 40.     CrossRef
  • 7,368 View
  • 66 Download
  • 1 Web of Science
  • Crossref

Steatotic liver disease

The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review
Young-Joo Jin
Clin Mol Hepatol 2023;29(2):414-416.
Published online February 28, 2023
DOI: https://doi.org/10.3350/cmh.2023.0055

Citations

Citations to this article as recorded by  Crossref logo
  • Exercise as a Metabolic Therapy for MASLD: Beyond Weight Loss Toward Sustainable Exercise Strategies
    Hee-Tae Roh, Ju-Yong Bae
    Medicina.2026; 62(4): 784.     CrossRef
  • The impact of resistance training in patients diagnosed with metabolic dysfunction-associated steatotic liver disease: a systematic review
    Daniele Gorski Medeiros, Luis Fernando Ferreira, Jessica da Silva Lamp, Luis Henrique Telles da Rosa
    European Journal of Gastroenterology & Hepatology.2025; 37(2): 129.     CrossRef
  • 8,839 View
  • 85 Download
  • Crossref

Reviews

Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives
Shang-Chin Huang, Chun-Jen Liu
Clin Mol Hepatol 2023;29(2):320-331.
Published online February 1, 2023
DOI: https://doi.org/10.3350/cmh.2022.0422
The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) has increased among the general population and chronic hepatitis B (CHB) patients worldwide. Although fatty liver disease is a well-known risk factor for adverse liver outcomes like cirrhosis and hepatocellular carcinoma, its interactions with the hepatitis B virus (HBV) and clinical impacts seem complex. The presence of hepatic steatosis may suppress HBV viral activity, potentially leading to attenuated liver injury. In contrast, the associated co-morbidities like diabetes mellitus or obesity may increase the risk of developing adverse liver outcomes. These findings implicate that components of MAFLD may have diverse effects on the clinical manifestations of CHB. To this end, a clinical strategy is proposed for managing patients with concurrent CHB and MAFLD. This review article discusses the updated evidence regarding disease prevalence, interactions between steatosis and HBV, clinical impacts, and management strategies, aiming at optimizing holistic health care in the CHB population.

Citations

Citations to this article as recorded by  Crossref logo
  • Unraveling the metabolic thread: Type 2 diabetes and fibrosis in chronic hepatitis B with steatosis
    Won-Mook Choi, Wai-Kay Seto
    Hepatology.2026; 83(5): 1046.     CrossRef
  • Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease in a Cohort of Patients With Chronic Hepatitis B
    Maria Kalafateli, Roberta Forlano, Eleanor Barnes, Laura Martinez-Gili, Madeleine Lacey, Giordano Sigon, Benjamin H. Mullish, Vincent Mallet, Lucia Parlati, Paul Richardson, Niamh Forde, Gaetano Serviddio, Rosanna Villani, Sabela Lens, Maria Buti, Elena V
    Clinical Gastroenterology and Hepatology.2026; 24(3): 701.     CrossRef
  • Triglyceride-based lipotoxicity in the pathophysiology of chronic diseases
    Junjun Liu, Xiude Fan, Yongfeng Song, Jiajun Zhao
    Trends in Endocrinology & Metabolism.2026; 37(4): 371.     CrossRef
  • CRISPR: a precise genome editing strategy for the treatment of hepatocellular carcinoma
    Subhrojyoti Mukherjee, Manish Kumar
    Expert Review of Anticancer Therapy.2026; 26(5): 599.     CrossRef
  • Metabolic health in antiviral era of chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”
    Shang-Chin Huang, Jia-Horng Kao
    Clinical and Molecular Hepatology.2026; 32(1): 423.     CrossRef
  • The impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of pegylated interferon-based therapy in patients with chronic hepatitis B
    Jiaxin Han, Lianxin Xu, Yuqin Li, Ziling Wang, Minghui Zeng, Jieru Gao, Yuqiang Mi, Wentao Kuai, Huiling Xiang, Liang Xu
    Frontiers in Immunology.2026;[Epub]     CrossRef
  • Association between fatty liver and risk of liver failure in patients with acute hepatitis B: a retrospective cohort study
    Xiao-hao Wang, Yu-nan Chang, Lu Zhang, Yan-li Yang, Lu-wen Liang, Yi Zeng, Zhi Zhou, Shan Zhong, Hu Li
    Frontiers in Cellular and Infection Microbiology.2026;[Epub]     CrossRef
  • Viral hepatitis and liver disease in the Mongolian community in London ('MoLo'): A mixed methods study protocol to investigate the epidemiology and burden of disease to inform clinical and public health interventions
    Emily Martyn, Nara Dashdorj, Jessica Carter, Indrajit Ghosh, Enkh-Oyun Amarbayasgalan, Khadija Said Mohammed, Elizabeth Waddilove, Marion Delphin, Kathryn Jack, Camila Picchio, Joy Ko, Michelle Berkeley, Rubin Rose-Key, Eleni Nastouli, Sema Mandal, Monica
    Wellcome Open Research.2026; 11: 72.     CrossRef
  • Clinical and histopathological features of chronic hepatitis B with normal alanine aminotransferase levels with or without concomitant non-alcoholic fatty liver disease
    Wencong Li, Shiheng Liu, Weiguang Ren, Xiaoxiao Zhang, Lingdi Liu, Fang Han, Ying Zhang, Yuemin Nan, Suxian Zhao
    Frontiers in Medicine.2026;[Epub]     CrossRef
  • Association between diabetes and in‐hospital outcomes in patients with metabolic dysfunction‐associated steatotic liver disease hospitalized for cardiovascular disease: A nationwide database study
    Soichi Komaki, Michikazu Nakai, Yunosuke Matsuura, Kinuko Yamamoto, Hiroki Tanaka, Yuri Komaki, Masashi Yamaguchi, Kohei Moribayashi, Takeshi Ideguchi, Hiroshi Kawakami, Toshihiro Tsuruda, Koichi Kaikita
    Diabetic Medicine.2026;[Epub]     CrossRef
  • Hepatitis B virus exposure and metabolic dysfunction-associated steatotic liver disease in U.S. adults: A nationally representative analysis from NHANES 2017-2020
    Youping Lin, Yanjuan Song, Qiuming Lin, Minran Li
    The American Journal of the Medical Sciences.2026; 372(1): 52.     CrossRef
  • Nomogram integrating serological markers and clinical parameters for predicting severe hepatic steatosis in patients with abnormal glucose metabolism
    Ping Hu, Ao Zhong, Yuting Shen, Yinchen Yuan, Qing Jin, Quan Chen
    Diabetology & Metabolic Syndrome.2026;[Epub]     CrossRef
  • Steatosis paradox: Unraveling pathways of suppressive effect of hepatic steatosis on hepatitis B virus
    Shang-Chin Huang, Jia-Horng Kao
    Biomedical Journal.2026; 49(3): 100969.     CrossRef
  • Periodontitis and Chronic Liver Disease: Mechanistic Insights Focusing on Porphyromonas gingivalis—A Narrative Review
    Yue Ying, Yuwei Nie, Jiahui Zhao, Qin Dong, Meixian Chen, Aijia Jiang, Nan Liu, Tong Xu, Junchao Liu, Yaping Pan, Li Lin, Dongmei Zhang
    Microorganisms.2026; 14(4): 736.     CrossRef
  • Predicting the highly imbalanced hepatitis B virus infection outcome in Chinese middle-aged and older adults using an ensemble machine learning approach
    Chen Sun, Xiaohan Yi, Nyi Nyi Soe, Phyu Mon Latt, Biying Wang, Zhongqun Zhao, Zhen Yu, Xianglong Xu
    Discover Public Health.2026;[Epub]     CrossRef
  • The stealthy saboteur: hepatic steatosis and its erosion of APRI and FIB-4 accuracy
    Huaying Zhou, Yuhong Li, Maoping Li, Jing Ma
    Frontiers in Medicine.2026;[Epub]     CrossRef
  • Mechanisms and Management Strategies of Hepatocarcinogenesis Driven by Chronic Hepatitis B Comorbid with Type 2 Diabetes
    Qin Lou, Jiarong Cai, Jianhua Yin
    Microorganisms.2026; 14(4): 853.     CrossRef
  • Treatment strategies for patients with hepatitis B virus infection coexisting with hepatitis C virus or metabolic dysfunction-associated steatotic liver disease
    Chieh Liu, Yi-Fen Shih, Chun-Jen Liu
    Clinical and Molecular Hepatology.2026; 32(2): 565.     CrossRef
  • Retrospective analysis of predictors for significant hepatic inflammation in metabolic-associated fatty liver disease with chronic hepatitis B
    Long Hao Xu, Run Yan He, Yan Neng Kang, Heng Hong Lin, Jia En Yang, Hua Xiao Chen, Xue Ting Huang, Xiao Lu Wu, Bao Hui Pei, Chao Zhou, Min Wang
    PeerJ.2026; 14: e21186.     CrossRef
  • Diagnosing and defining MASLD in people living with chronic hepatitis B
    Emily Martyn, Alejandro Arenas-Pinto, Richard Gilson, Nomathemba Chandiwana, Stuart Flanagan, Douglas MacDonald, Emmanuel A. Tsochatzis, W. D. Francois Venter, Jennifer Manne-Goehler, Philippa C. Matthews
    Communications Medicine.2026;[Epub]     CrossRef
  • Limited Utility of Serum Scores vs. Shear Wave Elastography for Graft Fibrosis in Adult and Pediatric Liver Transplant Recipients
    Si-Rui Wang, Shu-Chun Wang, Zhan-Xiong Yi, En-Hui He, Jun-Feng Zhao, Xiang-Dong Hu
    Ultrasound in Medicine & Biology.2026; 52(8): 1671.     CrossRef
  • The Chronic Hepatitis B and Metabolic Dysfunction-Associated Steatotic Liver Disease Paradox: Friend or Foe?
    Shang-Chin Huang, Tai-Chung Tseng
    Gut and Liver.2026; 20(3): 350.     CrossRef
  • Knowledge, attitude, and practice towards fatty liver disease among the general population in Shanghai, China: a community-based cross-sectional study
    Xue Yang, Hui Chang, Limei Feng, Bin Wang
    Frontiers in Public Health.2026;[Epub]     CrossRef
  • What is the impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on outcomes in people living with chronic hepatitis B (CHB)? An umbrella review protocol
    Emily Martyn, Jessica Carter, Maeve Barlow, Flora Olcott, Indrajit Ghosh, Elizabeth Waddilove, Alejandro Arenas-Pinto, Richard Gilson, Stuart Flanagan, WD Francois Venter, Jennifer Manne-Goehler, Sally Hargreaves, Emmanouil Tsochatizis, Douglas MacDonald,
    Wellcome Open Research.2026; 11: 285.     CrossRef
  • Coexistent Hepatitis B Virus and Metabolic Dysfunction-Associated Steatotic Liver Disease Under the New Definition: A New Era for Established Diseases
    Ahmed Tawheed, Abdulla A. Mahmoud, Hussein Hassan Aly, Mohamed El-Kassas
    Livers.2026; 6(3): 44.     CrossRef
  • Beyond fibrosis: The imperative for dual steatosis and fibrosis assessment in chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease co-pathology
    Francesco Giangregorio, Elisa Civaschi, Samanta Mazzocchi, Davide Romano, Paolo Clini, Esther Centenara, Umberto Casale, Davide Catucci
    World Journal of Hepatology.2026;[Epub]     CrossRef
  • Aloe emodin isolated from Cassiae semen upregulates IFITM1 to suppress hepatitis B virus replication via the interferon signaling pathway
    Xin Wen, Xincan Yu, Yuxin Hu, Jiamin Chen, Dongwei Zhang, Yalin Hou, Shui Liu, Xuemeng Shi, Jun Xu, Felicia Goodrum
    mSphere.2026;[Epub]     CrossRef
  • Metabolic dysfunction-associated fatty liver disease in chronic hepatitis B: dual effects on hepatocarcinogenesis and evolving strategies for risk prediction
    Huihui Tao, Yuxin Duan, Guoyang Yu, Wei Yan, Jianhua Yin
    Frontiers in Immunology.2026;[Epub]     CrossRef
  • The coexistence of MAFLD increases fibrosis burden in patients with chronic hepatitis B
    Alaa Mohamed Mostafa, Yasser Fouad, Nadia Abdelaaty Abdelkader, Omar Magdy, Nehal Refaat Raouf, Mohammed Eslam
    Scientific Reports.2026;[Epub]     CrossRef
  • Pre-Existing and New-Onset Metabolic Dysfunctions Increase Cirrhosis and Its Complication Risks in Chronic Hepatitis B
    Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Sih-Han Liao, Shih-Jer Hsu, Chun-Ming Hong, Ting-Yuan Lan, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Jia-Horng Kao
    American Journal of Gastroenterology.2025; 120(2): 401.     CrossRef
  • Trajectories of hepatic steatosis and incidence of cardiovascular disease over a 29‐year follow‐up
    Ming‐Whei Yu, Wan‐Jung Wu, Chih‐Lin Lin, Chun‐Jen Liu, Wei‐Ya Peng, Pin‐Yu Huang, Yi‐Wen Huang, Jui‐Ting Hu, Hung‐Chuen Chang, Jyh‐Ming Liou
    Hepatology Research.2025; 55(1): 46.     CrossRef
  • All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease
    Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Shih-Jer Hsu, Chun-Ming Hong, Ting-Yuan Lan, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Jia-Horng Kao
    Journal of Hepatology.2025; 83(1): 43.     CrossRef
  • Hepatitis B virus infection and metabolic dysfunction associated steatotic liver disease: Rising pandemic with complex interaction
    Ammara A Majeed, Amna S Butt
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Impact of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease on Hepatocellular Carcinoma Incidence and Long-Term Prognosis Post-Liver Resection: A Systematic Review and Meta-Analysis
    Qingyan Kong, Diao Kong, Bei Li, Wei Peng, Zheyu Chen
    Academic Radiology.2025; 32(11): 6514.     CrossRef
  • Hepatocellular carcinoma surveillance after sustained virological response in chronic hepatitis C: Editorial on “Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus: A systematic review and meta-ana
    Ho Soo Chun, Minjong Lee
    Clinical and Molecular Hepatology.2025; 31(1): 261.     CrossRef
  • Inflammatory Indices and MAFLD Prevalence in Hypertensive Patients: A Large-Scale Cross-Sectional Analysis from China
    Di Shen, Xintian Cai, Junli Hu, Shuaiwei Song, Qing Zhu, Huimin Ma, Yingying Zhang, Rui Ma, Pan Zhou, Wenbo Yang, Jing Hong, Delian Zhang, Nanfang Li
    Journal of Inflammation Research.2025; Volume 18: 1623.     CrossRef
  • Divergent roles of MASLD components in chronic hepatitis B: A double-edged sword
    Shang-Chin Huang, Tung-Hung Su
    Journal of Hepatology.2025; 83(1): e34.     CrossRef
  • Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma
    Toru Nakamura, Atsutaka Masuda, Dan Nakano, Keisuke Amano, Tomoya Sano, Masahito Nakano, Takumi Kawaguchi
    Cells.2025; 14(6): 428.     CrossRef
  • Association of concomitant MASLD and hepatitis B virus with clinical prognosis in hepatocellular carcinoma after curative resection
    Chih-Jan Ko
    American Journal of Cancer Research.2025; 15(2): 737.     CrossRef
  • Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B
    Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto
    Clinical and Molecular Hepatology.2025; 31(Suppl): S182.     CrossRef
  • SLC22A1 Resists Hepatitis B Virus by Activating the JAK/STAT Pathway and Predicts the Effect of Pegylated Interferon α–Based Therapy on Chronic Hepatitis B
    Huiying Yu, Bin Li, Huili Guo, Lin Li, Xiaoquan Liu, Lili Wu, Na Gao, Qiyi Zhao, Xiuqing Pang, Zhiliang Gao
    The Journal of Infectious Diseases.2025; 232(2): 474.     CrossRef
  • Safety of tenofovir alafenamide in the context of hyperlipidemia and cardiovascular diseases: a nationwide analysis
    Jae-Young Kim, Hyuk Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim
    Hepatology International.2025; 19(4): 959.     CrossRef
  • Non-invasive Assessment of Advanced Fibrosis and Steatosis in Chronic Hepatitis B Patients with Comorbid NAFLD
    Zhenhua Zhou, Feng Chen, Rongrong Zou, Qianhui Li, Xiaomin Xu
    Hepatitis Monthly.2025;[Epub]     CrossRef
  • Study on Ultrasound-Assisted Diagnosis of CHB Complicated with NAFLD Hepatic Fibrosis Based on Deep Learning
    Xiuling Huang, Shan Huang, Changfeng Dong, Nuo Chen, Yuxuan Wang, Changmiao Wang, Yongquan Zhang, Cheng Feng
    Journal of Imaging Informatics in Medicine.2025; 38(6): 4349.     CrossRef
  • Unraveling Demographic Patterns in Hepatitis B Clinical and Laboratory Profiles: Insights From a Ghanaian Cohort: A Retrospective Study
    Napoleon Bellua Sam, Saeed Folorunsho Majeed, Adams Dramani
    Health Science Reports.2025;[Epub]     CrossRef
  • Molecular mechanisms of pyroptosis in non-alcoholic steatohepatitis and feasible diagnosis and treatment strategies
    Dong-fang Shang, Wen-qian Xu, Qing Zhao, Chen-lu Zhao, Si-ying Wang, Yong-li Han, He-guo Li, Ming-hao Liu, Wen-xia Zhao
    Pharmacological Research.2025; 216: 107754.     CrossRef
  • Racing toward the future of chronic hepatitis B management: Achieving functional cure and enhancing hepatocellular carcinoma surveillance through precision medicine
    Yaru Shi, Rong Fan
    Interdisciplinary Medicine.2025;[Epub]     CrossRef
  • The Associations of Serum Folate Forms with Metabolic Dysfunction-Associated Fatty Liver Disease and Liver Fibrosis: A Nationwide Cross-Sectional Study
    Hai Zhao, Wei Fan, Yan Yan, Yuxing Liu, Xuejun Kang
    Metabolites.2025; 15(6): 370.     CrossRef
  • Managing Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Primary Care Settings: A Review
    Vignesh Rajan, Ambarish Das, J. Venkatachalam, K. K. Lohani, Chandrakant Lahariya
    Preventive Medicine: Research & Reviews.2025; 2(4): 183.     CrossRef
  • Hepatitis B virus promotes liver cancer by modulating the immune response to environmental carcinogens
    Mei Huang, Dongyao Wang, Jiao Huang, An-Na Bae, Yun Xia, Xutu Zhao, Mahsa Mortaja, Marjan Azin, Michael R. Collier, Yevgeniy R. Semenov, Jong Ho Park, Shadmehr Demehri
    Nature Communications.2025;[Epub]     CrossRef
  • Natural active botanical metabolites: targeting AMPK signaling pathway to treat metabolic dysfunction-associated fatty liver disease
    Hualing Wang, Xinyu Liu, Chunyi Wang, Shishuang Yu, Xiuli Yang, Xiyu Cao, Maocai Luo, Shiwei Liu, Chuantao Zhang
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • The Role of Chinese Medicine in the Treatment of Chronic Hepatitis B
    Shihao Zheng, Qiuyue Wang, Wenying Qi, Jinchi Xie, Xiaobin Zao, Xiaoke Li, Peng Zhang, Yongan Ye
    The American Journal of Chinese Medicine.2025; 53(05): 1285.     CrossRef
  • Steatotic Liver Disease‐Related Polygenetic Risk Score Prediction of Hepatocellular Carcinoma in Nucleotide/Nucleoside Analog‐Treated Chronic Hepatitis B
    Tyng‐Yuan Jang, Chih‐Wen Wang, Po‐Cheng Liang, Yu‐Ju Wei, Ming‐Lun Yeh, Yi‐Hung Lin, Chao‐Kuan Huang, Pei‐Chien Tsai, Yu‐Min Ko, Yi‐Shan Tsai, Kuan‐Yu Chen, Ching‐Chih Lin, Zu‐Yau Lin, Jee‐Fu Huang, Chia‐Yen Dai, Chung‐Feng Huang, Wan‐Long Chuang, Ming‐Lu
    Journal of Gastroenterology and Hepatology.2025; 40(9): 2290.     CrossRef
  • Association between dietary inflammatory index and hepatic steatosis: cross-sectional evidence from the NHANES 2007–2020
    Zhounan Wu, Yuhang Liang, Li Zeng, Jiayi Fang, Jinshen He
    Journal of Health, Population and Nutrition.2025;[Epub]     CrossRef
  • HBV and host metabolic crosstalk: Reprogramming pathways for viral replication and pathogenesis
    YanYing Yan, Zhiqiang Wei, Min Zheng, Mengji Lu, Xueyu Wang
    Virologica Sinica.2025; 40(5): 685.     CrossRef
  • Predictive Value of Hepatic Steatosis for Postoperative Recurrence in Hepatitis B-Related Hepatocellular Carcinoma: Development of a Machine Learning-Based Prognostic Model
    Aoyun Hao, Changlei Li, Ruitao Sun, Bin Tan, Guanming Shao, Kun Li, Na Li, Weiyu Hu, Chao Qu, Jingyu Cao
    Journal of Hepatocellular Carcinoma.2025; Volume 12: 2459.     CrossRef
  • Identification and Validation of Lipid Metabolism-Related Biomarkers GPD1 and CEBPD in Metabolic Dysfunction-Associated Steatohepatitis
    Jianyu Zhou, Chunying Xiao, Bin Huang, Fenfang Chen
    Journal of Inflammation Research.2025; Volume 18: 14805.     CrossRef
  • Knowledge, attitudes, and practices toward fatty liver disease in patients with hepatitis B combined fatty liver disease
    Qian Li, Yongping Qiu, Lang Xiao, Lijian Ran, Hongli Deng, Xin Lu, Shilian Li, Yan Guo, Maolan Fu, Xuqing Zhang, Jie Xia, Huimin Liu
    Scientific Reports.2025;[Epub]     CrossRef
  • Effects of Non-Alcoholic Fatty Liver Disease on Baseline Histology and 96-Week Entecavir Response in Treatment-Naïve Chronic Hepatitis B
    Xiaohui Gu, Weiguang Yang, Yue Hu, Yixin Li, Liwei Zheng, Bei Jiang
    Infection and Drug Resistance.2025; Volume 18: 6817.     CrossRef
  • Association Between SGLT2 Inhibitor Use and Reduced Risk of Liver-Related Events, Including Hepatocellular Carcinoma, in Diabetic Patients with Viral Hepatitis: A Nationwide Cohort Study
    Seong Hee Kang, Jimi Choi, Hyung Joon Yim, Young Kul Jung, Sun Young Yim, Young-Sun Lee, Yeon Seok Seo, Ji Hoon Kim, Jong Eun Yeon, Kwan Soo Byun
    Cancers.2025; 18(1): 120.     CrossRef
  • Usefulness of the Fibrosis‐4 index and alanine aminotransferase at 1 year of nucleos(t)ide analog treatment for prediction of hepatocellular carcinoma in chronic hepatitis B patients
    Jun Inoue, Takehiro Akahane, Tomoo Kobayashi, Osamu Kimura, Kosuke Sato, Masashi Ninomiya, Tomoaki Iwata, Satoshi Takai, Norihiro Kisara, Toshihiro Sato, Futoshi Nagasaki, Masahito Miura, Takuya Nakamura, Teruyuki Umetsu, Akitoshi Sano, Mio Tsuruoka, Masa
    Hepatology Research.2024; 54(2): 131.     CrossRef
  • The interplay between chronic hepatitis B and diabetes mellitus: A narrative and concise review
    Shang‐Chin Huang, Jia‐Horng Kao
    The Kaohsiung Journal of Medical Sciences.2024; 40(1): 6.     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease Facilitates Hepatitis B Surface Antigen Seroclearance and Seroconversion
    Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Chi-Ling Chen, Shih-Jer Hsu, Chen-Hua Liu, Sih-Han Liao, Chun-Ming Hong, Ting-Yuan Lan, Hung-Chih Yang, Chun-Jen Liu, Pei-Jer Chen, Jia-Horng Kao
    Clinical Gastroenterology and Hepatology.2024; 22(3): 581.     CrossRef
  • Low liver fat in non‐alcoholic steatohepatitis‐related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality
    Sung Won Lee, Daniel Q. Huang, Ricki Bettencourt, Veeral Ajmera, Monica Tincopa, Nabil Noureddin, Maral Amangurbanova, Harris Siddiqi, Egbert Madamba, Abdul M. Majzoub, Tarek Nayfeh, Nobuharu Tamaki, Namiki Izumi, Atsushi Nakajima, Masato Yoneda, Ramzan I
    Alimentary Pharmacology & Therapeutics.2024; 59(1): 80.     CrossRef
  • Metabolic dysfunction associated steatotic liver disease in patients with plaque psoriasis: a case–control study and serological comparison
    Zheng Lin, Yue-yi Shi, Lu-yan Yu, Chen-xi Ma, Si-yi Pan, Yuan Dou, Qiu-jun Zhou, Yi Cao
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • The interplay of metabolic dysfunction‐associated fatty liver disease and viral hepatitis on liver disease severity: A large community‐based study in a viral endemic area
    Chung‐Feng Huang, Po‐Cheng Liang, Pei‐Chien Tsai, Yu‐Ju Wei, Ching‐I Huang, Chih‐Wen Wang, Tyng‐Yuan Jang, Ming‐Lun Yeh, Po‐Yao Hsu, Ming‐Yen Hsieh, Yi‐Hung Lin, Chia‐Yen Dai, Wan‐Long Chuang, Jee‐Fu Huang, Ming‐Lung Yu
    Journal of Gastroenterology and Hepatology.2024; 39(1): 193.     CrossRef
  • High prevalence of fatty liver and its association with metabolic syndrome among rural adults with chronic hepatitis C: Implications for primary healthcare
    Ta-Jen Wang, Mei-Yen Chen, Yu-Chih Lin, Wen-Nan Chiu, Tung-Jung Huang, Hsu-Huei Weng
    BMC Public Health.2024;[Epub]     CrossRef
  • Chronic Viral Hepatitis B and C Outweigh MASLD in the Associated Risk of Cirrhosis and HCC
    Mei-Hsuan Lee, Yi-Ting Chen, Yu-Han Huang, Sheng-Nan Lu, Tsai-Hsuan Yang, Jee-Fu Huang, Szu-Ching Yin, Ming-Lun Yeh, Chung-Feng Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu, Hwai-I Yang, Hsuan-Yu Chen, Chien-Jen Chen
    Clinical Gastroenterology and Hepatology.2024; 22(6): 1275.     CrossRef
  • Reply
    Shang-Chin Huang, Tung-Hung Su, Jia-Horng Kao
    Clinical Gastroenterology and Hepatology.2024; 22(9): 1957.     CrossRef
  • Current perspectives of viral hepatitis
    Daisuke Usuda, Yuki Kaneoka, Rikuo Ono, Masashi Kato, Yuto Sugawara, Runa Shimizu, Tomotari Inami, Eri Nakajima, Shiho Tsuge, Riki Sakurai, Kenji Kawai, Shun Matsubara, Risa Tanaka, Makoto Suzuki, Shintaro Shimozawa, Yuta Hotchi, Ippei Osugi, Risa Katou,
    World Journal of Gastroenterology.2024; 30(18): 2402.     CrossRef
  • Serum ApoB/ApoA1 ratio in patients with CHB and the occurrence of HBV related cirrhosis and HBV related hepatocellular carcinoma
    Xin Cai, Shi Peng, Xuan Xiao, Zhaoyang Huang, Pingan Zhang
    Scientific Reports.2024;[Epub]     CrossRef
  • The overlap with metabolic dysfunction‐associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis
    María Hernández‐Pérez, Daniel Riado, Eva Pena, Carmen Méndez, Fernando Pinedo, Paloma Ramos, Pilar Castillo, Miriam Romero, Conrado Fernández‐Rodríguez, Antonio Olveira
    Alimentary Pharmacology & Therapeutics.2024; 60(5): 613.     CrossRef
  • Hepatitis B surface antigen loss in chronic hepatitis B patients with low‐viral‐load
    Tyng‐Yuan Jang, Batbold Batsaikhan, Yo‐Chia Chen, Chia‐Yen Dai
    Journal of Gastroenterology and Hepatology.2024; 39(11): 2327.     CrossRef
  • Response to the letter of HEPI-D-24–00252
    Shang-Chin Huang, Tung-Hung Su, Jia-Horng Kao
    Hepatology International.2024; 18(4): 1340.     CrossRef
  • Functional cure of chronic hepatitis B encounters resmetirom
    Nai-Bin Yang, Wai-Kay Seto, Ming-Hua Zheng
    Clinical and Molecular Hepatology.2024; 30(3): 580.     CrossRef
  • Hepatic macrophage niche: a bridge between HBV-mediated metabolic changes with intrahepatic inflammation
    Jun Wang, Hongzhou Lu, Qian Li
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Outcome of bariatric surgery in patients with unexpected liver cirrhosis: A multicenter study from China
    Xia Sun, Libin Yao, Xing Kang, Weihua Yu, Fidele Kakule Kitaghenda, Mohammad Sajjad Ibn Rashid, Angeline Nogue Taguemkam, Jian Hong, Zhiyong Dong, Xitai Sun, Xiaocheng Zhu
    Liver Research.2024; 8(3): 172.     CrossRef
  • Disease modifiers and novel markers in hepatitis B virus-related hepatocellular carcinoma
    Lung-Yi Mak
    Journal of Liver Cancer.2024; 24(2): 145.     CrossRef
  • Comparison of Non-invasive Biochemical Fibrosis Markers According to Obesity-Based Metabolic Profile in Chronic Liver Disease with Chronic Hepatitis B Etiology
    Sedat Çiftel
    Ağrı Tıp Fakültesi Dergisi.2024; 2(3): 113.     CrossRef
  • Effect of dyslipidemia on HBsAg clearance in nucleos(t)ide analogues-experienced chronic hepatitis B patients treated with peginterferon alfa
    Kaimin Song, Lan Ren, Yunyun Qian, Huitong Wang, Zhixiang Guo, Huatang Zhang, Yijie Lin, Yijuan Zheng, Dawu Zeng, Yongjun Zhou, Zhijun Su, Xueping Yu
    BMC Infectious Diseases.2024;[Epub]     CrossRef
  • Effect of tenofovir versus entecavir on the long-term prognosis in hepatocellular carcinoma patients with concurrent metabolic dysfunction-associated steatotic liver disease and hepatitis B
    Qingyan Kong, Qianqian Gao, Wenjie Li, Zheyu Chen
    Asian Journal of Surgery.2024; 47(11): 4725.     CrossRef
  • Retrospective cohort evaluation study in terms of cardiovascular and metabolic diseases in chronic hepatitis B patients
    Aysun Yakut
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • An insight into the updated pharmacotherapy of metabolic-associated fatty liver disease (MAFLD) or metabolic dysfunction-associated steatohepatitis (MASH) in lean individuals: a review
    Sanjay Bandyopadhyay, Shambo Samrat Samajdar, Sirshendu Chaudhuri, Saibal Das
    Hospital Practice.2024; 52(4-5): 123.     CrossRef
  • Impact of concurrent MASLD on early-stage HCC following curative resection in chronic hepatitis B
    Cao-Ngoc Huynh
    American Journal of Cancer Research.2024; 14(9): 4567.     CrossRef
  • Obesity and risk for liver disease: a two-sample Mendelian randomisation study
    Wen An, Jing Luo, Zhe Yu, Mengqi Li, Herui Wei, Aqian Song, Yuanpeng Mao, Hao Bian, Lingling He, Fan Xiao, Hongshan Wei
    British Journal of Nutrition.2024; 132(10): 1403.     CrossRef
  • Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate
    Shenglong Lin, Wanlong Huang, Ziyuan Liao, Huaxi Ma, Wenjun Wu, Minghua Lin, Defu Huang, Haibing Gao
    Scientific Reports.2024;[Epub]     CrossRef
  • Revolutionizing the understanding of liver disease: Metabolism, function and future
    Arnulfo E Morales-Galicia, Mariana M Ramírez-Mejía, Guadalupe Ponciano-Rodriguez, Nahum Méndez-Sánchez
    World Journal of Hepatology.2024; 16(12): 1365.     CrossRef
  • Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology
    Eileen Laurel Yoon, Dae Won Jun
    Clinical and Molecular Hepatology.2023; 29(2): 371.     CrossRef
  • Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B
    Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Chi-Ling Chen, Shih-Jer Hsu, Sih-Han Liao, Chun-Ming Hong, Chen-Hua Liu, Ting-Yuan Lan, Hung-Chih Yang, Chun-Jen Liu, Pei-Jer Chen, Jia-Horng Kao
    Hepatology International.2023; 17(5): 1139.     CrossRef
  • Reply to: ‘A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Has the correct patient cohort been targeted?’
    Hyun Yang, Ji Hoon Kim, Ji Won Han, Soon Kyu Lee, Jeong Won Jang
    Journal of Hepatology.2023; 79(4): e155.     CrossRef
  • Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients
    Mi Na Kim, Kyungdo Han, Juhwan Yoo, Seong Gyu Hwang, Xuehong Zhang, Sang Hoon Ahn
    International Journal of Cancer.2023; 153(8): 1448.     CrossRef
  • 20,939 View
  • 596 Download
  • 92 Web of Science
  • Crossref

Steatotic liver disease

Non-alcoholic fatty liver disease: Definition and subtypes
Seul Ki Han, Soon Koo Baik, Moon Young Kim
Clin Mol Hepatol 2023;29(suppl):S5-S16.
Published online December 28, 2022
DOI: https://doi.org/10.3350/cmh.2022.0424
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide, with a global prevalence of approximately 30%. However, the prevalence of NAFLD has been variously reported depending on the comorbidities. The rising prevalence of obesity in both the adult and pediatric populations is projected to consequently continue increasing NAFLD prevalence. It is a major cause of chronic liver disease worldwide, including cirrhosis and hepatocellular carcinoma (HCC). NAFLD has a variety of clinical phenotypes and heterogeneity due to the complexity of pathogenesis and clinical conditions of its occurrence, resulting in various clinical prognoses. In this article, we briefly described the basic definition of NAFLD and classified the subtypes based on current knowledge in this field.

Citations

Citations to this article as recorded by  Crossref logo
  • Multi-omics reveals an association of the gut butyrate-IDO1-tryptophan axis with Yinchenhaotang plus Zexietang-ameliorated NASH in a microbiota-dependent manner
    Weimeng Liu, Xiaoyu Sha, Na Zhao, Baoying Liu, Guanlin Yang, Lianqun Jia, Guoyuan Sui
    Chinese Medicine.2026;[Epub]     CrossRef
  • Interaction of uteroplacental insufficiency and postnatal Western diet on the hepatic transcriptome in young adult female and male Guinea pigs
    Ousseynou Sarr, Jennifer A. Thompson, Natalie L.H. Lam, Patti K. Kiser, Timothy R.H. Regnault
    Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2026; 1872(2): 168054.     CrossRef
  • Association of nitrogen dioxide with non-alcoholic fatty liver disease in Chinese rural older adults: The mediating role of fasting plasma glucose
    Yuantao Zhang, Xianglong Liu, Yunkai Hu, Xuqiu Cheng, Wenyuan Liu, Ziwei Tian, Yan Zhang, Guimei Chen, Bing Hu, Changliu Liang, Chunmei Liang, Fangbiao Tao, Linsheng Yang
    Environmental Research.2026; 290: 123518.     CrossRef
  • Ultrafiltered mulberry leaf glutelin mitigates non-alcoholic fatty liver disease through modulation of lipid metabolism, inflammation, and serum metabolomics
    Mingxi Li, Hongyan Li, Jia Zou, Renqin Li, Haoqi Zhang, Wenhan Yang, Xiyang Wu, Chongzhen Sun
    Food & Function.2026; 17(2): 819.     CrossRef
  • Sleep Disorders and Nonalcoholic Fatty Liver Disease: Evidence From Meta-Analysis and Mendelian Randomization
    Haibo Wang, Linyin Huang, Meng Yu, Shifang Qu, Yanqi Wang, Xu Cao, Yiwen Meng, Yongxia Gao, Bing Ding, Wei Bai, Yan Yao
    Journal of Prevention.2026; 47(3): 467.     CrossRef
  • Evaluation of the Protective Efficiency of Ethyl Gallate Against Non-Alcoholic Fatty Liver Disease Induced by a High-Fat Diet in Mice
    Yara Annouf, Eswar K. Kilari
    Tropical Journal of Natural Product Research.2026;[Epub]     CrossRef
  • Long non-coding RNAs in human peripheral blood as biomarkers for age prediction
    Anqi Chen, Yujia Xuan, Fan Yang, Yanan Liu, Jinyuan Zhao, Mengxiao Liao, Yanfang Lu, Yu Xing, Suhua Zhang, Chengtao Li
    Forensic Science International: Genetics.2026; 82: 103419.     CrossRef
  • The impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of pegylated interferon-based therapy in patients with chronic hepatitis B
    Jiaxin Han, Lianxin Xu, Yuqin Li, Ziling Wang, Minghui Zeng, Jieru Gao, Yuqiang Mi, Wentao Kuai, Huiling Xiang, Liang Xu
    Frontiers in Immunology.2026;[Epub]     CrossRef
  • Identification of shared oxidative stress related hub genes in NAFLD and atherosclerosis using bioinformatics and machine learning
    Gong Qing, Bo Peng, Huizhen Peng
    Scientific Reports.2026;[Epub]     CrossRef
  • Subtype-specific associations of steatotic liver disease with gastric and esophageal cancers: a nationwide cohort study
    Yeo Wool Kang, Minkook Son, Jong Yoon Lee, Sang Yi Moon, Myeongseok Koh
    Gastric Cancer.2026; 29(2): 365.     CrossRef
  • Association between blood cell count inflammatory biomarkers and non-alcoholic fatty liver disease: A systematic review and meta-analysis
    Shaista Ahmed, Garzain Bint e Attar, Aleena Subhani, Md Masoom, Vineet Jain, Dharmander Singh, Mohd Ashif Khan
    Endocrine.2026;[Epub]     CrossRef
  • Liver Lipodystrophy in Barraquer–Simons Syndrome: How Much Should We Worry About?
    Doina Georgescu, Daniel Florin Lighezan, Roxana Buzas, Paul Gabriel Ciubotaru, Oana Elena Țunea, Ioana Suceava, Teodora Anca Albu, Aura Jurescu, Mihai Ioniță, Daniela Reisz
    Life.2026; 16(1): 156.     CrossRef
  • The association between organophosphate pesticide residue exposure and non-alcoholic fatty liver disease: A systematic review
    Bahare Mohamadi, Mohammadreza Tolou Ostadan, Samira Shokri, Alireza Bakhtiyari, Rokhsana Rasooli, Parisa Sadighara, Saeed Aghebat-Bekheir
    Toxicology Reports.2026; 16: 102216.     CrossRef
  • Metabolic dysfunction-associated fatty liver disease and liver fibrosis: predictive value of the CALLY index
    Bowen Cheng, Qihui Fu, Wenjie Shi, Jiasheng Fang, Xiaojiang Zhou, Xiaoyan Chen
    Critical Public Health.2026;[Epub]     CrossRef
  • High-protein diets and metabolic dysfunction-associated steatotic liver disease: A double-edged sword in liver health
    Hong-Yuan Yin, Qian-Hui You, Wei-Jie Zhang, Guang Ji, Yan-Qi Dang
    World Journal of Gastroenterology.2026;[Epub]     CrossRef
  • Quantifying non-alcoholic fatty liver: liver–spleen CT ratio and fat concentration in dual-energy spectral CT
    Min Zhang, Nan Yu, Chuangbo Yang, Haifeng Duan, Zhanli Ren
    Die Radiologie.2026;[Epub]     CrossRef
  • Association between metabolic dysfunction-associated steatotic liver disease and kidney stone risk in individuals with metabolic dysfunction: evidence from cross-sectional and cohort analyses
    Yushuang Wei, Lingyu Ye, Mingli Li, Boteng Yan, Yining Lin, Sihua Lai, Zengnan Mo, Chaoyan Tang
    Frontiers in Endocrinology.2026;[Epub]     CrossRef
  • Comparison of patients with HCC with and without MASLD after surgical resection
    Chia-Jung Ho, Hao-Jan Lei, Chun-Ting Ho, Gar-Yang Chau, Shu-Cheng Chou, Elise Chia-Hui Tan, Pei-Chang Lee, Yi-Hsiang Huang, Ying-Ying Yang, Teh-Ia Huo, Ming-Chih Hou, Jaw-Ching Wu, Chien-Wei Su
    JHEP Reports.2026; 8(4): 101768.     CrossRef
  • Lactiplantibacillus plantarum Q180 supplementation restores high-fat diet-induced gut dysbiosis and intestinal barrier dysfunction in mice
    Minseo Cho, Jaeryang Chu, Chae-Won No, Yeon-Woo Kim, Jiwoo Lee, Hyunchae Joung, Yoo Jin Kwon, Chang Hun Shin, Jisu Lee, Jung-Heun Ha
    Journal of Applied Microbiology.2026;[Epub]     CrossRef
  • Comparative Efficacy of Pioglitazone, Saroglitazar, and Silymarin on Biochemical and Histopathological Hepatic Outcomes in a Wistar Rat Model of Non-alcoholic Fatty Liver Disease and Their Correlation With Insulin Sensitivity
    Ipshita Jain, Rajendra Nath, Madhu Kumar, Rishi Pal, Rakesh Dixit
    Cureus.2026;[Epub]     CrossRef
  • Cross-sectional association between gallstone disease and nonalcoholic fatty liver disease: Exploring the mediating roles of hematological and biochemical markers
    Rongxuan Li, Bingchen Wang, Xiao Chen, Angshu Cai, Dayong Cao, Jianguo Zhou
    Medicine.2026; 105(8): e47759.     CrossRef
  • FOXN3 integrates the KU70/KU80/SREBP-1 complex to regulate lipid metabolism in non-alcoholic fatty liver disease
    Jiang Du, Lele Jin, Suhui Wang, Xinghong Hu, Jinjin Yu, Jingyu Yu, Qingyang Huo, Nan Wu, Xiaotian Liu, Yan Yang, Yong Zhang, Sizhou Huang, Jihong Zhou, Song Guo Zheng, Chunfu Zheng, Xinxing Zhu
    Nucleic Acids Research.2026;[Epub]     CrossRef
  • Serum Inflammatory Markers and Dietary Inflammatory Index in Obese Individuals With Fatty Liver Disease: A Case–Control Study
    Faezeh Tejareh, Laleh Payahoo, Seyed Ali Keshavarz
    Endocrinology, Diabetes & Metabolism.2026;[Epub]     CrossRef
  • Kaempferol reprograms pro-inflammatory macrophage polarization by targeting the PTGS2-PGE2 axis: A multi-omics deconvolution of a traditional anti-inflammatory herb pair
    Han Chen, Shuying Chen, Haixia Huang, Kai Chen, Huimin Wan, Ruifen Zhang, Linya Wu, Qifang Wu, Haibin Tong, Gang Xu
    Biochemical Pharmacology.2026; 248: 117865.     CrossRef
  • Clinical Profile, Laboratory Parameters and Comorbid Associations in Non-alcoholic Fatty Liver Disease
    Sanket P. Bharadwaj, Pankaj Garg, Khushali L. Patel, Ami P. Parikh
    Apollo Medicine.2026;[Epub]     CrossRef
  • Prevalence and dietary factors associated with nonalcoholic fatty liver disease in a sample of obese middle-aged Egyptian women
    Maha I. A. Moaty, Salwa M. El Shebini, Rehab A. Mohamed, Safenaz Y. El Sherity, Nihad H. Ahmed
    Scientific Reports.2026;[Epub]     CrossRef
  • Inflammatory parameters and liver fibrosis in patients with steatosis: A cross-sectional analysis
    Melina Borba Duarte, Juliana Czermainski, Luis F Ferreira, Cristiane V Tovo, Randhall B Carteri
    World Journal of Hepatology.2026;[Epub]     CrossRef
  • Food-derived dihydromyricetin and metabolic dysfunction-associated steatotic liver disease: a preclinical systematic review and meta-analysis
    Dachuan Jin, Shunqin Jin, Tao Zhou, Guoping Sheng, Mingfei Yao, Peng Gao, Guangming Li
    Frontiers in Nutrition.2026;[Epub]     CrossRef
  • The C-reactive protein-albumin-lymphocyte index: a novel biomarker for metabolic dysfunction-associated fatty liver disease across three ethnic cohorts
    Yaojian Shao, Yusheng Zhang, Lulu Yin, Jianhua Yin, Yifan Lin
    Frontiers in Public Health.2026;[Epub]     CrossRef
  • Therapeutic potential of EGCG in treating vascular and metabolic disorders
    Zijian Li, Huifang Ge, Suowen Xu, Yijun Wang
    Journal of Functional Foods.2026; 140: 107284.     CrossRef
  • The role of Traditional Chinese Medicine in the management of liver disease: targeting gut microbiome
    Yifan Zhang, Hongkun Li, Fei Yu, Mengmeng Gao, Yang Wang, Siyu Xin, Jiating Yang, Zhiwei Wang, Lujie Xiang, Qingjing Ru, Na Jiang
    Chinese Medicine.2026;[Epub]     CrossRef
  • Gut Microbiota Mediates HFPO–DA-Induced Hepatotoxicity via Arginine Reprogramming in Lean NAFLD Mice
    Rui Ding, Li He, Rui Guo, Xiaochun Tian, Linlin Chen, Nana Zhan, Lisong Chen, Yan Wu, Jie Zhang, Feng Zhao
    Environmental Science & Technology.2026; 60(16): 12133.     CrossRef
  • Mechanistic insights and evidence-based management of metabolic dysfunction-associated steatotic liver disease (MASLD; formerly NAFLD) through combined diet and exercise interventions: an evidence-based narrative review
    Yuanyuan Chen, Rongqin Liu, Renli Huang, Qinwei Li, Yu Zhang
    Journal of Clinical Biochemistry and Nutrition.2026; 79(1): 1.     CrossRef
  • Liver biopsy in children: indications, contraindications, complications, information content. A review
    Svetlana N. Borzakova, Ismail M. Osmanov, Ekaterina V. Scorobogatova, Dmitrii A. Pykhteev, Artur G. Godiatskii, Yurij Yu. Sokolov, Elena L. Tumanova, Irina N. Zakharova
    Pediatrics. Consilium Medicum.2026; (1): 70.     CrossRef
  • NAMPT improves high-fat diet-induced nonalcoholic fatty liver disease (NAFLD) via the SIRT1–C/EBPβ–STEAP4–NRF2 axis
    Jingwu Zhao, Qinjin Li, Yi Wang, Bingbing Liu, Sisi Gui, Yazhen Zheng, Xiaodong Chen, Feng Liu
    Journal of Molecular Cell Biology.2026;[Epub]     CrossRef
  • Discrimination of Steatotic and Non-Steatotic Chemicals Through Transcriptome Analysis in Primary Human Hepatocytes
    Christina A. Cramer von Clausbruch, Marcha Verheijen, Giulia Callegaro, Jonathan H. Freedman, Rita Ortega-Vallbona, Martina Palomino-Schätzlein, Florian Caiment, Carsten Weiss
    International Journal of Molecular Sciences.2026; 27(9): 3825.     CrossRef
  • Diagnostic accuracy of shear wave elastography for staging liver fibrosis in diabetic patients with NAFLD
    V.N. Najafova
    Shidnoevropejskij zurnal vnutrisnoi ta simejnoi medicini.2026; 2026(1): 46.     CrossRef
  • Pirfenidone Suppresses Liver Fibrosis Through Inhibition of TGF-β-Associated Lipid Metabolic Remodeling in Hepatic Stellate Cells
    Yuelu Lan, Sijia Li, Shuangli Zhu, Can Pan, Kai Fu, Xueping Wang, Liwu Fu, Fang Wang
    International Journal of Molecular Sciences.2026; 27(9): 4061.     CrossRef
  • Causal insights into how NAFLD progression drives abdominal aortic aneurysm: A bidirectional MR study integrating genetic and multi-omics profiling
    Rongyang Xi, Jiuqing Yan, Yu Wang, Lexi Li, Yongshun Liang, Siying Cai, Yijingxuan Duan
    Medicine.2026; 105(19): e48613.     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease: An Update Narrative Review of the Therapeutic Potential of Combining Probiotics and Metformin
    Syifa Mustika, Sri Utami, Nur Estu Wijayanti Saputri, Levrita Nindya Poetri, Putu Ijiya Danta Awatara, Achmad Rudijanto, Hery Djagat Purnomo, Cosmas Rinaldi A. Lesmana, Ahmad Taufiq
    Biomedicines.2026; 14(5): 1147.     CrossRef
  • Non-alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus: A Cross-Sectional Study Assessing Metabolic Indices and Microvascular Complications
    Shubham R Desale, Shubhransu Patro, Sambit Das, Varun Jindal, Sai Sri Karlapudi, Mouneesh Karanam, Prithviraj U Naik, Jyoti Prakash Sahoo
    Cureus.2026;[Epub]     CrossRef
  • Hepatocellular Carcinoma in Southeast Asian Americans: Epidemiologic Trends, Screening Challenges, and Policy Implications
    Ahauve M. Orusa, Abby M. Lohr, Khalid F. Abu-Zeinah, Irene G. Sia, Jennifer L. Ridgeway, Aminah Jatoi, Nguyen H. Tran
    Healthcare.2026; 14(10): 1314.     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Clinical Profile, Phenotypes, and Risk Stratification. A Narrative Review
    Zalina Yuryevna Sozaeva, Marina Vsevolodovna Atayeva, Elizaveta Olegovna Salatova, Irina Kazbekovna Alikova, Alexandra Evgenievna Dolgaya, Amin Gasaevich Magomedov, Kamilla Ramisovna Hafsi, Nur-Mukhamed Aslanovich Shomakhov, Elena Mukhadinovna Pshukova, Y
    Journal of Biochemical Technology.2026; 17(2): 30.     CrossRef
  • Evaluation of Hypolipidemic Activity of Ayurvedic Formulations on Blood Markers in Albino Rats with Experimental NAFLD
    Sajja Keerthi Vathsalya, A. Gnanavel, N. Hima Bindu, S. Saravana Kumar, B. Naveen Kumar
    Research Journal of Pharmacy and Technology.2026; 19(5): 2201.     CrossRef
  • Research Progress of TGR5 in Non-Alcoholic Fatty Liver Disease
    家豪 廖
    Advances in Clinical Medicine.2026; 16(06): 468.     CrossRef
  • High-Intensity Interval Training Attenuates Hepatic Fibrosis by Remodeling Lactate Metabolism in MASLD
    Xuefei Chen, Jie Su, Wenhua Huang, Yanjun Li, Jing Zhang
    Metabolites.2026; 16(6): 413.     CrossRef
  • Assessment of the Diagnostic Potential of Lecithin-Cholesterol Acyltransferase in Non-Alcoholic Fatty Liver Disease
    Sara Mazin Muhammed Ali, Ali Abdulhussain Kasim, Mohammed H. Al-Rikabi
    Al Mustansiriyah Journal of Pharmaceutical Sciences.2026; 26(2): 234.     CrossRef
  • Therapeutic potential and mechanisms of flavonoids from Citrus grandis ‘Tomentosa’ in metabolic dysfunction-associated steatotic liver disease: a focus on immune-inflammatory signaling pathways
    Dong Li, Huan Zheng, Baoyi Chen, Hui Zhang, Guifang Su
    Frontiers in Pharmacology.2026;[Epub]     CrossRef
  • Oleanolic Acid Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Inhibiting Ferroptosis through Targeting PTGS2 as a Key Molecular Node and Activating the AMPK/ACC Signaling Pathway
    Wei Ye, Lei Wang, Ye Fan, Li Ma, Zaohong Chen, Jinmeng Zhang, Rong Zeng, Xiang Liu
    Journal of Agricultural and Food Chemistry.2026;[Epub]     CrossRef
  • Frequency of Metabolic Risk Factors and Association with Demographic Characteristics in Patients with Non-alcoholic Fatty Liver Disease
    Tajwar Gul, Saera Suhail Kidwai, Muhammad Kamran, Hafiz Abdul Basit, Afsheen Ishfaq, Mehrunisa Umar
    Pakistan Journal of Health Sciences.2026; : 152.     CrossRef
  • Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study
    Byungyoon Yun, Heejoo Park, Sang Hoon Ahn, Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon
    American Journal of Gastroenterology.2025; 120(2): 410.     CrossRef
  • Incidence of non-alcoholic fatty liver disease in antiretroviral therapy-naïve people with human immunodeficiency virus who start DTG/ABC/3TC compared to BIC/FTC/TAF at 48-week follow-up
    Ana Luz Cano Díaz, Salma Triana González, Gloria Elizabeth Salinas Velázquez, José Antonio Mata Marín, Jesús Enrique Gaytán Martínez, Stefan Mauss
    International Journal of STD & AIDS.2025; 36(1): 36.     CrossRef
  • Exacerbated hepatotoxicity in in vivo and in vitro non-alcoholic fatty liver models by biomineralized copper sulfide nanoparticles
    Jinbin Cui, Gang Zhao, Wei Xie, Yang Yang, Xing Fu, Hezhang Meng, He Liu, Mengfei Tan, Dandan Chen, Chao Rong, Yangyun Wang, Yong Wang, Leshuai W. Zhang
    Biomaterials Advances.2025; 168: 214117.     CrossRef
  • The impact of resistance training in patients diagnosed with metabolic dysfunction-associated steatotic liver disease: a systematic review
    Daniele Gorski Medeiros, Luis Fernando Ferreira, Jessica da Silva Lamp, Luis Henrique Telles da Rosa
    European Journal of Gastroenterology & Hepatology.2025; 37(2): 129.     CrossRef
  • Causal associations of metabolic dysfunction-associated steatotic liver disease with gestational hypertension and preeclampsia: a two-sample Mendelian randomization study
    Lu Zhang, Liang Fang, Jiahua Zou, Dong Zhou, Haonan Xie, Aihua Chen, Qingming Wu
    Hypertension in Pregnancy.2025;[Epub]     CrossRef
  • The role and function of lncRNA in ageing-associated liver diseases
    Peyman Kheirandish Zarandi, Mohsen Ghiasi, Mohammad Heiat
    RNA Biology.2025; 22(1): 1.     CrossRef
  • Immunology and treatments of fatty liver disease
    Sainan Tang, Shanshan Wu, Wenzhe Zhang, Lili Ma, Li Zuo, Hua Wang
    Archives of Toxicology.2025; 99(1): 127.     CrossRef
  • Statin use and liver-related prognosis among patients with MASLD
    Byungyoon Yun, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon
    JHEP Reports.2025; 7(4): 101313.     CrossRef
  • Exploring the association between air pollution and the incidence of liver cancers
    Xin Wu, Xin Zhang, Xiaopeng Yu, Hongyuan Liang, Shaoshan Tang, Yao Wang
    Ecotoxicology and Environmental Safety.2025; 290: 117437.     CrossRef
  • Cardiometabolic phenotype linked to fibrosis and mortality in metabolic dysfunction-associated steatotic liver disease
    Rui Dong, Ting Tian, Zhenghan Luo, Dongchun Chang, Hong Xue, Sen Qu, Jia Wang, Chao Shen, Ru Zhang, Jie Wang
    Nutrition, Metabolism and Cardiovascular Diseases.2025; 35(3): 103797.     CrossRef
  • Effects of Probiotics on Liver Diseases: Current In Vitro and In Vivo Studies
    Maryam Sadri, Zahra Shafaghat, Mona Roozbehani, Akram Hoseinzadeh, Fatemeh Mohammadi, Fahimeh Lavi Arab, Sara Minaeian, Soheil Rahmani Fard, Fatemeh Faraji
    Probiotics and Antimicrobial Proteins.2025; 17(3): 1688.     CrossRef
  • The Role of microRNA-22 in Metabolism
    Simone Tomasini, Paolo Vigo, Francesco Margiotta, Ulrik Søberg Scheele, Riccardo Panella, Sakari Kauppinen
    International Journal of Molecular Sciences.2025; 26(2): 782.     CrossRef
  • Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes
    Meng-Yuan Miao, Jie-Qiong Lyu, Wei Jiang, Zhong-Yue Liu, Guo-Chong Chen
    Clinical and Molecular Hepatology.2025; 31(1): e35.     CrossRef
  • Cardiovascular Risk From Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factor Count, and Their Longitudinal Changes: A Nationwide Cohort Study
    Hyeok-Hee Lee, Han Ah Lee, Eun-Jin Kim, Hwi Young Kim, Hyeon Chang Kim, Sang Hoon Ahn, Hokyou Lee, Seung Up Kim
    American Journal of Gastroenterology.2025; 120(10): 2321.     CrossRef
  • The value of sex hormones and sex hormone-binding globulin in metabolic dysfunction-associated fatty liver disease among boys with obesity
    Ying Wang, Shuyi Yang, Suming Zhang, Ye Yang, Siqing Li, Meiyu Zhang, Xiaona Li, Hua Bai, Peiliang Luo, Yingdi Yuan
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • The Role of Dietary Protein in Mitigating the Risk of Nonalcoholic Fatty Liver Disease
    Abia Shariq, Sarosh Khan, Shajie Ur Rehman Usmani
    Nutrition Reviews.2025; 83(8): 1537.     CrossRef
  • Role of triggering receptor expressed on myeloid cells 2 in the pathogenesis of non-alcoholic fatty liver disease
    Li-Hui Zhang, Su-Tong Liu, Qing Zhao, Xiao-Yan Liu, Tong Liu, Qiang Zhang, Ming-Hao Liu, Wen-Xia Zhao
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Isoschaftoside in Fig Leaf Tea Alleviates Nonalcoholic Fatty Liver Disease in Mice via the Regulation of Macrophage Polarity
    Tatsuya Abe
    Nutrients.2025; 17(5): 757.     CrossRef
  • Quinoa bran polyphenol extract attenuates high-fat diet induced non-alcoholic fatty liver disease in mice
    Minjun Sun, Haoyuan Ma, Ying Miao, Meili Zhang
    Food & Function.2025; 16(6): 2291.     CrossRef
  • Non-Alcoholic Fatty Liver Disease in Everyday Clinical Practice: From Diagnosis to Therapy
    Marcin Kosmalski, Łukasz Mokros
    Life.2025; 15(3): 363.     CrossRef
  • Unraveling the molecular mechanisms of Fufangduzhong formula in alleviating high-fat diet-induced non-alcoholic fatty liver disease in mice
    Yu Mou, Yao Tang, Xiuyan Zheng, Xiang Liu, Xuemei Wu, Hongji Wang, Jie Zeng, Qing Rao, Yaacov Ben-David, Yanmei Li, Lei Huang
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Predicting hepatic steatosis degree in metabolic dysfunction-associated steatotic liver disease using obesity and lipid-related indices
    Paniz Forouzesh, Sorayya Kheirouri, Mohammad Alizadeh
    Scientific Reports.2025;[Epub]     CrossRef
  • Clinical Research Progress of Apolipoprotein B/Apolipoprotein A1
    小红 李
    Advances in Clinical Medicine.2025; 15(03): 253.     CrossRef
  • miR-125b-5p regulates FFA-induced hepatic steatosis in L02 cells by targeting estrogen-related receptor alpha
    Fen Gao, Yanhua Ma, Chun Yu, Qianchen Duan
    Gene.2025; 959: 149419.     CrossRef
  • Effectiveness of body roundness index for the prediction of nonalcoholic fatty liver disease: a systematic review and meta-analysis
    Shaghayegh Khanmohammadi, Parisa Fallahtafti, Amirhossein Habibzadeh, Ali Ezzatollahi Tanha, Amir Ali Alamdari, Parsa Fallahtafti, Mohammad Shafi Kuchay
    Lipids in Health and Disease.2025;[Epub]     CrossRef
  • Waist circumference as a predictor for severity of liver fibrosis in non-alcoholic fatty liver disease patients
    Shalini Suri, Shraddha Singh, Sushma Swaraj Rapelly, Sumit Rungta, Ehsan Ahmad
    Journal of Family Medicine and Primary Care.2025; 14(3): 1073.     CrossRef
  • Relationship between diabesity and elevated values of metabolic-associated steatotic liver disease risk scales in Spanish workers using body mass index and the body adiposity estimator criteria of Clínica de Navarra
    Emilio Martínez-Almoyna Rifá, Ángel Arturo López González, Pedro Juan Tárraga López, Hernán Paublini, Daniela Vallejos, José Ignacio Ramírez Manent
    Nutrición Hospitalaria.2025;[Epub]     CrossRef
  • Identification of CACNB1 protein as an actionable therapeutic target for hepatocellular carcinoma via metabolic dysfunction analysis in liver diseases: An integrated bioinformatics and machine learning approach for precise therapy
    Jing Sun, Run Shi, Zhaokai Zhou, Weilong Xu, Jiaxuan Huai, Yutian Cao, Wenhui Zhang, Lijuan Nie, Gaoxiang Wang, Qianhua Yan, Xuanbin Wang, Minglun Li, Zhuyuan Fang, Xiqiao Zhou
    International Journal of Biological Macromolecules.2025; 308: 142315.     CrossRef
  • Three-Dimensional Vector MR Elastography for Evaluating Tissue Mechanical Heterogeneity to Assess Liver Disease Progression
    Hao Wu, Zheng Zhu, Jiahui Li, Caixin Qiu, Peng Xu, Kevin J. Glaser, Matthew C. Murphy, Sudhakar K. Venkatesh, Usman Yaqoob, Rondell Graham, Taofic Mounajjed, Armando Manduca, Christopher T. Winkelmann, Hiroaki Yashiro, Rohan Manohar, Alina M. Allen, Vijay
    Radiology.2025;[Epub]     CrossRef
  • Ketogenic Diet in Steatotic Liver Disease: A Metabolic Approach to Hepatic Health
    Fabrizio Emanuele, Mattia Biondo, Laura Tomasello, Giorgio Arnaldi, Valentina Guarnotta
    Nutrients.2025; 17(7): 1269.     CrossRef
  • An inverted U-shaped association between high-sensitivity C-reactive protein and the albumin ratio and hepatic steatosis and liver fibrosis: a population-based study
    Xiaorong Ma, Baoyu Li, Yuwei Liu, Xiaoyan Guo
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in metabolic dysfunction-associated steatohepatitis livers
    Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Xiao-Chen Ma, Chen-He Yi, Bao-Rui Tao, Bo Zhang, Yue Ma, Guo Zhang, Rui Zhang, Yan Geng, Jing Lin, Jin-Hong Chen
    Clinical and Molecular Hepatology.2025; 31(2): 409.     CrossRef
  • Kaili sour soup in alleviation of hepatic steatosis in rats via lycopene route: an experimental study
    Yi Li, Shuo Cong, Rui Chen, Juan Tang, Liqiong Zhai, Yongmei Liu
    Annals of Medicine.2025;[Epub]     CrossRef
  • Activation of TRPA1 prevents metabolic dysfunction-associated steatotic liver disease in diet-induced obese mice through stimulating the AMPK/CPT1A signaling pathway
    Dan Wang, Sen Liu, Jindong Wan, Shichao Chen, Kaige Feng, Jixin Hou, Yi Yang, Peijian Wang
    Journal of Physiology and Biochemistry.2025; 81(2): 359.     CrossRef
  • Association Between Perfluoroalkyl Substance (PFAS) Exposure and Nonalcoholic Fatty Liver Disease in Korean Adults: Results From the KoNEHS 2018–2020: A Cross‐Sectional Study
    Jisuk Yun, Young‐Sun Min
    American Journal of Industrial Medicine.2025; 68(7): 588.     CrossRef
  • Are mesenchymal stem/stromal cells a novel avenue for the treatment of non-alcoholic fatty liver disease?
    Milton Artur Ruiz, Roberto Luiz R Kaiser Junior, Gabriel Piron-Ruiz, Luiz Gustavo de Quadros
    World Journal of Stem Cells.2025;[Epub]     CrossRef
  • Chronic Inflammation and Immune Dysregulation in Metabolic-Dysfunction-Associated Steatotic Liver Disease Progression: From Steatosis to Hepatocellular Carcinoma
    Young-Min Jee, Jeong-Yoon Lee, Tom Ryu
    Biomedicines.2025; 13(5): 1260.     CrossRef
  • Exploring the Prevalence and Risk Factors of MASLD in Patients with Newly Diagnosed Diabetes Mellitus: A Comprehensive Investigation
    Hatice Beyazal Polat, Mehmet Beyazal, Medeni Arpa, Bayram Kızılkaya, Teslime Ayaz, Ömer Lütfi Gündoğdu, Kamil Konur, Zehra Polat, Fatma Beyazal Çeliker, Halil Atasoy
    Journal of Clinical Medicine.2025; 14(10): 3513.     CrossRef
  • Association Between Bioimpedance-Determined Metabolic Age and MASLD Risk Scores in Spanish Workers
    Ignacio Ramírez-Gallegos, Carla Busquets-Cortes, Hernán Paublini, Ángel Arturo López-González, Emilio Martínez-Almoyna-Rifá, Pedro Juan Tárraga López, José Ignacio Ramírez-Manent
    Metabolites.2025; 15(5): 343.     CrossRef
  • Asprosin‐FABP5 Interaction Modulates Mitochondrial Fatty Acid Oxidation through PPARα Contributing to MASLD Development
    Yuan‐Yuan Yu, Min Feng, Yi Chen, Hong‐Lin Jia, Qi Zhang, Ming Tong, Yan‐Xi Li, Yu Zhao, Xin‐Xin Liu, Shi‐Feng Cao, Zheng‐kai Wang, Hou‐wei Li, Xue Liu, Yan Zhang
    Advanced Science.2025;[Epub]     CrossRef
  • Efficacy of interventions with live combined Bacillus subtilis and Enterococcus faecium enteric-coated capsules in metabolic associated fatty liver disease patients: a meta-analysis of randomized controlled trials
    Yutong Wu, Hao Wu, Hang Yi
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Identification of key genes in membranous nephropathy and non-alcoholic fatty liver disease by bioinformatics and machine learning
    Jiachen Fan, Na Li, Yanfang Lu, Huixia Cao
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Hepatic stellate cell inhibition by angiotensin II receptor blocker mitigates liver injury and fibrosis via NF-κB-galectin-3 suppression in a rat nonalcoholic steatohepatitis model
    Xiaochen Kuang, Aya Naiki-Ito, Hayato Kawamura, Akihiro Murakami, Masayuki Komura, Hiroyuki Kato, Yuko Nagayasu, Satoru Takahashi
    Archives of Toxicology.2025; 99(8): 3393.     CrossRef
  • Ferroptosis in Gastrointestinal Diseases: A New Frontier in Pathogenesis and Therapy
    Adam Wawrzeńczyk, Katarzyna Napiórkowska-Baran, Ewa Alska, Alicja Gruszka-Koselska, Ewa Szynkiewicz, Józef Sławatycki, Paula Klemenska, Zbigniew Bartuzi
    Journal of Clinical Medicine.2025; 14(12): 4035.     CrossRef
  • Polygala tenuifolia Willd. Extract delays non-alcoholic fatty liver disease progression in rats via the COX2 and PERK-elF2α-ATF4 pathway
    Zhiliang Sun, Zhongshi Zhou, Kezheng Liao, Yanju Liu, Yanyun Liu, Chaoyang Wang, Zhihua Zhang, Li Wen
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Inhibition of lysosomal LAMTOR1 increases autophagy by suppressing the MTORC1 pathway to ameliorate lipid accumulations in MAFLD
    Yunyeong Jang, Minjeong Ko, Ju Yeon Lee, Jin Young Kim, Eun-Woo Lee, Ho Jeong Kwon
    Autophagy.2025; 21(12): 2633.     CrossRef
  • Relationship Between Fat-to-Muscle Ratio and Nonalcoholic Fatty Liver Disease in Middle-Aged and Older Adults with Type 2 Diabetes: Cross-Sectional Study
    Lei Zhang, Yulu Sun, Yiran Zhao, Xin Wu, Xiaofang Han
    Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 2067.     CrossRef
  • Associations Between Shift Work, Sociodemographic and Lifestyle Characteristics, Body Measurements, and MASLD
    Javier Tosoratto, Pedro Juan Tárraga López, Ángel Arturo López-González, Carla Busquets-Cortes, Joan Obrador de Hevia, José Ignacio Ramirez-Manent
    Life.2025; 15(6): 961.     CrossRef
  • Integrated serum pharmacochemistry, network pharmacology and experimental verification to explore the mechanism of Angelicae Pubescentis Radix in the treatment of NASH
    Xunhai Huang, Zirui Ding, Tianyan Feng, Zijie Xia, Hailong Xu, Lianghao Wei, Youbo Zhang, Gaigai Deng
    Fitoterapia.2025; 185: 106685.     CrossRef
  • Regulatory Mechanisms of Phenolic Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review
    Shengyu Zhang, Congcong Shen, Han Di, Yanhong Wang, Feng Guan
    Antioxidants.2025; 14(7): 760.     CrossRef
  • Laminin γ2 accelerates non-alcoholic fatty liver disease progression by enhancing lipid accumulation and fibrogenesis in hepatocytes
    Hui Chen, Guanggang Meng, Aiting Yang
    Biochemical and Biophysical Research Communications.2025; 777: 152266.     CrossRef
  • Incidence and Characterization of SIBO in NAFLD Patients
    Zaigham Abbas, Shamim Nazir, Sania Maqbool, Manesh Kumar, Darayus P Gazder, Aqsa Shahid
    Euroasian journal of hepato-gastroenterology.2025; 15(1): 38.     CrossRef
  • TyG-BMI as a superior predictor of MAFLD and pre-MAFLD in Chinese adults: a cross-sectional study
    Xinru Huang, Yanyun Hu, Lining Dong, Liying Zhu, Jie Li, Ji Hu, Wei Shao, Yongde Peng, Fang Liu
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Exploring the role of xanthine oxidase and aldehyde oxidase in metabolic dysfunction-associated steatotic liver disease (MASLD)
    Neha Gupta, Kavita Singh
    Journal of Molecular Histology.2025;[Epub]     CrossRef
  • Non-invasive detection of fibrosis in non-alcoholic fatty liver disease by serum microfibrillar-associated protein 4 and its correlation with FIB-4 and transient elastography
    Heba Abdel Rahman Eltony, Gamal Kasem, Radwa Mahmoud Elsharaby, Rehab Badawi, Eman M. Helal
    Egyptian Liver Journal.2025;[Epub]     CrossRef
  • Targeting the root cause of obesity-related comorbidities through weight independent and dependent actions on insulin sensitivity: Benefits of dual amylin and calcitonin receptor agonists
    Anna Thorsø Larsen, Simone Anna Melander, Khaled Elhady Mohamed, Emilie Ahmt Petersen, Meryem Benmarce, Morten Asser Karsdal, Kim Henriksen
    Biomedicine & Pharmacotherapy.2025; 190: 118388.     CrossRef
  • Computational investigation of lignans as potential target for non-alcoholic fatty liver disease: Insights from network pharmacology, docking, DFT, and dynamics simulation analysis
    Rajappan Chandra Satish Kumar, Akash Jayaraman, Ramesh Venkatachalapathy
    Human Gene.2025; 46: 201457.     CrossRef
  • Predicting the risk of lean non-alcoholic fatty liver disease based on interpretable machine models in a Chinese T2DM population
    Shixue Bao, Qiankai Jin, Tieqiao Wang, Yushan Mao, Guoqing Huang
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • In-Silico Analysis of Costunolide and Dehydrocostuslactone Interactions with NAFLD-Related Proteins
    Fransiska Ambarukmi Pontjosudargo, Hendri Priyadi, Agung Hermawanto, Tatang Bisri
    Journal of Applied Nursing and Health.2025; 7(2): 221.     CrossRef
  • Assessment of Liver Enzymes and the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) Among Information Technology (IT) Professionals
    Thirumoorthi Natarajan, Shenbaga Lalitha S, Sujatha Lakshminarayanan, Balakrishnan Madhavan, Devi Krishna Ravichandran, Krishna Prasanth
    Cureus.2025;[Epub]     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease: From a Very Low-Density Lipoprotein Perspective
    Yan Chen, Kaiwen Lei, Yanglong Liu, Jianshen Liu, Kunhua Wei, Jiao Guo, Zhengquan Su
    Biomolecules.2025; 15(7): 990.     CrossRef
  • Multidimensional insights into exosomes in hepatocellular carcinoma: from genesis to clinical application
    Xiang Zhang, Cheng Zhang, Zheng Zhang, Xuan Zhang
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Association of Apolipoprotein C-III Gene Polymorphisms (rs2854116 and rs2854117) with Susceptibility to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Turkish Population
    Damla Karaagac, Suat Morkuzu, Naci Senkal, Ersel Bilgin, Yasemin Oyacı, Tufan Tükek, Sacide Pehlivan, Alpay Medetalibeyoglu
    Medicina.2025; 61(8): 1479.     CrossRef
  • The Impact of Menopausal Hormone Therapy on Liver and Biliary Tract Health
    A. O. Bueverov, N. I. Tapilskaya
    Russian Journal of Gastroenterology, Hepatology, Coloproctology.2025; 35(3): 104.     CrossRef
  • Bufalin inhibits hepatocellular carcinoma progression by blocking EGFR-mediated RAS-RAF-MEK-ERK pathway activation
    Jingwen Liu, Jia Jiang, Ju Huang, Zhi-E Fang, Lexi Liu, Yong Liu, Weiqi Nian, Jianyuan Tang, Zhilei Wang
    Journal of Experimental & Clinical Cancer Research.2025;[Epub]     CrossRef
  • Impact of a high dietary fiber cereal meal intervention on the progression of liver fibrosis in T2DM with MASLD
    Xi-Shuang Chen, Hui-Zhen Liu, Fang Huang, Jian Meng, Jing-Xian Fang, Yu Han, Hui-Ming Zou, Qing Gu, Xue Hu, Qian-Wen Ma, Yue-Xia Han, Sui-Jun Wang
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Metabolic syndrome components as determinants of NAFLD progression in Bangladesh: a cross-sectional study
    Jannatul Efte Ekra, Pulak Kanti Palit, Mohammed Mehadi Hassan Chowdhury, Israt Jahan Sourna, Sanzida Islam, Farhana Arefin, Md. Asaduz Zaman, Joyonti Datta, Nafsoon Rahman, Adiba Anjum, Subodh Kumar Sarkar, Ashekul Islam
    Egyptian Liver Journal.2025;[Epub]     CrossRef
  • Investigation of the association between nitric oxide synthase gene variants and NAFLD in adolescents with obesity
    Sevde Hasanoğlu Sayın, İbrahim Kandemir, Yasemin Oyacı, Shahri Khudiyeva, Memduh Şahin, Aylin Yetim Şahin, Sacide Pehlivan
    Journal of Pediatric Endocrinology and Metabolism.2025; 38(11): 1169.     CrossRef
  • Lutein as a liver guardian: Insights into its hepatoprotective mechanisms, bioavailability, and emerging therapeutic roles
    Akash Vikal, Rashmi Maurya, Preeti Patel, Balak Das Kurmi
    Pharmacological Research - Natural Products.2025; 9: 100387.     CrossRef
  • Association between a Single-time Measurement of Fatty Liver Index and Occurrence of Sepsis among Individuals without Excessive Alcohol Consumption
    Dayeong Kim, Sang Hoon Han, Eun Hwa Lee, Hye Seong, Kyu-na Lee, Yebin Park, Kyung-Do Han
    Infection & Chemotherapy.2025; 57(3): 389.     CrossRef
  • Association Between Whole Blood Iron and Nonalcoholic Fatty Liver Disease in Elderly: A Case–Control Study
    Zhe-Ying Jiang, Wei-Jia Meng, Ying Wang, Hua-Qin Su, Bi-Xiu Mao, Cai-Li Wang, Feng-Lian Peng, Cui-Ping Li, Lian-Ping He
    Biological Trace Element Research.2025; 204(4): 2652.     CrossRef
  • NAFLD in adolescents aged 10–19: Global Burden of Disease analysis from 1990 to 2021
    Yuandong Luo, Lili Wang, Xuefeng Yang, Lingping Zhu
    Medicine.2025; 104(40): e45051.     CrossRef
  • Paired snRNA-seq and scRNA-seq analysis of MASLD patients to identify early-stage markers for disease progression
    Suebin Park, Su-Hyeon Lee, Se-eun Han, Beom Kyung Kim, Byungjin Hwang
    Hepatology Communications.2025;[Epub]     CrossRef
  • Comparison of the characteristics of non-alcoholic fatty liver disease in C57BL/6J-Leprem1hwl/Korl and C57BLKS/J-Leprdb/J mice
    Seungwoo Lee, Jae-Hong Min, Myoung Jun Kim, Somi Yun, Min Kyoung Seo, Jong Kwon Lee
    Experimental Animals.2025; 74(4): 440.     CrossRef
  • Combined effect of metformin and ezetimibe on PPAR-γ and adiponectin gene expression and biochemical parameters in MAFLD patients with type 2 diabetes
    Asiyeh Masaeli, Mohammad Taghi Goodarzi, Adel Mohammadalipour, Safa Ali-Asgari, Mohammad Reza Mirzaei, Mohsen Hani
    Scientific Reports.2025;[Epub]     CrossRef
  • From traditional metabolic markers to ensemble learning: comparative application of machine learning models for predicting NAFLD risk in adolescents
    Chenming Zhang, Bin Niu, Rong Wang, Liaoyun Zhang
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Evaluation of Nomenclature of Fatty Liver Disease in Association with Hepatocellular Carcinoma: A 14.5-Year Cohort Study in Korea
    Tung Hoang, Jeonghee Lee, Bo Hyun Kim, Yuri Cho, Jeongseon Kim
    Cancer Research and Treatment.2025; 57(4): 1144.     CrossRef
  • Translational framework linking perfluoroheptanoic acid (PFHpA) exposure to metabolic dysfunction associated steatotic liver disease in adolescents
    Brittney O. Baumert, Ana C. Maretti-Mira, Douglas I. Walker, Zhenjiang Li, Nikos Stratakis, Hongxu Wang, Yinqi Zhao, Fabian Christoph Fischer, Qiran Jia, Damaskini Valvi, Scott M. Bartell, Jiawen Carmen Chen, Thomas Inge, Justin R. Ryder, Todd Jenkins, St
    Communications Medicine.2025;[Epub]     CrossRef
  • Mechanistic Insights into N-Oleoylethanolamide-Mediated Hepatoprotection via PPAR-α
    Darya Ivashkevich, Arina Ponomarenko, Igor Manzhulo, Inessa Dyuizen
    BIOCELL.2025; 49(4): 607.     CrossRef
  • Traditional Chinese medicine for non-alcoholic fatty liver disease: an overview of systematic reviews with evidence mapping and metabolic outcome assessment
    Juanjuan Li, Ruimin Jiao, Wenquan Su, Wei Chen, Xiangyu Hu, Shuai Xu, Lie Xu, Weiwei Yao, Kejia Liu, Hong You, Jingjie Zhao
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Carvacrol-Loaded Chitosan Nanoparticles as a Multifunctional Nanotherapeutic Strategy Targeting Oxidative Stress, Inflammation, Apoptosis, and Genotoxicity in Nonalcoholic Fatty Liver Disease
    M. Alfawaz, Ekramy M. Elmorsy, Ahmad Najem Alshammari, Noor A. Hakim, Najlaa M. M. Jawad, Soha A. Hassan, Manal S. Fawzy, Safya E. Esmaeel
    Antioxidants.2025; 14(12): 1432.     CrossRef
  • Bacillus subtilis pb2441 Ameliorates Hepatic Steatosis by Decoupling Liver and Fat Tissue Lipid Accumulation in a High-Fat Diet-Fed Mouse Model
    Jung-Yun Lee, Sung-Su Park, Il Kyu Cho, Kyoung-Sik Moon, Yangrae Cho
    Journal of Medicinal Food.2025; 28(12): 1213.     CrossRef
  • Colon-Targeted astragalus polysaccharide nanoparticles prevent NAFLD-Driven hepatocarcinogenesis via microbiota remodeling and NF-κB Inhibition
    Dan Liu, Runtian Li, Mingzhu Li, Ying Liang, Zhao Wang, Yang Sun, Pengling Ge
    Journal of Experimental & Clinical Cancer Research.2025;[Epub]     CrossRef
  • Extrahepatic Comorbidities Associated with Metabolic Dysfunction-Associated Steatotic Liver Disease; A Tertiary Hospital Experience
    Masoudreza Sohrabi, Mozhdeh Mosalli, Parvin Hassanzadeh, Somayeh Bahrami, Mahmoodreza Khoonsari, Hossein Ajdarkosh, Farhad Zamani
    Middle East Journal of Digestive Diseases.2025; 17(2): 96.     CrossRef
  • “Efficacy of SGLT2 inhibitors in non-diabetic non-alcoholic fatty liver disease: a systematic review and meta-analysis”
    Muhammad Sharjeel Abbas, Mrunalini Dandamudi, Tooba Rehman, Muhammad Aqib Faizan, Izza Zahra, John Cedric Mojica, Musab Riyan Ahmed, Karishma Bai, Izza Shakeel, Zunaira Shahzad, Juliana Giorgi
    Journal of Diabetes & Metabolic Disorders.2025;[Epub]     CrossRef
  • The Importance of Serum Perilipin-2 Level as an Early Indicator of Inflammation in Non-Alcoholic Fatty Liver Disease
    Omer Vehbi Alpaydin, Eda Nur Duran, Ayse Hur Alpaydin, Iskender Ekinci, Seyma Dumur, Hafize Uzun, Murat Akarsu, Isa Yalcinkaya, Omur Tabak
    Diagnostics.2025; 16(1): 106.     CrossRef
  • Frequency and Association of Dyslipidemia with Clinical and Biochemical Parameters among Patients with Non-alcoholic Fatty Liver Disease
    Arslan Ahmad, Shazia Siddique, Amanullah Bhalli, Amina Umer, Umayma Asad, Muhammad Irfan Jamil
    Pakistan Journal of Health Sciences.2025; : 75.     CrossRef
  • STEATOTIC LIVER DISEASE: THE IMPACT OF TEA AND COFFEE CONSUMPTION. LITERATURE REVIEW
    V.S. Rakhmetova
    Наука и здравоохранение.2025; (5(27)): 261.     CrossRef
  • Physiological and biochemical effects of experimental hepatic steatosis in male albino rabbits
    R. S. AL-Juwary, M. M. AL-Kattan
    BULGARIAN JOURNAL OF VETERINARY MEDICINE.2025; 28(4): 646.     CrossRef
  • The interplay between chronic hepatitis B and diabetes mellitus: A narrative and concise review
    Shang‐Chin Huang, Jia‐Horng Kao
    The Kaohsiung Journal of Medical Sciences.2024; 40(1): 6.     CrossRef
  • LncRNA Gm28382 promotes lipogenesis by interacting with miR-326-3p to regulate ChREBP signaling pathway in NAFLD
    Sen Yang, Yang Zhang, Yan Zhang, Lianhong Yin, Xu Han, Xuerong Zhao, Ning Wang, Lina Xu
    International Immunopharmacology.2024; 127: 111444.     CrossRef
  • Role of Perturbated Hemostasis in MASLD and Its Correlation with Adipokines
    Salvatore Pezzino, Tonia Luca, Mariacarla Castorina, Stefano Puleo, Saverio Latteri, Sergio Castorina
    Life.2024; 14(1): 93.     CrossRef
  • From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease: Out with the Old, in with the New
    Iyiad Alabdul Razzak, Mazen Noureddin, Hirsh Trivedi
    Journal of Clinical Medicine.2024; 13(3): 880.     CrossRef
  • Research Progress of MIF in Nonalcoholic Fatty Liver Disease
    ·阿不力提浦 阿依古扎丽
    Advances in Clinical Medicine.2024; 14(02): 2483.     CrossRef
  • Hepatic Stellate Cell‐Targeting Micelle Nanomedicine for Early Diagnosis and Treatment of Liver Fibrosis
    Lei Wang, Jieying Zhou, Jian Wang, Xiaotang Wang, Haijuan Dong, Lingzhi Zhao, Junchen Wu, Juanjuan Peng
    Advanced Healthcare Materials.2024;[Epub]     CrossRef
  • Not Only Metabolic Complications of Childhood Obesity
    Sebastian Ciężki, Emilia Odyjewska, Artur Bossowski, Barbara Głowińska-Olszewska
    Nutrients.2024; 16(4): 539.     CrossRef
  • Effect of Statins for Primary Prevention of Cardiovascular Disease According to the Fatty Liver Index
    Joonsang Yoo, Jimin Jeon, Minyoul Baik, Jinkwon Kim
    Journal of Epidemiology and Global Health.2024; 14(3): 710.     CrossRef
  • Ferroptosis in Liver Disease: Natural Active Compounds and Therapeutic Implications
    Zhili Wu, Yanru Zhu, Wenchao Liu, Balamuralikrishnan Balasubramanian, Xiao Xu, Junhu Yao, Xinjian Lei
    Antioxidants.2024; 13(3): 352.     CrossRef
  • Lipidomic Analysis of Liver and Adipose Tissue in a High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Mice Model Reveals Alterations in Lipid Metabolism by Weight Loss and Aerobic Exercise
    Thomai Mouskeftara, Olga Deda, Grigorios Papadopoulos, Antonios Chatzigeorgiou, Helen Gika
    Molecules.2024; 29(7): 1494.     CrossRef
  • Puerarin Induces Macrophage M2 Polarization to Exert Antinonalcoholic Steatohepatitis Pharmacological Activity via the Activation of Autophagy
    Xiaoxue Fang, Xintian Lan, Ming Zhu, Min He, Mengmeng Sun, Yiming Cao, Difu Zhu, Dean Guo, Haoming Luo
    Journal of Agricultural and Food Chemistry.2024; 72(13): 7187.     CrossRef
  • Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics?
    Antonella Mosca, Andrea Pietrobattista, Giuseppe Maggiore
    Pediatric Reports.2024; 16(2): 288.     CrossRef
  • Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD
    Devaraj Ezhilarasan
    Metabolism.2024; 155: 155912.     CrossRef
  • Non-alcoholic fatty liver disease: new additional non-invasive diagnostic markers and risks of comorbid diseases
    Kh.A. Moskva, O.P. Kikhtyak, M.L. Farmaha, Ya.L. Leshchuk, M.Yu. Horecha
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2024; 20(2): 99.     CrossRef
  • SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea
    Hyo Jung Cho, Eunyoung Lee, Soon Sun Kim, Jae Youn Cheong
    Scientific Reports.2024;[Epub]     CrossRef
  • Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice
    Bin Wang, Xiaochan Zhu, Siting Yu, Huan Xue, Lijiao Deng, Yushan Zhang, Yi Zhang, Yunfeng Liu
    Biochemical and Biophysical Research Communications.2024; 722: 150170.     CrossRef
  • Small intestinal bacterial overgrowth in obese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: a cross-sectional study
    Nicolás Ortiz-López, Ana María Madrid, Larissa Aleman, Alejandra Zazueta, Gladys Smok, Lucía Valenzuela-Pérez, Jaime Poniachik, Caroll J. Beltrán
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • The effect of probiotic consumption on lipid profile, glycemic index, inflammatory markers, and liver function in NAFLD patients: A systematic review and meta-analysis of randomized controlled trials
    Sadegh Mozaffari, Mahdeyeh Aliari, Solaleh Emamgholipour, Hossein Hosseini, Pedram Rezaei Amirkiasar, Mina Zare, Niki Katsiki, Ghodratollah Panahi, Amirhossein Sahebkar
    Journal of Diabetes and its Complications.2024; 38(8): 108780.     CrossRef
  • SPRED2 Is a Novel Regulator of Autophagy in Hepatocellular Carcinoma Cells and Normal Hepatocytes
    Tianyi Wang, Tong Gao, Masayoshi Fujisawa, Toshiaki Ohara, Masakiyo Sakaguchi, Teizo Yoshimura, Akihiro Matsukawa
    International Journal of Molecular Sciences.2024; 25(11): 6269.     CrossRef
  • The independent and joint associations of vitamin B12 and methylmalonic acid on the risk of mortality in individuals with metabolic dysfunction-associated steatotic liver disease
    Peng Wang, Jing Yu, Yaxuan Zhao, Rukiya Simayi, Dan Shi
    European Journal of Nutrition.2024; 63(7): 2541.     CrossRef
  • Lycopene: A Potent Antioxidant with Multiple Health Benefits
    Mercy Omoye Shafe, Nontobeko Myllet Gumede, Trevor Tapiwa Nyakudya, Eliton Chivandi, Toshikazu Suzuki
    Journal of Nutrition and Metabolism.2024;[Epub]     CrossRef
  • Association between hemoglobin and non-alcoholic fatty liver disease (NAFLD) in United States adults: Results from NHANES 2017–2020
    Kang Yao, Zheng Chen, Wei Zhou, Zhihua Liu, Wei Cui
    Preventive Medicine Reports.2024; 44: 102798.     CrossRef
  • Effects of a Two-Year Lifestyle Intervention on Intrahepatic Fat Reduction and Renal Health: Mitigation of Inflammation and Oxidative Stress, a Randomized Trial
    Maria Magdalena Quetglas-Llabrés, Margalida Monserrat-Mesquida, Cristina Bouzas, Silvia García, David Mateos, Miguel Casares, Cristina Gómez, Lucía Ugarriza, Josep A. Tur, Antoni Sureda
    Antioxidants.2024; 13(7): 754.     CrossRef
  • The causal relationship between non-alcoholic fatty liver disease, hypertension, and cardiovascular diseases: implications for future research
    Toshiki Maeda
    Hypertension Research.2024; 47(9): 2580.     CrossRef
  • Role of Nonalcoholic Fatty Liver Disease in Periodontitis: A Bidirectional Relationship
    Hardika S Vegda, Bhavin Patel, Gaurav A Girdhar, Mohd. Shabankhan H Pathan, Rahnuma Ahmad, Mainul Haque, Susmita Sinha, Santosh Kumar
    Cureus.2024;[Epub]     CrossRef
  • Temporal relationship between hepatic steatosis and fasting blood glucose elevation: a longitudinal analysis from China and UK
    Yujie Liu, Xian Liang, Yifan Hu, Ning Zhang, Xingren Zhu, Yuemei Feng, Zixiu Qin, Zihao Wang, Baima Kangzhuo, Xiong Xiao, Xing Zhao
    BMC Public Health.2024;[Epub]     CrossRef
  • YinChen WuLing powder attenuates non-alcoholic steatohepatitis through the inhibition of the SHP2/PI3K/NLRP3 pathway
    Xingxing Yuan, Liuxin Yang, Tinting Gao, Jiawei Gao, Bingyu Wang, Chengxiang Liu, Wei Yuan
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis
    Xiaoyan Li, Jie He, Qiuhua Sun
    Clinical Nutrition.2024; 43(9): 2005.     CrossRef
  • Reversal of Fatty Liver With Regression of Acute Necrotizing Pancreatitis: A Rare Case
    Sanjay M Khaladkar, Sayali Paidlewar, Purnachandra Lamghare, Ankita Pandey
    Cureus.2024;[Epub]     CrossRef
  • Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes
    Merve Cebi, Yusuf Yilmaz
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Innovative treatments for obesity and NAFLD: A bibliometric study on antioxidants, herbs, phytochemicals, and natural compounds
    Salvatore Pezzino, Maria Sofia, Chiara Mazzone, Giorgia Litrico, Luigi Piero Greco, Luisa Gallo, Gaetano La Greca, Saverio Latteri
    Heliyon.2024; 10(16): e35498.     CrossRef
  • The pivotal role of dysregulated autophagy in the progression of non-alcoholic fatty liver disease
    Qiaohui Shen, Ming Yang, Song Wang, Xingyu Chen, Sulan Chen, Rui Zhang, Zhuang Xiong, Yan Leng
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • MASLD-Related Hepatocarcinoma: Special Features and Challenges
    Carmen Yagüe-Caballero, Diego Casas-Deza, Andrea Pascual-Oliver, Silvia Espina-Cadena, Jose M. Arbones-Mainar, Vanesa Bernal-Monterde
    Journal of Clinical Medicine.2024; 13(16): 4657.     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease in Japan: Prevalence Trends and Clinical Background in the 10 Years before the Coronavirus Disease 2019 Pandemic
    Akira Sato, Yumiko Oomori, Rika Nakano, Tomokazu Matsuura
    Medicina.2024; 60(8): 1330.     CrossRef
  • Beneficial Effects of the Ketogenic Diet on Nonalcoholic Fatty Liver Disease (NAFLD/MAFLD)
    Damian Dyńka, Łukasz Rodzeń, Mateusz Rodzeń, Dorota Łojko, Sebastian Kraszewski, Ali Ibrahim, Maria Hussey, Adam Deptuła, Żaneta Grzywacz, Alexandre Ternianov, David Unwin
    Journal of Clinical Medicine.2024; 13(16): 4857.     CrossRef
  • Impact of non-alcoholic fatty liver disease on coronavirus disease 2019: A systematic review
    Abdul Moeed, Muhammad Omar Larik, Muhammad Ahmed Ali Fahim, Hafsah Alim Ur Rahman, Lubna Najmi, Mah I Kan Changez, Muhammad Moiz Javed, Md Al Hasibuzzaman
    World Journal of Hepatology.2024; 16(8): 1185.     CrossRef
  • Inter-visit and inter-reader reproducibility of multi-parametric diffusion-weighted MR imaging in longitudinally imaged patients with metabolic dysfunction-associated fatty liver disease and healthy volunteers.
    Anton Volniansky, Thierry L. Lefebvre, Merve Kulbay, Boyan Fan, Emre Aslan, Kim-Nhien Vu, Emmanuel Montagnon, Bich Ngoc Nguyen, Giada Sebastiani, Jeanne-Marie Giard, Marie-Pierre Sylvestre, Guillaume Gilbert, Guy Cloutier, An Tang
    Magnetic Resonance Imaging.2024; 113: 110223.     CrossRef
  • NFKBIE is a predictive factor of survival and is correlated with immune infiltration and antigen processing and presentation in hepatocellular carcinoma
    Yang Zhang, Jinqi Tu, Jian Wang, Tiancheng Dai, Lin Zheng, Sinan Sun, Conyin Tu, Heng Li, Liting Qian
    Oncology Letters.2024;[Epub]     CrossRef
  • New Onset of Acute and Chronic Hepatic Diseases Post-COVID-19 Infection: A Systematic Review
    Ahamed Lebbe, Ali Aboulwafa, Nuran Bayraktar, Beshr Mushannen, Sama Ayoub, Shaunak Sarker, Marwan Nour Abdalla, Ibrahim Mohammed, Malik Mushannen, Lina Yagan, Dalia Zakaria
    Biomedicines.2024; 12(9): 2065.     CrossRef
  • Emerging Therapies for Non-Alcoholic Steatohepatitis (NASH): A Comprehensive Review of Pharmacological and Non-Pharmacological Approaches
    Shradha P Kakde, Maham Mushtaq, Maryyam Liaqat, Husnain Ali, Muhammad Muaz Mushtaq, Muhammad Asad Sarwer, Sami Ullah, Muhammad Wali Hassan, Asma Khalid, Syed Faqeer Hussain Bokhari
    Cureus.2024;[Epub]     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study
    Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon, Hyung Ho Lee, Heejoo Park, Jian Lee, Youngsun Park, Byungyoon Yun, Jinsoo Chung
    Cancers.2024; 16(18): 3161.     CrossRef
  • Rifaximin alleviates MCD diet-induced NASH in mice by restoring the gut microbiota and intestinal barrier
    Yan Yun SHU, Li Lin HU, Jin YE, Ling YANG, Yu JIN
    Life Sciences.2024; 357: 123095.     CrossRef
  • Salidroside may target PPARα to exert preventive and therapeutic activities on NASH
    Xueru Chu, Shousheng Liu, Baozhen Qu, Yongning Xin, Linlin Lu
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
    Yewan Park, Jooyi Jung, Seungbong Han, Gi‐Ae Kim
    Alimentary Pharmacology & Therapeutics.2024; 60(11-12): 1599.     CrossRef
  • Association between hepatocyte TM4SF5 expression and gut microbiome dysbiosis during non-alcoholic fatty liver disease development
    Yangie Dwi Pinanga, Kyung-hee Pyo, Eun-Ae Shin, Haesong Lee, Eun Hae Lee, Wonsik Kim, Soyeon Kim, Ji Eon Kim, Semi Kim, Jung Weon Lee
    Life Sciences.2024; 358: 123164.     CrossRef
  • Serum microRNA 143 and 223 Gene Expression Profiles as Potential Biomarkers in Individuals with Hepatitis and COVID-19
    Lucas Lima da Silva, Luciane Almeida Amado Leon, Otacílio da Cruz Moreira, Wagner Luis da Costa Nunes Pimentel Coelho, Vanessa Duarte da Costa, Claudia Alexandra Pontes Ivantes, Priscila Pollo-Flores, Lia Laura Lewis-Ximenez, Vanessa Salete de Paula, Livi
    Viruses.2024; 16(11): 1734.     CrossRef
  • Antioxidant and Anti-Inflammatory Effects of Opuntia Extracts on a Model of Diet-Induced Steatosis
    Irene Besné-Eseverri, María Ángeles Martín, Gloria Lobo, M. Pilar Cano, María P. Portillo, Jenifer Trepiana
    Antioxidants.2024; 13(11): 1416.     CrossRef
  • From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome – current insights and future directions
    Bruno Basil, Blessing K. Myke-Mbata, Onyinye E. Eze, Augustine U. Akubue
    Clinical Diabetes and Endocrinology.2024;[Epub]     CrossRef
  • Nidogen 2 Overexpression Promotes Hepatosteatosis and Atherosclerosis
    Ishita Kathuria, Aditi Prasad, Bal Krishan Sharma, Ravi Varma Aithabathula, Malvin Ofosu-Boateng, Maxwell A. Gyamfi, Jianxiong Jiang, Frank Park, Udai P. Singh, Bhupesh Singla
    International Journal of Molecular Sciences.2024; 25(23): 12782.     CrossRef
  • Arctium lappa L. Extract Alleviates Non-Alcoholic Fatty Liver Injury in Mices
    娜 李
    Hans Journal of Medicinal Chemistry.2024; 12(04): 309.     CrossRef
  • Systemic treatment type is not associated with abnormal post-treatment noninvasive liver stiffness measurement in psoriasis
    Yue Xiao, Jingya Gao, Yiyi Wang, Dan Hao, Wei Yan, Dingke Wen, Siyi Zeng, Shiqi Yang, Yingyu Shi, Wei Li
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Etiology-Dependent Microbiome Differences in Hepatocellular Carcinoma Development
    Nevena Todorovic, Serena Martinelli, Giulia Nannini, Ralf Weiskirchen, Amedeo Amedei
    International Journal of Molecular Sciences.2024; 25(24): 13510.     CrossRef
  • Correlation of serum cotinine with fatty liver index in adults: data from the NHANES March 2017 and 2018
    Guangwen Chen, Nan Chen, Lijian Liu, Xiaoyan Huang, Jianfeng Li, Jinxiu Wei, Yuqing Wang, Chengning Yang, Sheng Xie
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • Effects of Phytochemicals on Metabolic Diseases and Human Health
    María Ángeles Martín, Sonia Ramos
    Nutrients.2024; 16(24): 4323.     CrossRef
  • Influence of phytosomal curcumin on anthropometric indices for nonalcoholic fatty liver disease: A meta-analysis
    Nana Liu, Hongting Li
    Medicine.2024; 103(52): e40538.     CrossRef
  • Dyslipidaemia in Liver Diseases
    Jiří Hlušička, Aleš Žák
    Folia Biologica.2024; 70(5-6): 239.     CrossRef
  • Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
    Ho Soo Chun, Minjong Lee
    Clinical and Molecular Hepatology.2023; 29(2): 377.     CrossRef
  • The Janus-Faced Role of Lipid Droplets in Aging: Insights from the Cellular Perspective
    Nikolaus Bresgen, Melanie Kovacs, Angelika Lahnsteiner, Thomas Klaus Felder, Mark Rinnerthaler
    Biomolecules.2023; 13(6): 912.     CrossRef
  • Protective effects of statins on the incidence of NAFLD–related decompensated cirrhosis in T2DM
    Szu‐Yuan Wu, Wan‐Ming Chen, Ming‐Feng Chiang, Hung‐Chieh Lo, Ming‐Shun Wu, Ming‐Che Lee, Ruey‐Shyang Soong
    Liver International.2023; 43(10): 2232.     CrossRef
  • Editorial: Will MRI‐PDFF become the new standard for steatosis assessment in NAFLD?
    Angeliki Pappa, Tobias Wenzl
    Alimentary Pharmacology & Therapeutics.2023; 58(3): 364.     CrossRef
  • Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”
    Seogsong Jeong, Yohwan Lim, Su Kyoung Lee, Hyun Wook Han
    Clinical and Molecular Hepatology.2023; 29(3): 810.     CrossRef
  • Non-Alcoholic Fatty Liver Disease and Echocardiographic Parameters of Left Ventricular Diastolic Function: A Systematic Review and Meta-Analysis
    Athina Goliopoulou, Panagiotis Theofilis, Evangelos Oikonomou, Artemis Anastasiou, Panteleimon Pantelidis, Maria Ioanna Gounaridi, Georgios E. Zakynthinos, Ourania Katsarou, Eva Kassi, Vaia Lambadiari, Dimitris Tousoulis, Manolis Vavuranakis, Gerasimos Si
    International Journal of Molecular Sciences.2023; 24(18): 14292.     CrossRef
  • Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
    Gi-Ae Kim, Joon Ho Moon, Won Kim
    Clinical and Molecular Hepatology.2023; 29(4): 831.     CrossRef
  • Association between Impaired Ketogenesis and Metabolic-Associated Fatty Liver Disease
    Jaehyun Bae, Byung-Wan Lee
    Biomolecules.2023; 13(10): 1506.     CrossRef
  • The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
    Landon L. Chan, Stephen L. Chan
    Clinical and Molecular Hepatology.2023; 29(4): 909.     CrossRef
  • Comparison of the efficacy and safety of hypoglycemic treatments in patients with non-alcoholic fatty liver disease and type-2 diabetes: a systematic review and Bayesian network analysis
    Nuojin Guo, Hekai Shi, Hao Zhang, Hua Wang
    European Journal of Clinical Pharmacology.2023; 79(11): 1465.     CrossRef
  • Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment
    Yuping Ding, Quanjun Deng, Mei Yang, Haiyan Niu, Zuoyu Wang, Shihai Xia
    Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 3303.     CrossRef
  • Relationships between nonalcoholic fatty liver disease and polycystic ovary syndrome
    E.H. Manzhalii, T.F. Tatarchuk, T.M. Tutchenko, N.V. Kosei, R.O. Mnevets
    REPRODUCTIVE ENDOCRINOLOGY.2023; (70): 40.     CrossRef
  • Health in All Policies: Working Across Sectors in Cooperative Extension to Promote Health for All
    Michele Walsh, Deborah John, Nicole Peritore, Andrea Morris, Carolyn Bird, Marion Ceraso, Sarah Eichberger, Rachel Novotny, Laura Stephenson, Suzanne Stluka, Roberta Riportella
    Journal of Human Sciences and Extension.2018;[Epub]     CrossRef
  • 31,599 View
  • 817 Download
  • 201 Web of Science
  • Crossref

Original Article

Steatotic liver disease

The independent effect of exercise on biopsy-proven non-alcoholic fatty liver disease: A systematic review
George Chen, Bubu Banini, Albert Do, Joseph K. Lim
Clin Mol Hepatol 2023;29(Suppl):S319-S332.
Published online December 14, 2022
DOI: https://doi.org/10.3350/cmh.2022.0366
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. Although previous studies have demonstrated that exercise independently reduces hepatic steatosis measured by imaging modalities in NAFLD, the effect of exercise on histological endpoints remains unclear. We aimed to conduct a systematic review of the independent effect of exercise on hepatic steatosis, steatohepatitis, and liver fibrosis as measured by histological assessment or non-invasive tests (NITs) in biopsy-proven NAFLD. A systematic literature search of PubMed, Embase, and Web of Science databases was performed using keywords related to exercise, NAFLD, and biopsy. Articles were selected based on the following inclusion criteria: (1) involved human subjects with biopsy-proven NAFLD, (2) analyzed the independent effect of exercise, (3) assessed changes in hepatic steatosis, steatohepatitis, or liver fibrosis via either histological evaluation or NITs, and (4) were original research studies. We identified a total of six studies that analyzed the independent effect of exercise on histological endpoints in biopsy-proven NAFLD. Two randomized controlled trials (RCTs) did not detect significant histological improvement following exercise interventions, while other non-randomized interventional studies showed that exercise reduces hepatocyte ballooning and liver fibrosis. In addition, five studies assessed NIT outcomes, collectively demonstrating that exercise improves hepatic steatosis measured by magnetic resonance imaging-based techniques but not serum biomarkers for steatohepatitis and liver fibrosis. Additional large RCTs and meta-analyses are warranted to investigate the independent effect of exercise on histological and clinical outcome endpoints in NAFLD.

Citations

Citations to this article as recorded by  Crossref logo
  • Physical Activity Improves Overall Survival in Patients with Hepatocellular Carcinoma
    Byeong Geun Song, Myeongcheol Lee, Juhee Cho, Geum-Youn Gwak, Danbee Kang, Dong Hyun Sinn
    Liver Cancer.2026; : 1.     CrossRef
  • Differential Exercise Requirements for Nonalcoholic Fatty Liver Disease Resolution Across Age Groups: A Longitudinal Study of Korean Military Officers
    Jaejun Lee, Dong Yeup Lee, Jae Hyeop Jung, Eunkyoung Bae, Jeong A. Yu, Hyun Yang
    Journal of Physical Activity and Health.2025; 22(3): 323.     CrossRef
  • Acetyl-CoA Carboxylase Inhibitors for Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Nurina Hasanatuludhhiyah, Arifa Mustika, Viskasari P. Kalanjati, Muhammad Miftahussurur, Naoto Uemura
    Pharmaceuticals.2025; 18(9): 1276.     CrossRef
  • NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic–Metabolic Interplay
    Simona Cernea
    Life.2024; 14(2): 272.     CrossRef
  • The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review
    Young-Joo Jin
    Clinical and Molecular Hepatology.2023; 29(2): 414.     CrossRef
  • Diet and non-alcoholic fatty liver disease, a short narrative review
    W.J. Kwanten
    Acta Gastro Enterologica Belgica.2023; 86(2): 306.     CrossRef
  • Higher oxidative balance scores are associated with lower nonalcoholic fatty liver disease and not with fibrosis in US adults
    Xuna Liu, Yiwen Wang, Xuyan Liu, Beibei Zeng, Boxu Zhu, Yue Zhang, Yan Zhuang, Yanqi Zhang, Fei Dai
    Nutrition, Metabolism and Cardiovascular Diseases.2023; 33(12): 2488.     CrossRef
  • Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia
    Yohwan Lim, Seogsong Jeong, Myunghee Hong, Hyun Wook Han
    Reviews in Cardiovascular Medicine.2023;[Epub]     CrossRef
  • 9,171 View
  • 127 Download
  • 10 Web of Science
  • Crossref

Reviews

Steatotic liver disease

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima
Clin Mol Hepatol 2023;29(Suppl):S123-S135.
Published online December 12, 2022
DOI: https://doi.org/10.3350/cmh.2022.0357
Non-alcoholic fatty liver disease is currently the most common chronic liver disease, affecting up to 25% of the global population. Simple fatty liver, in which fat is deposited in the liver without fibrosis, has been regarded as a benign disease in the past, but it is now known to be prognostic. In the future, more emphasis should be placed on the quantification of liver fat. Traditionally, fatty liver has been assessed by histological evaluation, which requires an invasive examination; however, technological innovations have made it possible to evaluate fatty liver by non-invasive imaging methods, such as ultrasonography, computed tomography, and magnetic resonance imaging. In addition, quantitative as well as qualitative measurements for the detection of fatty liver have become available. In this review, we summarize the currently used qualitative evaluations of fatty liver and discuss quantitative evaluations that are expected to further develop in the future.

Citations

Citations to this article as recorded by  Crossref logo
  • Near-Infrared Fluorescent Lipid Droplet Polarity Probe for Distinguishing Different Liver Injury Diseases
    Xiaodong Tan, Yijia Liu, Siyu Jiang, Zhoupeng Zheng, Guoqiang Feng
    Chemical & Biomedical Imaging.2026; 4(5): 924.     CrossRef
  • Evaluation of thyroid function in patients diagnosed with metabolic dysfunction-associated fatty liver disease: a cross-sectional study
    Ahmed M. Eldaba, Mona M. Watany, Galal El Din M. Elkassas, Rehab B. El sheshtawy
    Tanta Medical Journal.2026; 54(1): 143.     CrossRef
  • Circulating hepatocyte-derived extracellular particles as potential biomarker of steatohepatitis progression to fibrogenesis: Exploring the impact of smoking
    Oumnia Masrour, Justine Morvan, Alison Rapin, Alexis Aimé, Agnès Burel, Valentine Genêt, Stéphanie Brisset, Dominique Lagadic-Gossmann, Edouard Bardou-Jacquet, Corinne Martin-Chouly
    Digestive and Liver Disease.2026; 58(3): 355.     CrossRef
  • Performance of three clinical scores for steatosis and steatohepatitis and their interaction with metabolic syndrome in obese individuals
    Giovani Schulte Farina, Bárbara Brambilla, Emanuelle Mendonça Pandolfo, Laura Kalil Nader Lazzaretti, Stéfano Mateus Schio Kuiava, Ana Maria Graciolli, Vitória Maria Kriger, Carlos Henrique Dal Bem Fistarol, Augusto Cardoso Sgarioni, Henrique Prataviera G
    World Journal of Hepatology.2026;[Epub]     CrossRef
  • A Standardized Extract of Centella asiatica (ECa 233) Protects Against Liver Injury and Fatty Liver in Wild‐Type and Beta‐Thalassemia Mice With Iron Overload
    Paranee Yatmark, Puntita Anutagerngkun, Somkiat Huaijantug, Mayuree H. Tantisira, Saovaros Svasti, Noppawan Phumala Morales, Anjali Chauhan
    Advances in Pharmacological and Pharmaceutical Sciences.2026;[Epub]     CrossRef
  • Diagnostic performance of controlled attenuation parameter for grading hepatic steatosis in MASLD: an MRI-PDFF-referenced study in a Chinese cohort
    Siying Wang, Dongfang Shang, Chenlu Zhao, Lihui Zhang, Sutong Liu, Qing Zhao, Qiang Zhang, Wenxia Zhao
    Frontiers in Medicine.2026;[Epub]     CrossRef
  • Three-Dimensional In Situ Sensing and Spatiotemporal Imaging Analysis of Dual Targets in Steatotic Liver Disease
    Meiqi Song, Ke Shen, Zhuo Liu, Jinghui Zhang, Congcong Jiang, Qinghua Hao, Wei Shen, Hian Kee Lee, Sheng Tang
    Analytical Chemistry.2026; 98(22): 16355.     CrossRef
  • Relevance of lipid droplets in metabolic dysfunction-associated steatotic liver disease
    Ralf Weiskirchen, Amedeo Lonardo
    Expert Opinion on Therapeutic Targets.2026; 30(5): 473.     CrossRef
  • Thyroid Stimulating Hormone Levels Are Related to Fatty Liver Indices Independently of Free Thyroxine: A Cross-Sectional Study
    Federica Sileo, Alessandro Leone, Ramona De Amicis, Andrea Foppiani, Laila Vignati, Francesca Menichetti, Giorgia Pozzi, Simona Bertoli, Alberto Battezzati
    Journal of Clinical Medicine.2025; 14(7): 2401.     CrossRef
  • The application performance of MRI-PDFF detection values of different hepatic lobes in diagnosing liver steatosis
    Fengjie Qiao, Yan Xue, Chen Zou, Kun Liu, Jie Yuan, Longshan Ji, Lingying Huang, Man Li, Yueqiu Gao
    Clinical and Experimental Medicine.2025;[Epub]     CrossRef
  • The value of ultrasonic attenuation parameters and serum indicators on MASLD patients with liver fat degenerationality
    Yan Liu, Wen Kang, Jingya Su, Yin Yang, Kui Li, Juntao Yang
    Journal of Radiation Research and Applied Sciences.2025; 18(3): 101647.     CrossRef
  • Quantification of liver steatosis of metabolic dysfunction-associated steatotic liver disease based on body composition analysis
    Toshikazu Kohira, Satoshi Oeda, Erina Eto, Yoshihito Kubotsu, Misa Norita, Kaori Inoue, Nagisa Hara, Shotaro Noge, Kenichi Tanaka, Shigenobu Yoshimura, Noriko Oza, Keizo Anzai, Yuichiro Eguchi, Cheng Han Ng, Daniel Q. Huang, Mark D. Muthiah, Atsushi Kawag
    Scientific Reports.2025;[Epub]     CrossRef
  • Discovery of ultrasound-derived fat fraction as a non-invasive tool for MASLD diagnosis
    Huiru Jin, Mengfan Jiao, Chengxiao Yu, Tingting Ren, Qingling Chen, Zixing Dai, Erfu Xie, Longfeng Jiang, Yuwen Li
    European Journal of Medical Research.2025;[Epub]     CrossRef
  • Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Non-Alcoholic Fatty Liver Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Simei Huang, Yu Xi, Yanqing Hong, Chenliang Hu
    Hormone and Metabolic Research.2025; 57(10): 593.     CrossRef
  • Current Update on Nomenclature, Diagnosis, and Management of Metabolic Dysfunction–associated Steatotic Liver Disease: Radiologists’ Perspective
    Eri G. Osta, Florentino Saenz Rios, Sriram Jaganathan, Courtney Thomas, Eugenia Tsai, Venkateswar Surabhi, Srinivasa R. Prasad, Venkata S. Katabathina
    RadioGraphics.2025;[Epub]     CrossRef
  • 3D multiparametric ultrasound imaging of steatotic liver disease in a study with male rats
    Donghyun Lee, Jinseok Heo, Hyeonji Mun, Donghyeon Oh, Yongjoo Ahn, Chulhong Kim
    Nature Communications.2025;[Epub]     CrossRef
  • Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis
    Chung‐Feng Huang, Po‐Cheng Liang, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Yao Hsu, Pei‐Chien Tsai, Yu‐Ju Wei, Ming‐Lun Yeh, Ming‐Yen Hsieh, Yi‐Hung Lin, Chao‐Kuan Huang, Chia‐Yen Dai, Jee‐Fu Huang, Wan‐Long Chuang, Ming‐Lung Yu
    The Kaohsiung Journal of Medical Sciences.2024; 40(4): 374.     CrossRef
  • Utilizing fully-automated 3D organ segmentation for hepatic steatosis assessment with CT attenuation-based parameters
    Jeongin Yoo, Ijin Joo, Sun Kyung Jeon, Junghoan Park, Soon Ho Yoon
    European Radiology.2024; 34(9): 6205.     CrossRef
  • Non–small cell lung cancer and immune checkpoint inhibitor therapy: does non-alcoholic fatty liver disease have an effect?
    Yi Li, Bingxin Gong, Yusheng Guo, Weiwei Liu, Chao Chen, Shanshan Jiang, Feng Pan, Jiyu Song, Lian Yang, Guofeng Zhou
    BMC Cancer.2024;[Epub]     CrossRef
  • Head-to-head comparison of three different US-based quantitative parameters for hepatic steatosis assessment: a prospective study
    Yan Zhou, Mengjin Nie, Hongyu Zhou, Feng Mao, Lin Zhao, Jianmin Ding, Xiang Jing
    Abdominal Radiology.2024; 49(7): 2262.     CrossRef
  • Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
    Farah Abdelhameed, Chris Kite, Lukasz Lagojda, Alexander Dallaway, Kamaljit Kaur Chatha, Surinderjeet S. Chaggar, Maria Dalamaga, Eva Kassi, Ioannis Kyrou, Harpal S. Randeva
    Current Obesity Reports.2024; 13(3): 510.     CrossRef
  • Maternal obesity and metabolic (dysfunction) associated fatty liver disease in pregnancy: a comprehensive narrative review
    Bianca M. Leca, Lukasz Lagojda, Chris Kite, Emmanouil Karteris, Eva Kassi, Harpal S. Randeva, Ioannis Kyrou
    Expert Review of Endocrinology & Metabolism.2024; 19(4): 335.     CrossRef
  • Diagnosis and non‐invasive assessment of MASLD in type 2 diabetes and obesity
    Wah‐Kheong Chan, Salvatore Petta, Mazen Noureddin, George Boon Bee Goh, Vincent Wai‐Sun Wong
    Alimentary Pharmacology & Therapeutics.2024;[Epub]     CrossRef
  • This Is What Metabolic Dysfunction–Associated Steatotic Liver Disease Looks Like: Potential of a Multiparametric MRI Protocol
    Anja M. Fischer, Nazim Lechea, Harvey O. Coxson
    Seminars in Liver Disease.2024; 44(02): 226.     CrossRef
  • Correspondence to editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”
    Hayeon Kim, Min Jeong Park, Myeong Gyu Kim, Kyungim Kim
    Clinical and Molecular Hepatology.2024; 30(4): 989.     CrossRef
  • From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome – current insights and future directions
    Bruno Basil, Blessing K. Myke-Mbata, Onyinye E. Eze, Augustine U. Akubue
    Clinical Diabetes and Endocrinology.2024;[Epub]     CrossRef
  • Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
    Lynna Alnimer, Mazen Noureddin
    Clinical and Molecular Hepatology.2023; 29(2): 394.     CrossRef
  • Application of attenuation imaging for the detection of fatty liver in potential liver donors
    Jae Seok Bae, Dong Ho Lee, Kyung-Suk Suh, Kwang-Woong Lee, Nam-Joon Yi, Suk Kyun Hong
    European Journal of Radiology.2023; 166: 110958.     CrossRef
  • Editorial: Will MRI‐PDFF become the new standard for steatosis assessment in NAFLD?
    Angeliki Pappa, Tobias Wenzl
    Alimentary Pharmacology & Therapeutics.2023; 58(3): 364.     CrossRef
  • Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis
    Martina Maurelli, Paolo Gisondi, Francesco Bellinato, Alessandro Mantovani, Giovanni Targher, Giampiero Girolomoni
    Journal of Clinical Medicine.2023; 12(18): 6057.     CrossRef
  • 11,806 View
  • 263 Download
  • 29 Web of Science
  • Crossref

Steatotic liver disease

Identification of high-risk subjects in nonalcoholic fatty liver disease
Christiane Stern, Laurent Castera
Clin Mol Hepatol 2023;29(Suppl):S196-S206.
Published online December 5, 2022
DOI: https://doi.org/10.3350/cmh.2022.0431
Non-alcoholic fatty liver disease (NAFLD) is becoming the most common liver disease worldwide, and its burden is expected to increase due to the growing epidemic of obesity and diabetes. The key challenge among NAFLD patients is to identify those with advanced fibrosis (F3F4), who are at high risk of developing complications and will benefit from specialized management and treatment with new pharmacotherapies when they are approved. Liver biopsy appears unrealistic and unsuitable in practice, given the large number of high-risk patients and its well-known limitations. Non-invasive sequential algorithms using fibrosis-4 index as first-line test, followed by vibration-controlled transient elastography or patented blood test, are the best strategy for case finding of high-risk subjects. In fact, they are now recommended by several international guidelines, and should be used and disseminated to increase awareness among physicians beyond liver clinics where most NAFLD patients are seen.

Citations

Citations to this article as recorded by  Crossref logo
  • Integration of PNPLA3 and TM6SF2 genotypes provides incremental improvement in advanced fibrosis prediction among MASLD patients with type 2 diabetes mellitus
    Dong Yun Kim, Hyun-Soo Zhang, Jae Seung Lee, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Hyun Woong Lee, Heon Yung Gee, Jung Il Lee, Jun Yong Park
    JHEP Reports.2026; 8(2): 101713.     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa
    Mohamed El-Kassas, C. Wendy Spearman, Manal El-Sayed, Zobair M. Younossi
    Clinics in Liver Disease.2026; 30(2): 513.     CrossRef
  • Moving beyond Ultrasound for Hepatocellular Carcinoma Surveillance in High-Risk Patients with Chronic Hepatitis B
    Hae Lim Lee
    Gut and Liver.2026; 20(2): 174.     CrossRef
  • Imaging-Based Modalities for Identifying At Risk MASH. A Diagnostic Test Meta-Analysis
    Shyna Zhuoying Gunalan, Michelle Shi Ni Law, Yi Xin Kua, Zhenning Yu, Ryan Yan Zhe Lim, Asvin Selvakumar, Nicholas Syn, Karn Wijarnpreecha, Benjamin Nah, Zi Xuan Zhang, Ming-Hua Zheng, Toru Nakamura, Asahiro Morishita, Won Mook Choi, Vincent L. Chen, Chen
    American Journal of Gastroenterology.2026;[Epub]     CrossRef
  • Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study
    Byungyoon Yun, Heejoo Park, Sang Hoon Ahn, Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon
    American Journal of Gastroenterology.2025; 120(2): 410.     CrossRef
  • Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis
    Zobair M. Younossi, Shira Zelber-Sagi, Jeffrey V. Lazarus, Vincent Wai-Sun Wong, Yusuf Yilmaz, Ajay Duseja, Yuichiro Eguchi, Laurent Castera, Mário Guimarães Pessoa, Claudia Pinto Oliveira, Mohamed El-Kassas, Emmanuel Tsochatzis, Jian-Gao Fan, C. Wendy Sp
    Gastroenterology.2025; 169(5): 1017.     CrossRef
  • Comparative evaluation of FIB-3 and FIB-4 indices for liver fibrosis screening in workplace-based health checkups
    Kota Fukai, Shoko Nakazawa, Kosuke Sakai, Yuko Furuya, Yuya Watanabe, Toru Honda, Takeshi Hayashi, Toru Nakagawa, Masaaki Korenaga, Masayuki Tatemichi
    Journal of Occupational Health.2025;[Epub]     CrossRef
  • Mechanism of Huanglian Wendan Decoction in ameliorating non-alcoholic fatty liver disease via modulating gut microbiota-mediated metabolic reprogramming and activating the LKB1/AMPK pathway
    Jianping Zhu, Yuzhen Chen, Yidi Han, Ji Li, Fahrul Nurkolis
    PLOS One.2025; 20(9): e0331303.     CrossRef
  • Sugar Rationing in the First 1000 Days After Conception and Long-term Risk of Metabolic Dysfunction-associated Steatotic Liver Disease and Major Adverse Liver Outcomes: A Natural Experiment Study
    Jiazhen Zheng, Zhen Zhou, Jinghan Huang, Qiang Tu, Haisheng Wu, Quan Yang, Qi Qi, Wenbo Huang, Junchun Shen, Xianbo Wu, Chuang Yang, Daniel J. Cuthbertson
    Clinical Gastroenterology and Hepatology.2025;[Epub]     CrossRef
  • The interplay of metabolic dysfunction‐associated fatty liver disease and viral hepatitis on liver disease severity: A large community‐based study in a viral endemic area
    Chung‐Feng Huang, Po‐Cheng Liang, Pei‐Chien Tsai, Yu‐Ju Wei, Ching‐I Huang, Chih‐Wen Wang, Tyng‐Yuan Jang, Ming‐Lun Yeh, Po‐Yao Hsu, Ming‐Yen Hsieh, Yi‐Hung Lin, Chia‐Yen Dai, Wan‐Long Chuang, Jee‐Fu Huang, Ming‐Lung Yu
    Journal of Gastroenterology and Hepatology.2024; 39(1): 193.     CrossRef
  • Liver Biopsy Handling of Metabolic-Associated Fatty Liver Disease (MAFLD): the Children’s Hospital of Eastern Ontario grossing protocol
    Consolato M. Sergi, Mohit Kehar, Carolina Jimenez-Rivera
    Therapeutic Advances in Endocrinology and Metabolism.2024;[Epub]     CrossRef
  • Investigating the Role of Non-Coding RNA in Non-Alcoholic Fatty Liver Disease
    Samar A. Zailaie, Basmah B. Khoja, Jumana J. Siddiqui, Mohammad H. Mawardi, Emily Heaphy, Amjad Aljagthmi, Consolato M. Sergi
    Non-Coding RNA.2024; 10(1): 10.     CrossRef
  • The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes
    Zobair M. Younossi, Pegah Golabi, Jillian Kallman Price, Soroor Owrangi, Nagashree Gundu-Rao, Romona Satchi, James M. Paik
    Clinical Gastroenterology and Hepatology.2024; 22(10): 1999.     CrossRef
  • Diagnostic accuracy of the Fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: A systematic review and meta-analysis
    Ji Won Han, Hee Yeon Kim, Jung Hwan Yu, Mi Na Kim, Young Eun Chon, Ji Hyun An, Young-Joo Jin, Miyoung Choi, Seung Up Kim, Han Ah Lee, Dae Won Jun
    Clinical and Molecular Hepatology.2024; 30(Suppl): S147.     CrossRef
  • Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?
    Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang
    Clinical and Molecular Hepatology.2023; 29(2): 404.     CrossRef
  • The effect of moderate alcohol consumption on nonalcoholic fatty liver disease
    Ji-Won Park, Ki Tae Suk
    Clinical and Molecular Hepatology.2023; 29(2): 408.     CrossRef
  • Prospective direct comparison of non‐invasive liver tests in outpatients with type 2 diabetes using intention‐to‐diagnose analysis
    Thierry Poynard, Olivier Deckmyn, Valentina Peta, Valérie Paradis, Jean‐Francois Gautier, Angélique Brzustowski, Pierre Bedossa, Laurent Castera, Stanislas Pol, Dominique Valla
    Alimentary Pharmacology & Therapeutics.2023; 58(9): 888.     CrossRef
  • Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia
    Thierry Poynard, Olivier Deckmyn, Valentina Peta, Mehdi Sakka, Pascal Lebray, Joseph Moussalli, Raluca Pais, Chantal Housset, Vlad Ratziu, Eric Pasmant, Dominique Thabut
    Hepatology Communications.2023;[Epub]     CrossRef
  • MASLD and aspartame: are new studies in the horizon?
    Consolato M. Sergi
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • 11,883 View
  • 321 Download
  • 18 Web of Science
  • Crossref

Letter to the Editor

Steatotic liver disease

Correspondence on Letter regarding “The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults”
Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn
Clin Mol Hepatol 2023;29(1):179-181.
Published online November 22, 2022
DOI: https://doi.org/10.3350/cmh.2022.0409

Citations

Citations to this article as recorded by  Crossref logo
  • Impact of smoking cessation on non-alcoholic fatty liver disease prevalence: a systematic review and meta-analysis
    Shengan Zhang, Zhidong Liu, Qinghua Yang, Zichun Hu, Wenjun Zhou, Guang Ji, Yanqi Dang
    BMJ Open.2023; 13(12): e074216.     CrossRef
  • 6,402 View
  • 54 Download
  • 1 Web of Science
  • Crossref

Reviews

Steatotic liver disease

Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease
Peter Konyn, Aijaz Ahmed, Donghee Kim
Clin Mol Hepatol 2023;29(Suppl):S43-S57.
Published online November 22, 2022
DOI: https://doi.org/10.3350/cmh.2022.0351
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the United States and worldwide. Though nonalcoholic fatty liver per se may not be independently associated with an increased risk for all-cause mortality, it is associated with a number of harmful metabolic risk factors, such as type 2 diabetes mellitus, hyperlipidemia, obesity, a sedentary lifestyle, and an unhealthy diet. The fibrosis stage is a predictor of all-cause mortality in NAFLD. Mortality in individuals with NAFLD has been steadily increasing, and the most common cause-specific mortality for NAFLD is cardiovascular disease, followed by extra-hepatic cancer, liver-related mortality, and diabetes. High-risk profiles for mortality in NAFLD include PNPLA3 I148M polymorphism, low thyroid function and hypothyroidism, and sarcopenia. Achieving weight loss through adherence to a high-quality diet and sufficient physical activity is the most important predictor of improvement in NAFLD severity and the benefit of survival. Given the increasing health burden of NAFLD, future studies with more long-term mortality data may demonstrate an independent association between NAFLD and mortality.

Citations

Citations to this article as recorded by  Crossref logo
  • Association between dietary amino acid intake and the risk of metabolic dysfunction-associated steatotic liver disease
    Ruoqi Zhou, Xinrong Zhang, Xinxin Liu, Rui Huang, Yuwei Wang, Dajing Xia, Xue Li, Yihua Wu, Yu Shi
    Journal of Advanced Research.2026; 80: 893.     CrossRef
  • Reliability of Ultrasonic Hepatorenal Indices in Assessing Hepatic Steatosis: A Systematic Review and Meta‐Analysis
    Jin‐Li Wang, Jian Dong, Si‐Rui Wang, Chun‐Li Cao, Jin Tong, WenXiao Li, Ting‐Ting Du, Ting‐Ting He, Xiao‐Wu Yuan, Jun Li, Hong Zhai
    Journal of Clinical Ultrasound.2026; 54(1): 164.     CrossRef
  • Dietary vitamin E intake in metabolic dysfunction–associated steatotic liver disease and all-cause/cause-specific mortality
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed
    European Journal of Gastroenterology & Hepatology.2026; 38(1): 63.     CrossRef
  • Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed
    Alimentary Pharmacology & Therapeutics.2026; 63(5): 662.     CrossRef
  • Placebo Rates in Metabolic Dysfunction–Associated Steatohepatitis Clinical Trials: A Systematic Review and Meta-Analysis
    Francisco Idalsoaga, Luis Antonio Díaz, Saleh Alghsoon, Bishoy Lawendy, Neha Sharma, Hailemichael Desalegn, Yuhong Yuan, My Ha, Jessica Le, John K. MacDonald, Marco Arrese, Rohit Loomba, Vipul Jairath, Mohammad Qasim Khan, Juan Pablo Arab
    Clinical Gastroenterology and Hepatology.2026; 24(5): 1258.     CrossRef
  • Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD—Insights From a National Analysis. Authors' Reply
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed
    Alimentary Pharmacology & Therapeutics.2026; 63(5): 752.     CrossRef
  • Unveiling the Burden of Steatotic Liver Disease: Mortality Risks by Subtype and Fibrosis Stage in a Nationwide Cohort
    Qi Feng, Pinelopi Manousou, Chioma N. Izzi‐Engbeaya, Rohit Loomba, Mark Thursz, Mark Woodward
    Liver International.2026;[Epub]     CrossRef
  • Subtype-specific associations of steatotic liver disease with gastric and esophageal cancers: a nationwide cohort study
    Yeo Wool Kang, Minkook Son, Jong Yoon Lee, Sang Yi Moon, Myeongseok Koh
    Gastric Cancer.2026; 29(2): 365.     CrossRef
  • Toward a more nuanced evaluation of endoscopic sleeve gastroplasty: beyond biomarkers to clinical meaning
    Bin Wei, Xin Hu, YiChong Duan, XiaoRong Wu
    Gastrointestinal Endoscopy.2026; 103(2): 380.     CrossRef
  • Integrated lifestyle management to mitigate MASLD risk in patients with chronic kidney disease: a prospective cohort study
    Chao Yan, Xinxin Shen, Shaojie Han, Jinzheng He, Tongxu Wang, Xiaobing Gong, Jindong Ding Petersen
    Journal of Translational Medicine.2026;[Epub]     CrossRef
  • Hepatoprotective effect of administering a probiotic strain (Lactobacillus acidophilus) to mice when consuming sucrose
    Marco Soria-Mamani, Oscar Gustavo Huaman Gutierrez
    Nutrire.2026;[Epub]     CrossRef
  • Association of the C-reactive protein–triglyceride glucose index with all-cause and cardiovascular mortality among U.S. adults with metabolic dysfunction-associated steatotic liver disease: a national cohort study
    Ramin Assempoor, Fatemeh Jodeiri, Minoo Javadi, Niloofar Seighali, Seyed Amir Seyed Shenava, Kimia Najafi, Ibrahim Antoun, Ali Fatehi Hassanabad, Toshiki Kuno, Tor Biering-Sørensen, Adrian V. Hernandez, John R. Nelson, Kaveh Hosseini
    Cardiovascular Diabetology.2026;[Epub]     CrossRef
  • The association of frailty with cardiovascular diseases and mortality in metabolic dysfunction-associated steatotic liver disease
    Fuyi Ma, Huanyu Wang, Kang Wan, Yuan Li, Yuhang Chen, Ru Wang
    Annals of Hepatology.2026; 31(2): 102214.     CrossRef
  • Contemporary epidemiology of metabolic dysfunction-associated steatotic liver disease
    Do Han Kim, Donghyun Ko, Aijaz Ahmed, Donghee Kim
    Expert Review of Gastroenterology & Hepatology.2026; 20(6): 603.     CrossRef
  • Association of high-sensitivity troponin with advanced fibrosis in metabolic dysfunction-associated steatotic liver disease and the potential mediating role of inflammation: A cross-sectional study of NHANES, 1999 to 2004
    Chun Yu Li, Yun Xiu Wu, Qing Zhang, Kai Wang
    Medicine.2026; 105(27): e49537.     CrossRef
  • Non-alcoholic fatty liver disease: Modern approaches to therapy and possibilities of using tirzepatide
    V. V. Gorban, E. V. Gorban, P. E. Kocherga
    Meditsinskiy sovet = Medical Council.2026; (8): 126.     CrossRef
  • Secondary Growth Hormone Deficiency That Developed into Cirrhosis after Several Years of Interrupted Growth Hormone Replacement Therapy
    Ayana Sueki, Daisuke Kaya, Shinsaku Nagamatsu, Chisa Yamamoto, Kohei Ohta, Yuya Matsuo, Yuya Nishio, Yusuke Komeda, Shoma Kikukawa, Kyohei Matsuura, Hideki Matsuo, Masakazu Uejima, Kei Moriya
    Internal Medicine.2025; 64(3): 387.     CrossRef
  • Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study
    Byungyoon Yun, Heejoo Park, Sang Hoon Ahn, Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon
    American Journal of Gastroenterology.2025; 120(2): 410.     CrossRef
  • The Fibrosis-4 index predicts all-cause mortality in a cohort of patients at high cardiovascular risk partly through glomerular filtration rate reduction
    Antonio Mirijello, Gabriella Pacilli, Antonio Siena, Antonio Mangiacotti, Maria Maddalena D'Errico, Daria Dilalla, Olga Lamacchia, Andrea Fontana, Massimiliano Copetti, Pamela Piscitelli, Giovanni Targher, Salvatore A. De Cosmo
    Nutrition, Metabolism and Cardiovascular Diseases.2025; 35(1): 103768.     CrossRef
  • Secondhand Smoke Exposure and Metabolic Dysfunction-associated Steatotic Liver Disease in US Adolescents
    Donghee Kim, Brandon J. Perumpail, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed
    Clinical Gastroenterology and Hepatology.2025; 23(4): 665.     CrossRef
  • Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply
    Yewan Park, Jooyi Jung, Gi‐Ae Kim
    Alimentary Pharmacology & Therapeutics.2025; 61(2): 400.     CrossRef
  • Red cell distribution width/platelet ratio predicts decompensation of metabolic dysfunction-associated steatotic liver disease-related compensated advanced chronic liver disease
    Ming-Hua Zheng, Amedeo Lonardo
    World Journal of Gastroenterology.2025;[Epub]     CrossRef
  • PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”
    Baokai Sun, Likun Zhuang
    Clinical and Molecular Hepatology.2025; 31(1): e67.     CrossRef
  • Role of noninvasive tests on the prediction of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without cirrhosis: a systematic review and meta-analysis of aggregate and individual patient data
    Nanicha Siriwong, Supachaya Sriphoosanaphan, Pakanat Decharatanachart, Tanat Yongpisarn, Stephen J. Kerr, Sombat Treeprasertsuk, Thodsawit Tiyarattanachai, Terapap Apiparakoon, Hannes Hagström, Camilla Akbari, Mattias Ekstedt, Terry Cheuk-Fung Yip, Grace
    European Journal of Gastroenterology & Hepatology.2025; 37(3): 358.     CrossRef
  • Unmet needs of metabolic dysfunction – Associated “fatty or steatotic” liver disease
    Yu-Ming Cheng, Shao-Wen Wang, Ching Wang, Chia-Chi Wang
    Tzu Chi Medical Journal.2025; 37(2): 152.     CrossRef
  • Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank
    Tae Seop Lim, Sujin Kwon, Sung A. Bae, Hye Yeon Chon, Seol A. Jang, Ja Kyung Kim, Chul Sik Kim, Seok Won Park, Kyoung Min Kim
    Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub]     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management
    Luigi Elio Adinolfi, Aldo Marrone, Luca Rinaldi, Riccardo Nevola, Antonio Izzi, Ferdinando Carlo Sasso
    Exploration of Medicine.2025;[Epub]     CrossRef
  • The relationship between serum uric acid level and non-alcoholic fatty liver disease in northern China: a retrospective cohort study
    Qian He, Xinyue Liu, Guoyong Ding, Yiying Wang, Xiaoting Luo, Wenyuan Cao, Weijia Xing
    BMC Public Health.2025;[Epub]     CrossRef
  • Novel pyranopyridine derivatives and their radiolabeled nanoconjugates: An augmented approach for targeted cancer theranostics
    Hesham A. Shamsel-Din, Mohamed M. Swidan, Ahmed B. Ibrahim, Mohamed A. Motaleb, Tamer M. Sakr
    Journal of Drug Delivery Science and Technology.2025; 107: 106802.     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease in adults
    Daniel Q. Huang, Vincent W. S. Wong, Mary E. Rinella, Jerome Boursier, Jeffrey V. Lazarus, Hannele Yki-Järvinen, Rohit Loomba
    Nature Reviews Disease Primers.2025;[Epub]     CrossRef
  • Elevated red blood cell folate levels are associated with metabolic dysfunction-associated steatotic liver disease: results from NHANES 2017–2020
    Xin Liao, Song Yu, Lin Wang, Ruyue Zhang, Ke Yu
    Frontiers in Physiology.2025;[Epub]     CrossRef
  • Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
    Alimentary Pharmacology & Therapeutics.2025; 61(11): 1785.     CrossRef
  • Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
    Clinical and Molecular Hepatology.2025; 31(2): e180.     CrossRef
  • The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
    Clinical and Molecular Hepatology.2025; 31(2): e183.     CrossRef
  • Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
    Clinical and Molecular Hepatology.2025; 31(2): 382.     CrossRef
  • Associations between non-insulin-based insulin resistance surrogate markers and liver-related outcomes in metabolic dysfunction-associated steatotic liver disease: a nationwide cohort study in South Korea
    Sang Yi Moon, Minkook Son, Yeo Wool Kang, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Response to the Letter to the Editor: What Is the Optimal Anti‐Diabetic Regimen Among CHB and T2DM Patients?
    Beom Kyung Kim
    Liver International.2025;[Epub]     CrossRef
  • The new definition of metabolic dysfunction-associated steatotic liver disease: the role of ultrasound and elastography
    Xinrui Jin, Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Jimmy Che-To Lai
    Ultrasonography.2025; 44(3): 189.     CrossRef
  • Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease in Children with Down Syndrome at a Tertiary Care Center
    Maria D. Karaceper, Maria-Jose Villegas, Sanathan Sadh, Sierra Kawesa, Jamie Strain, Asha Nair, Alissa Dupuis, Mary Pothos, Ming-Hua Zheng, Mohit Kehar
    Journal of Clinical Medicine.2025; 14(9): 3239.     CrossRef
  • The Role of Global Physical Capacity Score in Key Parameters of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Nicola Verrelli, Caterina Bonfiglio, Isabella Franco, Claudia Beatrice Bagnato, Dolores Stabile, Endrit Shahini, Antonella Bianco
    Journal of Clinical Medicine.2025; 14(11): 3821.     CrossRef
  • Microwave Thermosphere Ablation Versus Radiofrequency Ablation in Hepatocellular Carcinoma: Optimizing Treatment Strategies for Tumor Size and Malignancy Grade
    Hideyuki Tamai, Jumpei Okamura
    Hepatology Research.2025; 55(9): 1274.     CrossRef
  • Association between impaired sensitivity to thyroid hormones and sedentary behavior: a cross-sectional study
    Hangzhou Yang, Jie Kang, Lingkang Dong, Zihan Lin, Qixian Lin, Bo Wu
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • ECM formation and degradation during fibrosis, repair, and regeneration
    Alejandro E. Mayorca-Guiliani, Diana Julie Leeming, Kim Henriksen, Joachim Høg Mortensen, Signe Holm Nielsen, Quentin M. Anstee, Arun J. Sanyal, Morten A. Karsdal, Detlef Schuppan
    npj Metabolic Health and Disease.2025;[Epub]     CrossRef
  • Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017–2023
    Donghee Kim, Rohit Loomba, Aijaz Ahmed
    Clinical and Molecular Hepatology.2025; 31(3): e235.     CrossRef
  • The Burden of Nonmalignant Metabolic Dysfunction‐Associated Steatotic Liver Disease in the Western Pacific Region: A Systematic Analysis From 1990 to 2021
    Qichao Ge, Yuan Lin, Mingwang Wang, Jianwei Zhu, Qingqing Zhang, Junjun Wang, Yufei Yang, Hanjing Zhangdi, Yuecheng Guo, Shanjuan Wang, Lungen Lu
    Food Science & Nutrition.2025;[Epub]     CrossRef
  • The association between serum pinenes and non-alcoholic fatty liver disease based on the NHANES 2013–2014
    Tuo Xiao, Xue Xing, Lulu Sun, Jin Shang
    Ecotoxicology and Environmental Safety.2025; 302: 118712.     CrossRef
  • Long-Term Feasibility and Outcomes of a Digital Health Program to Improve Liver Fat and Cardiometabolic Markers in Individuals With Nonalcoholic Fatty Liver Disease: Prospective Single-Arm Feasibility Study
    Sigridur Björnsdottir, Hildigunnur Ulfsdottir, Elias Freyr Gudmundsson, Bartosz Dobies, Kolbrun Sveinsdottir, Ari Pall Isberg, Gudlaug E A Magnusdottir, Thrudur Gunnarsdottir, Tekla Karlsdottir, Gudlaug Bjornsdottir, Sigurdur Sigurdsson, Saemundur Oddsson
    JMIR Cardio.2025; 9: e72074.     CrossRef
  • The effects of ellagic acid in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: a randomized, add-on, double-blind, controlled trial
    Mohammad Mahmoudi Azar, Matin Shirazinia, Mohsen Nematy, Vafa Baradaran Rahimi, Motahare Bateni, Fateme Tafaghodi Piadeh Gheibi, Farnood Rajabzadeh, Ladan Goshayeshi, Sara Honari, Mehran Mottahedi, Vahid Reza Askari
    Inflammopharmacology.2025; 33(9): 5583.     CrossRef
  • Comparison of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Steatotic Liver Disease
    Yunmi Ko, Moon Haeng Hur, Youngsu Park, Jeayeon Park, Hyunjae Shin, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
    Gut and Liver.2025; 19(5): 758.     CrossRef
  • Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease
    Anoushka Shenoy, Aijaz Ahmed, Donghee Kim
    Metabolism and Target Organ Damage.2025;[Epub]     CrossRef
  • Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends
    George S Zacharia, Muhammad H Ashraf, Franklin Sosa, Anu Jacob, Harish Patel
    World Journal of Gastrointestinal Pharmacology and Therapeutics.2025;[Epub]     CrossRef
  • Sex-specific differences in the prognostic value of METS-IR for long-term outcomes in patients with MASLD and advanced liver fibrosis: a nationwide study
    Binbin Song, Yuan Zhou, Rui Su, Yan Wang, Song Chen, Wenjin Chen
    European Journal of Medical Research.2025;[Epub]     CrossRef
  • Cost‐effectiveness study of FIB‐4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a NAFLD at‐risk population
    Huiyul Park, Eileen L. Yoon, Mimi Kim, Sun‐Hong Kwon, Donghee Kim, Ramsey Cheung, Hye‐Lin Kim, Dae Won Jun
    Liver International.2024; 44(4): 944.     CrossRef
  • Proposal of a Novel Serological Algorithm Combining FIB-4 and Serum M2BPGi for Advanced Fibrosis in Nonalcoholic Fatty Liver Disease
    Sang Yi Moon, Yang Hyun Baek, Se Young Jang, Dae Won Jun, Ki Tae Yoon, Young Youn Cho, Hoon Gil Jo, Ae Jeong Jo
    Gut and Liver.2024; 18(2): 283.     CrossRef
  • Editorial: Using machine learning to predict significant fibrosis in metabolic dysfunction‐associated steatotic liver disease
    Richie Manikat, Aijaz Ahmed, Donghee Kim
    Alimentary Pharmacology & Therapeutics.2024; 59(7): 893.     CrossRef
  • Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States
    Donghee Kim, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
    Alimentary Pharmacology & Therapeutics.2024; 60(1): 33.     CrossRef
  • Estimated pulse wave velocity in metabolic dysfunction‐associated steatotic liver disease and all‐cause/cause‐specific mortality
    Donghee Kim, Richie Manikat, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
    Journal of Gastroenterology and Hepatology.2024; 39(9): 1950.     CrossRef
  • Perspective article: determinants and assessment of cardiovascular risk in steatotic liver disease owing to metabolic dysfunction-addressing the challenge
    Mohamad Jamalinia, Amedeo Lonardo
    Metabolism and Target Organ Damage.2024;[Epub]     CrossRef
  • Accurate prediction of all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease using electronic health records
    Ignat Drozdov, Benjamin Szubert, Ian A. Rowe, Timothy J. Kendall, Jonathan A. Fallowfield
    Annals of Hepatology.2024; 29(5): 101528.     CrossRef
  • The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes‐related and cancer outcomes
    David R. Riley, Theresa Hydes, Gema Hernadez, Sizheng S. Zhao, Uazman Alam, Daniel J. Cuthbertson
    Liver International.2024; 44(10): 2538.     CrossRef
  • The Impact of Body Composition on the Prognosis of Nonalcoholic Fatty Liver Disease
    Do Seon Song
    Gut and Liver.2024; 18(4): 562.     CrossRef
  • Association of nonalcoholic fatty liver disease with new-onset atrial fibrillation stratified by age groups
    Eun Ju Cho, Goh Eun Chung, Jeong-Ju Yoo, Yuri Cho, Kyu Na Lee, Dong Wook Shin, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Su Jong Yu
    Cardiovascular Diabetology.2024;[Epub]     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease in Japan: Prevalence Trends and Clinical Background in the 10 Years before the Coronavirus Disease 2019 Pandemic
    Akira Sato, Yumiko Oomori, Rika Nakano, Tomokazu Matsuura
    Medicina.2024; 60(8): 1330.     CrossRef
  • Contemporary awareness of nonalcoholic fatty liver disease and viral hepatitis based on the stage
    Donghee Kim, Richie Manikat, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
    The American Journal of the Medical Sciences.2024; 368(6): 685.     CrossRef
  • High sensitivity troponins and mortality in the population with metabolic dysfunction-associated steatotic liver disease
    Jingjing Hu, Yuteng Du, Yidan Zhou, Huiying Wang
    Scientific Reports.2024;[Epub]     CrossRef
  • Impact of Korean Military Service on the Prevalence of Steatotic Liver Disease: A Longitudinal Study of Pre-enlistment and In-Service Health Check-Ups
    Jaejun Lee, Jae Hyeop Jung, Sung Jun Choi, Beomman Ha, Hyun Yang, Pil Soo Sung, Si Hyun Bae, Jeong-A Yu
    Gut and Liver.2024; 18(5): 888.     CrossRef
  • Vaccinium spp. Berries in the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease: A Comprehensive Update of Preclinical and Clinical Research
    Ewelina Książek, Zuzanna Goluch, Marta Bochniak
    Nutrients.2024; 16(17): 2940.     CrossRef
  • Metabolic bariatric surgery, alcohol misuse and liver cirrhosis: a narrative review
    Matthew L. Basa, Danielle S. Cha, David P. Mitchell, Daniel L. Chan
    Metabolism and Target Organ Damage.2024;[Epub]     CrossRef
  • Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
    Yewan Park, Jooyi Jung, Seungbong Han, Gi‐Ae Kim
    Alimentary Pharmacology & Therapeutics.2024; 60(11-12): 1599.     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study
    Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon, Hyung Ho Lee, Heejoo Park, Jian Lee, Youngsun Park, Byungyoon Yun, Jinsoo Chung
    Cancers.2024; 16(18): 3161.     CrossRef
  • Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease: Letter to the editor on “Prognosis of biopsy-confirmed metabolic dysfun
    Yixuan Zhu, Xiaoyan Ma, Wenjing Ni, Yee Hui Yeo, Junping Shi, Jie Li
    Clinical and Molecular Hepatology.2024; 30(4): 974.     CrossRef
  • Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
    Clinical and Molecular Hepatology.2024; 30(4): 982.     CrossRef
  • Unraveling the Association of Liver Steatosis and Fibrosis with Vitamin B12: A Cross-Sectional Study
    Silvia Espina, Diego Casas-Deza, Vanesa Bernal-Monterde, Ana Royo-Esteban, Maria Pilar García-Sobreviela, Pilar Calmarza, Ana B. Martinez-Martinez, Jesús Osada, Jose M. Arbones-Mainar
    Metabolites.2024; 14(11): 618.     CrossRef
  • Association between Body Fat Distribution and Nonalcoholic Fatty Liver Disease/Fibrosis Based on Race/Ethnicity
    Donghee Kim, George Cholankeril, Aijaz Ahmed
    Journal of Obesity & Metabolic Syndrome.2024; 33(4): 326.     CrossRef
  • Nonlinear correlation between fatty liver index and carotid intima media thickness among individuals undergoing health examination
    Yuanchen Zhou, Shaojie Duan, Rongrui Wang, Jialiang Chen, Shukun Yao
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • The growing burden of non-alcoholic fatty liver disease on mortality
    Ju-Yeon Cho, Won Sohn
    Clinical and Molecular Hepatology.2023; 29(2): 374.     CrossRef
  • Discovery of new pyridine heterocyclic hybrids; design, synthesis, dynamic simulations, and in vitro and in vivo breast cancer biological assays
    Menna M. Abdelshaheed, Hussein I. El Subbagh, Mohamed A. Tantawy, Reem T. Attia, Khairia M. Youssef, Iten M. Fawzy
    RSC Advances.2023; 13(23): 15689.     CrossRef
  • Synergistic Preventive Effect of Aerobic and Resistance Exercises on Nonalcoholic Fatty Liver Disease
    Ju-Yeon Cho, Won Sohn
    Gut and Liver.2023; 17(4): 487.     CrossRef
  • Comment on Clayton-Chubb et al. Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives. Nutrients 2023, 15, 687
    Ludovico Abenavoli, Giuseppe La Torre, Natasa Milic
    Nutrients.2023; 15(13): 2907.     CrossRef
  • Impact of Health Related QoL and Mediterranean Diet on Liver Fibrosis in Patients with NAFLD
    Nuria Perez-Diaz-del-Campo, Gabriele Castelnuovo, Chiara Rosso, Aurora Nicolosi, Marta Guariglia, Eleonora Dileo, Angelo Armandi, Gian Paolo Caviglia, Elisabetta Bugianesi
    Nutrients.2023; 15(13): 3018.     CrossRef
  • Aerobic and Resistance Exercise: Synergistic Influence for Nonalcoholic Fatty Liver Disease
    Ho Soo Chun
    Gut and Liver.2023; 17(4): 485.     CrossRef
  • From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials
    Ming-Lun Yeh, Ming-Lung Yu
    Clinical and Molecular Hepatology.2023; 29(4): 969.     CrossRef
  • Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity
    Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe
    Clinical and Molecular Hepatology.2023; 29(4): 987.     CrossRef
  • Lifestyle of patients with non-alcoholic fatty liver disease: assessment of dietary habits and physical activity
    T.S. Krolevets, M.I. Syrovenko, M.A. Livzan
    Russian Journal of Evidence-Based Gastroenterology.2023; 12(4): 43.     CrossRef
  • Current epidemiology of chronic liver disease
    Richie Manikat, Aijaz Ahmed, Donghee Kim
    Gastroenterology Report.2023;[Epub]     CrossRef
  • 15,594 View
  • 231 Download
  • 83 Web of Science
  • Crossref

Steatotic liver disease

Non-alcoholic fatty liver disease: the pathologist’s perspective
Wei-Qiang Leow, Anthony Wing-Hung Chan, Paulo Giovanni L. Mendoza, Regina Lo, Kihan Yap, Haeryoung Kim
Clin Mol Hepatol 2023;29(Suppl):S302-S318.
Published online November 15, 2022
DOI: https://doi.org/10.3350/cmh.2022.0329
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of diseases characterized by fatty accumulation in hepatocytes, ranging from steatosis, non-alcoholic steatohepatitis, to cirrhosis. While histopathological evaluation of liver biopsies plays a central role in the diagnosis of NAFLD, limitations such as the problem of interobserver variability still exist and active research is underway to improve the diagnostic utility of liver biopsies. In this article, we provide a comprehensive overview of the histopathological features of NAFLD, the current grading and staging systems, and discuss the present and future roles of liver biopsies in the diagnosis and prognostication of NAFLD.

Citations

Citations to this article as recorded by  Crossref logo
  • A new diphenylmethanone from Rumex crispus L. ameliorates sodium palmitate-oleate induced steatosis in HepG2 cells
    Wen-Yao Zou, Zheng-Hong Guo, Shuai Dou, Ting Xiao, Wu-de Yang
    Natural Product Research.2026; 40(13): 3936.     CrossRef
  • An electroneutral fluorescent probe for visualization of lipid droplets polarity heterogeneity and NAFLD detection
    Zhengshuai Wu, Fei Gao, Shuyu Wang, Mengqi Yan, Shuxian Cao, Junjun Liu, Xinyue Li, Guoxia Liu, Sumei Lu, Xuechen Li
    Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy.2026; 346: 126842.     CrossRef
  • Clinical Profile of Psoriasis Patients With Comorbid Fatty Liver and Risk Factors for Advanced Liver Fibrosis in Those With Metabolic Dysfunction–Associated Steatotic Liver Disease
    Hidenori Watabe, Tomomitsu Miyagaki, Kaori Nakajima, Ken Go, Tatsuro Okano, Takafumi Kadono
    The Journal of Dermatology.2026; 53(2): 237.     CrossRef
  • Effects of pemafibrate on liver fibrosis in patients with MASLD and hypertriglyceridemia: A 2-year retrospective observational study using MR elastography
    Hidenao Noritake, Takafumi Inoue, Takashi Yonekura, Hiroki Tamakoshi, Yuya Ida, Moe Matsumoto, Tomohiko Hanaoka, Maho Yamashita, Masahiro Umemura, Kazuyoshi Ohta, Takeshi Chida, Kazuhito Kawata
    Journal of Clinical Lipidology.2026; 20(5): 947.     CrossRef
  • Expression of caspase-8 in non-alcoholic fatty liver disease related to ligature-induced periodontitis in rats
    Felipe Rodolfo Pereira da Silva, Victor Brito Dantas Martins, Hélio Mateus Silva Nascimento, Paulo Roberto Carneiro Gomes, Nikaely Brandão Barbosa, Vinícius da Silva Caetano, Ivana Márcia Alves Diniz, Karine Duarte da Silva, Any Carolina Cardoso Guimarães
    Journal of Applied Oral Science.2026;[Epub]     CrossRef
  • Advances in Diagnostic and Therapeutic Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease
    Ryan Njeim, Omar Abureesh, Ali Sohail, Ryan Tam, Liliane Deeb
    Livers.2026; 6(3): 35.     CrossRef
  • Spatial hepatology: Decoding liver zonation for metabolic and regenerative therapeutics (Review)
    Guiqing Chen, Hongyan Jia, Kai Zhao, Chang Gao, Yue Liu, Hong Zhu, Dakai Yang, Yun Cai
    International Journal of Molecular Medicine.2026; 58(1): 1.     CrossRef
  • Alpha‑lipoic acid–loaded chitosan nanoparticles ameliorate streptozotocin‑induced diabetic liver injury via Nrf2/HO‑1 activation and TLR4/NF‑κB and JAK2/STAT1 inhibition
    Hussein Abdelaziz Abdalla, Ekramy M. Elmorsy, Najlaa M. M. Jawad, Nora Hosny, Ahmed S. Shams, Rawan Ahmed Ayaz, Manal S. Fawzy, Gehad E. Elshopakey
    Naunyn-Schmiedeberg's Archives of Pharmacology.2026;[Epub]     CrossRef
  • Dapansutrile mitigates methotrexate-induced hepatotoxicity in rats: roles of inflammation, oxidative stress, pyroptosis, and autophagy
    Haider H. Motlak, Mahmoud Elshal, Marwa S. Serrya
    Frontiers in Pharmacology.2026;[Epub]     CrossRef
  • Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study
    Byungyoon Yun, Heejoo Park, Sang Hoon Ahn, Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon
    American Journal of Gastroenterology.2025; 120(2): 410.     CrossRef
  • Female C57BL/6 mice exhibit protection against nonalcoholic fatty liver disease and diabesity accompanied by differential regulation of hepatic lipocalin prostaglandin D2 synthase
    Md Asrarul Islam, Rhema Khairnar, Joshua Fleishman, Sandra E. Reznik, Louis Ragolia, Shruthi Gobbooru, Sunil Kumar
    Molecular and Cellular Endocrinology.2025; 595: 112404.     CrossRef
  • Extracellular vesicle-mediated approaches for the diagnosis and therapy of MASLD: current advances and future prospective
    Swasthika Gurjar, Ramanarayana Bhat A, Raghavendra Upadhya, Revathi P. Shenoy
    Lipids in Health and Disease.2025;[Epub]     CrossRef
  • Do Child–Turcotte–Pugh and nutritional assessments predict survival in cirrhosis: A longitudinal study
    Randhall B Carteri, Claudio A Marroni, Luis F Ferreira, Letícia P Pinto, Juliana Czermainski, Cristiane V Tovo, Sabrina A Fernandes
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Unraveling the molecular mechanisms of Fufangduzhong formula in alleviating high-fat diet-induced non-alcoholic fatty liver disease in mice
    Yu Mou, Yao Tang, Xiuyan Zheng, Xiang Liu, Xuemei Wu, Hongji Wang, Jie Zeng, Qing Rao, Yaacov Ben-David, Yanmei Li, Lei Huang
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Elevated red blood cell folate levels are associated with metabolic dysfunction-associated steatotic liver disease: results from NHANES 2017–2020
    Xin Liao, Song Yu, Lin Wang, Ruyue Zhang, Ke Yu
    Frontiers in Physiology.2025;[Epub]     CrossRef
  • Investigating the Effects of Gossypetin on Liver Health in Diet-Induced Pre-Diabetic Male Sprague Dawley Rats
    Karishma Naidoo, Andile Khathi
    Molecules.2025; 30(8): 1834.     CrossRef
  • Prospective Comparison of 2D-Shear Wave Elastography and Vibration-Controlled Transient Elastography in Assessing Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Qingxin Li, Yanhang Gao, Dongxuan Wang, Xiaoxue Zhu, Jing Jia, Lili Liu, Huining Tian, Lishuang Wang, Yingwen Zhang, Dezhi Zhang
    Academic Radiology.2025; 32(9): 5100.     CrossRef
  • Alisol B alleviates MASLD by activating liver autophagy and fatty acid oxidation via Ces2a
    Congcong Zhang, Lin Chen, Yuwei Jiang, Jiannan Qiu, Yiyou Lin, Guilin Ren, Fangying Xu, Jiale Xi, Zhiling Yu, Xianglu Rong, Xiaobing Dou
    International Immunopharmacology.2025; 157: 114768.     CrossRef
  • Multiple machine learning algorithms identify 13 types of cell death-critical genes in large and multiple non-alcoholic steatohepatitis cohorts
    Renao Jiang, Longfei Dai, Xinjian Xu, Zhen Zhang
    Lipids in Health and Disease.2025;[Epub]     CrossRef
  • Therapeutic potential of Glycyrrhiza glabra L. extract and atorvastatin in HFD-induced MAFLD: in vitro and in vivo exploration
    Saumya Rastogi, Vishwajeet Bachhar, Vibha Joshi, Sanjay Kumar, Dharamveer Panjwani, Lakhveer Singh, Rajesh Haldhar
    3 Biotech.2025;[Epub]     CrossRef
  • Efficacy of interventions with live combined Bacillus subtilis and Enterococcus faecium enteric-coated capsules in metabolic associated fatty liver disease patients: a meta-analysis of randomized controlled trials
    Yutong Wu, Hao Wu, Hang Yi
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Deep learning-based method for grading histopathological liver fibrosis in rodent models of metabolic dysfunction-associated steatohepatitis
    Soo Min Ko, Jae-ik Shin, Yiyu Hong, Hyunji Kim, Insuk Sohn, Ji-Young Lee, Hyo-Jeong Han, Da Som Jeong, Yerin Lee, Woo-Chan Son
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • КЛІНІКО-МОРФОЛОГІЧНІ АСПЕКТИ ПЕРВИННОГО НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТУ ЗА НАЯВНОСТІ КОМОРБІДНОЇ ПАТОЛОГІЇ ЖОВЧНОГО МІХУРА
    О. Ю. Фофанова, В. В. Феденько, З. Я. Гурик, Е. О. Кіндратів, І. Г. Лаб'як
    Art of Medicine.2025; : 113.     CrossRef
  • Calycosin-7-O-β-D-glucoside alleviates nonalcoholic fatty liver disease by regulating short-chain fatty acids metabolism and metabolic regulators
    Yanping Zeng, Xinrun Huang, Yuci Ma, Xiaodie Di, Zhao Li, Hebin Wang, Xiaodong Wei
    The Journal of Nutritional Biochemistry.2025; 145: 110018.     CrossRef
  • Assessing Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Patients at a Tertiary Hospital, Addis Ababa, Ethiopia
    Edomias Adyamseged Berhe, Rediet Ambachew Sema, Yididya Mehari Tesfaye, Abel Andargie Berhane, Mikale Dawit, Ephrem Mamo Gebrehiwot, Subah Abderehim Yesuf, Balamurugan Ramatchandirin
    Journal of Diabetes Research.2025;[Epub]     CrossRef
  • Automated Detection of Non‐Alcoholic Fatty Liver Disease Using Histopathological Images: A Systematic Review
    Hamed Zamanian, Ahmad Shalbaf, Maryam Parvizi, Roohallah Alizadehsani, Ru‐San Tan, U. Rajendra Acharya
    WIREs Data Mining and Knowledge Discovery.2025;[Epub]     CrossRef
  • Polarity Prompting Vision Foundation Models for Pathology Image Analysis
    Chong Yin, Siqi Liu, Kaiyang Zhou, Vincent Wai-Sun Wong, Pong C. Yuen
    IEEE Transactions on Medical Imaging.2025; 44(11): 4579.     CrossRef
  • Matcha mitigates metabolic and inflammatory disturbances induced by high-fat-sucrose diets in rats
    Nourhan M. Abd El-Aziz, Marwa R. Elbakatoshy, Ebtehal A. Farrage, Oscar Zannou, Reza Tahergorabi, Ayman M. Khalifah, Majid Aminzare, Mohamed G. Shehata
    Journal of Functional Foods.2025; 135: 107112.     CrossRef
  • Metabolic Dysfunction-Associated Steatohepatitis in Focus: Pathogenesis, Non-Invasive Diagnostics, and Future Approaches
    Abdulrahman Ismaiel, Mhd Bashir Almonajjed, Cristina Sorina Catana, Stefan-Lucian Popa, Dan L. Dumitrascu
    Archives of Medical Research.2025; 56(8): 103350.     CrossRef
  • Occupational and lifestyle risk factors associated with metabolic fatty liver disease among university staff in Indonesia
    Mutmainnah Husaema, Lalu Muhammad Saleh, Muhammad Furqaan Naiem, Atjo Wahyu, Darmawansyah D
    Frontiers in Public Health.2025;[Epub]     CrossRef
  • STEATOTIC LIVER DISEASE: THE IMPACT OF TEA AND COFFEE CONSUMPTION. LITERATURE REVIEW
    V.S. Rakhmetova
    Наука и здравоохранение.2025; (5(27)): 261.     CrossRef
  • Association of Stroke With Metabolic Dysfunction–Associated Fatty Liver Disease With and Without CKD
    Yuhao Li, Shouling Wu, Jingli Gao, Yijun Zhang, Yingting Zuo, Xue Tian, Shuohua Chen, Aijun Xing, Anxin Wang, Yan He
    American Journal of Kidney Diseases.2024; 83(4): 477.     CrossRef
  • Sex-specific differences in ectopic fat and metabolic characteristics of paediatric nonalcoholic fatty liver disease
    Eun Hye Lee, Ji Young Kim, Hye Ran Yang
    International Journal of Obesity.2024; 48(4): 486.     CrossRef
  • Research progress, challenges and perspectives of phospholipids metabolism in the LXR‑LPCAT3 signaling pathway and its relation to NAFLD (Review)
    Junmin Wang, Jiacheng Li, Yugang Fu, Yingying Zhu, Liubing Lin, Yong Li
    International Journal of Molecular Medicine.2024;[Epub]     CrossRef
  • Proposal of a Novel Serological Algorithm Combining FIB-4 and Serum M2BPGi for Advanced Fibrosis in Nonalcoholic Fatty Liver Disease
    Sang Yi Moon, Yang Hyun Baek, Se Young Jang, Dae Won Jun, Ki Tae Yoon, Young Youn Cho, Hoon Gil Jo, Ae Jeong Jo
    Gut and Liver.2024; 18(2): 283.     CrossRef
  • Lipid droplet detection in histopathological images using reinforcement learning
    Yoshitomi Harada, Haruto Nishida, Keiko Matsuura
    Biotechnology & Biotechnological Equipment.2024;[Epub]     CrossRef
  • Evaluating the relative importance of different blood pressure indices in screening for NAFLD: a survey report based on a health examination population
    Chong Hu, Ziqi Yu, Changli Wei, Guotai Sheng, Jianyong Chen, Yang Zou
    Frontiers in Cardiovascular Medicine.2024;[Epub]     CrossRef
  • Perilipins: A family of five fat‐droplet storing proteins that play a significant role in fat homeostasis
    Preethi Chandrasekaran, Sabine Weiskirchen, Ralf Weiskirchen
    Journal of Cellular Biochemistry.2024;[Epub]     CrossRef
  • A preclinical model of severe NASH-like liver injury by chronic administration of a high-fat and high-sucrose diet in mice
    Rose A. Willett, Volodymyr P. Tryndyak, Jennifer M. Hughes Hanks, Lana Elkins, Suresh K. Nagumalli, Mark I. Avigan, Sharon A. Ross, Gonçalo Gamboa da Costa, Frederick A. Beland, Ivan Rusyn, Igor P. Pogribny
    Toxicology and Applied Pharmacology.2024; 491: 117046.     CrossRef
  • A peptide alleviated oxidative damages in the L02 cells and mice liver
    Gan Gao, Zhiyang Zhang, Qiheng Wang, Zhihui Xie, Bing Liu, Hongliang Huang
    Biochemical and Biophysical Research Communications.2024; 734: 150643.     CrossRef
  • Targeting long non-coding RNA H19 as a therapeutic strategy for liver disease
    Yulan Shi, Fenghua Qu, Shiyun Zeng, Xinchen Wang, Yuting Liu, Qirui Zhang, Ding Yuan, Chengfu Yuan
    Progress in Biophysics and Molecular Biology.2024; 194: 1.     CrossRef
  • Transcription factor ETV4 plays a critical role in the development of non-alcoholic fatty liver disease
    Bhavani Gadiraju, Jhansi Magisetty, Vijay Kondreddy
    International Journal of Biological Macromolecules.2024; 282: 137235.     CrossRef
  • Arctium lappa L. Extract Alleviates Non-Alcoholic Fatty Liver Injury in Mices
    娜 李
    Hans Journal of Medicinal Chemistry.2024; 12(04): 309.     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Review and Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
    Jaehyun Bae, Eugene Han, Hye Won Lee, Cheol-Young Park, Choon Hee Chung, Dae Ho Lee, Eun-Hee Cho, Eun-Jung Rhee, Ji Hee Yu, Ji Hyun Park, Ji-Cheol Bae, Jung Hwan Park, Kyung Mook Choi, Kyung-Soo Kim, Mi Hae Seo, Minyoung Lee, Nan-Hee Kim, So Hun Kim, Won-
    Diabetes & Metabolism Journal.2024; 48(6): 1015.     CrossRef
  • Evaluation of autoimmune phenomena in patients with nonalcoholic fatty liver disease on the basis of liver pathology
    Yu-Jin Zhu, Yan Zhang, Yao Rao, Yong Jiang, Yong-Gang Liu, Jian-Zhou Li, Jia-Qi Yuan, Ying Zhao, Wen-Wen Zheng, Lin Ma, Chun-Yan Wang, Jia Li
    World Journal of Hepatology.2024; 16(12): 1407.     CrossRef
  • Gut microbiome and nonalcoholic fatty liver disease
    Meng-Yuan Wu, Jian-Gao Fan
    Hepatobiliary & Pancreatic Diseases International.2023; 22(5): 444.     CrossRef
  • 15,642 View
  • 429 Download
  • 48 Web of Science
  • Crossref

Letters to the Editor

Steatotic liver disease

Letter regarding “The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults”
Hye Won Lee
Clin Mol Hepatol 2023;29(1):169-170.
Published online November 10, 2022
DOI: https://doi.org/10.3350/cmh.2022.0384

Citations

Citations to this article as recorded by  Crossref logo
  • Correspondence on Letter regarding “The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults”
    Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn
    Clinical and Molecular Hepatology.2023; 29(1): 179.     CrossRef
  • 6,773 View
  • 61 Download
  • 1 Web of Science
  • Crossref

Steatotic liver disease

Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”
Seung Min Lee, Dae Won Jun
Clin Mol Hepatol 2023;29(1):171-172.
Published online November 10, 2022
DOI: https://doi.org/10.3350/cmh.2022.0381
  • 6,332 View
  • 77 Download

COVID-19

Correspondence on Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis”
Ka Shing Cheung, Chiu Hang Mok, Wai Kay Seto, Man Fung Yuen
Clin Mol Hepatol 2023;29(1):176-178.
Published online November 10, 2022
DOI: https://doi.org/10.3350/cmh.2022.0377
  • 7,725 View
  • 59 Download

Correspondence

Steatotic liver disease

Correspondence on Editorial regarding “Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations”
Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn
Clin Mol Hepatol 2023;29(1):185-187.
Published online November 10, 2022
DOI: https://doi.org/10.3350/cmh.2022.0375
  • 6,446 View
  • 56 Download
Letter to the Editor

Steatotic liver disease

Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”
Yuanbin Liu, Mingkai Chen
Clin Mol Hepatol 2023;29(1):163-164.
Published online October 27, 2022
DOI: https://doi.org/10.3350/cmh.2022.0326

Citations

Citations to this article as recorded by  Crossref logo
  • Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”
    Seung Min Lee, Dae Won Jun
    Clinical and Molecular Hepatology.2023; 29(1): 171.     CrossRef
  • 7,162 View
  • 71 Download
  • 1 Web of Science
  • Crossref
First First Prev Prev
Page of 2
Next Next Last Last
Clin Mol Hepatol : Clinical and Molecular Hepatology
Twitter